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Abstract 
 
Chapter 1 begins with a general introduction to the main aspects of this work: Firstly, a 
species of electrogenic bacteria, Geobacter sulfurreducens is introduced. Their ability to take 
part in extracellular electron transfer, the mechanisms by which this happens, and their 
involvement in electricity generation and bioremediation when applied in microbial fuel cells 
is discussed; Secondly, microbial fuel cells (MFCs) as an alternative method of electricity 
generation to fossil fuels, their methods of operation and their potential for use in the 
treatment of wastewater is briefly reviewed; Finally, antimalarial drugs (including their semi-
synthetic and synthetic analogues) and their mechanisms of action are presented. The 
possibility of exploiting them as a template for bi-functional molecular wires that are capable 
of tethering bacteria to carbon and/or gold electrode surfaces is discussed in detail.  
Chapter 2 outlines our efforts towards novel analogues of synthetic antimalarials, dispiro-
1,2,4-trioxolanes, for use as bi-functional molecular wires. These are shown to be capable of 
immobilising heme on carbon and gold surfaces via appropriate functional groups.  
Chapter 3 discusses our efforts towards novel analogues of synthetic antimalarials, dispiro-
1,2,4,5-tetraoxanes for use as bi-functional molecular wires. The syntheses of many novel 
precursors; namely functionalised adamantanone derivatives and their corresponding 
tetraoxanes are presented. Synthetic routes towards bi-functional tetraoxane molecular wires 
have been extensively optimised and the incorporation of functional groups that are 
compatible with carbon/gold surfaces has been attempted. 
Chapter 4 briefly introduces the design and synthesis of β-turn mimetics and the synthesis of 
chiral enamine N-oxides. 
Chapter 5 details the experimental procedures. 
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1.1. Energy production and fossil fuels 
1.1.1. Global warming 
 For years, scientists argued over the evidence and governments refused to accept that 
global warming was happening. There is no longer any doubt that our use of fossil fuels to 
meet our energy needs is changing the climate. Since the industrial revolution, the burning of 
fossil fuels; coal, oil and gas – has massively increased to power factories, heat homes and 
drive cars. Burning fossil fuels releases carbon dioxide – the main man-made greenhouse gas. 
It exacerbates environmental damage by contributing to the greenhouse effect (Figure 1). 
Carbon dioxide creates an artificial greenhouse effect, thickening the natural canopy of gases 
in the atmosphere, causing more heat to become trapped. As a result, the global temperature 
increases, throwing the world's climate out of its natural balance.   
 
 
Figure 1: The Greenhouse Effect.
1 
 
 
 Electricity production currently accounts for 35% of total global fossil fuel use and 
around 41% of total energy-related carbon dioxide emissions. Coal is the most important 
energy source, producing 41% of the world’s electricity in 2008 but is also the most carbon-
intensive fuel and the single largest source of greenhouse gas emissions.
2, 3
 Our current rate 
of fossil fuel consumption is environmentally unsustainable because fossil fuels are finite 
natural resources and they are depleting rapidly. 
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It has been predicted that demand for fuel will exceed supply within the next ten to 
twenty years.
4
 Globally, energy use accounts for almost two thirds of greenhouse gas 
emissions, and these emissions are rising. Without urgent action to quit this fossil fuel 
addiction, the world is heading for dangerous levels of warming, well above the 1.5
o
C danger 
threshold.
5
  
 
1.1.2. The future of non-renewable energy 
 It is predicted that fossil fuels will dominate the future energy picture at least through 
to 2035. While renewable energy is expected to increase its share of electric generation, it is 
thought to remain a small portion of total generation over the next 25 years. Even if tax 
incentives for renewable technologies were to be extended, energy from renewable resources 
would still account for less than a 20% share of generation in 2035.
6
 Supplies of cheap, 
conventional oil and gas are declining while demands continue to rocket in emerging 
economies such as China and India. It is clear that our current reliance on fossil fuels cannot 
continue. 
 
1.1.3. Renewable Energy 
 By switching to renewable energy, a viable alternative to fossil fuels, the natural 
environment can be protected, the need for energy can be fulfilled and the consequences of 
global warming can be avoided. The Energy Report 2011 by the WWF outlines how the 
world’s energy needs could be provided by 100% renewable energy by 2050, cleanly, 
renewably and economically.
3
 They envisage that this goal could be achieved with a “do 
more with less” approach by, for example, using energy efficient materials in building 
construction, developing more efficient forms of transport, changing lifestyles, using 
electricity generated by wind, solar and hydropower. However, sustainability for this very 
much depends on international co-operation and collaboration on an unprecedented level. 
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 While it is well known that energy can be obtained from the sun, the Earth, water and 
wind, it has recently been found that with a microbial fuel cell (MFC), electricity can be 
generated from wastewater. The MFC converts organic material to electricity using bacteria, 
leaving behind clean drinking water in the process. This is an exciting prospect for people in 
countries where adequate sanitation and the means to afford it are lacking. Wastewater 
treatment plants also require a lot of power to treat water so a significant amount of money 
and resources would be saved if the wastewater itself could be used as a fuel. The form of 
renewable energy that will be the main focus in this work will be MFCs and the next section 
discusses the type of bacteria that are capable of generating electricity.  
 
1.2. Electrogenic bacteria: Geobacter sulfurreducens 
1.2.1. Introduction to Geobacter 
 Life evolved on the planet without an oxygen atmosphere and anaerobes evolved 
during this time using various methods to support metabolism without oxygen to drive 
respiration.
4
 The most fascinating bacteria are those that are able to transfer electrons outside 
the cell to an electron acceptor. Such bacteria are called exoelectrogens and the Geobacter 
genus is the main focus in this work. Like many bacteria, the Geobacteraceae family feed on 
and decompose organic material. Geobacter microbes were first discovered in 1987 under the 
Potomac River, downstream from Washington D.C. where there is no oxygen and plenty of 
iron. They have the unexpected ability of moving electrons into metal, which means that 
under the right conditions, Geobacter can simultaneously process waste and generate 
electricity.
7, 8
 In their natural environment, Geobacter grow on mineral surfaces where they 
can use solid metal oxides as the terminal electron acceptor for anaerobic respiration. 
 
1.2.2. Bacterial respiration 
 In a MFC, the bacteria oxidise organic matter, such as acetate to CO2, producing 
electrons that travel through a series of respiratory enzymes in the cell and make energy for 
the cell in the form of ATP. The electrons are then released to a terminal electron acceptor, 
which becomes reduced. Examples of terminal electron acceptors include oxygen, nitrate and 
sulfate, which can all readily diffuse into the cell to accept electrons and form products that 
can easily diffuse out of the cell. 
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 To improve the efficiency of MFCs, it is vital to understand how and why 
microorganisms exchange electrons with electrodes in a fuel cell. It is important to have some 
notion of metabolism to understand why external electron transfer is essential for the bacteria 
and how the exchange with the electrode is occurring. Bacteria can process lipids, proteins 
and carbohydrates to supply themselves with carbon and energy. All of these organic 
substrates act as electron donors for a complex system of redox reactions that result in the 
production of an energy carrier molecule (ATP). They can be converted through glycolysis 
into the acetyl unit of acetyl-CoA, which is fed into the citric acid cycle (Figure 2).  
 
 
Figure 2: Citric acid cycle.
9
  
 This is where oxidation reactions are coupled to the reduction of NAD
+
 and FAD to 
their electron carrier forms, NADH and FADH2 (Figures 3 and 4). These electron carriers 
then transfer electrons from the cytoplasm, where the citric acid cycle occurs, to the cell 
membrane. Before being transmitted to a terminal electron acceptor e.g. oxygen, electrons are 
transferred through different mediators, some of them pumping protons out of the cell as they 
are reduced. The energy of this proton gradient is used by the cell to phosphorylate ADP to 
produce ATP. The process in which ATP is produced by the reduction of an inorganic 
terminal electron acceptor is called respiration. 
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Figure 3: The redox reactions of NAD. 
 
 
Figure 4: Reduction of FAD to FADH2. 
 
1.2.3. Electrogenic properties of Geobacter sulfurreducens 
 Although Geobacter conserve energy for growth by using metal oxides for anaerobic 
respiration, it has been shown that they can also exchange the electrons produced with a 
polarized electrode.
10
 This is extremely fascinating, especially as electrodes, per se, are not 
part of the natural environment. Geobacter sulfurreducens are also known to produce the 
highest current densities of any microorganism available in pure culture.
11
 They can form 
multi-microbe thick, persistent biofilms not observed when respiring insoluble oxidants, in 
which microbes residing more than 20-cell lengths (20μm) away utilise the anode as their 
terminal electron acceptor.
12
 The combination of robust direct electron transfer and high cell 
surface density (microbes across the entire biofilm generating electrons, which are collected 
by the underlying anode) enables Geobacter biofilms to achieve higher anodic current 
densities than any other species. However, in most cases, electrical outputs of MFCs are 
currently too low for most perceived practical applications and for them to be considered a 
viable alternative energy source. This is because electrodes employed in electrochemical 
applications are made from materials such as platinum or carbon. They are not natural 
electron acceptors for these bacteria which have very specific requirements regarding the 
crystal structure of the electron acceptor in order to establish an efficient electrical 
communication.  
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 Most efforts for further optimisation have focused on modifying fuel cell architecture 
or electrode materials in an attempt to increase electrical current. To date, there has been little 
investigation into the properties of Geobacter sulfurreducens with the assumption that their 
current-production capacity was fixed. However, there was a breakthrough in 2012 when 
Lovley et al.
11
 showed for the first time that there is a direct correlation between biofilm 
conductivity and current production. This was attributed not only to reduced resistance to 
electron flow through the biofilm but also to a lower activation energy barrier for electron 
transfer between the biofilm and the anode.   
 It has been suggested that some microorganisms have evolved effective strategies for 
extracellular electron exchange with insoluble minerals.
13
 There is, however, a significant 
difference between insoluble minerals and electrodes. Electrodes provide a surface with long-
term electron-accepting or electron-donating capacity, whereas the ability of individual 
insoluble materials to accept or donate electrons is eventually depleted. This means that the 
relationship between cells and electrodes, and cells and minerals is significantly different and 
this is apparent with Geobacter species. Bond and Lovley
14
 showed that Geobacter 
sulfurreducens can grow on graphite electrodes and efficiently transfer electrons from the 
oxidation of acetate. The recovery of acetate as electrical current was found to be quantitative 
but the mechanism by which this transfer took place was not fully understood.  
 Before putting the idea of using bacteria in MFCs into practice, it is essential to 
decipher the exact mechanism by which the bacteria transfer electrons to the electrode. The 
rate is currently too slow so the power generated as a result is very small. One possible 
explanation for this, as proposed by Rittmann
7
, is that physical contact with the electrode 
surface is limiting electron transfer. Even though the bacteria are on the surface of the anode, 
only a tiny part of each cell actually touches the metal, and this may be hindering electron 
movement. Another possible factor is the voltage on the electrode; it needs to be high enough 
to make the bacteria give up their electrons. 
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1.2.4. Mechanisms of electron transfer 
 There are three most commonly considered mechanisms for electron transfer between 
bacteria and extracellular electron acceptors and each of these is discussed in the next section: 
1) Electron “hopping” resulting from direct contact between redox-active proteins on the 
outer surface of the bacterial cells and the electron acceptor. 
2) Electron transfer via soluble electron shuttling molecules (redox mediators). 
3) The conduction of electrons along pili (natural nanowires).  
 
 
1) Short-range direct electron transfer via redox-active proteins; c-type cytochromes 
 Geobacter sulfurreducens is the only microorganism capable of producing high 
current densities with direct electron transfer to electrodes in which the mechanisms for this 
electron transfer have been investigated.
15
 One possible electron transfer path between a 
microbe and an electrode is direct electron transfer (electron “hopping”) where the active 
centre of the bacterial membrane is connected directly to the electrode. In this case, the 
electron transfer rate can be very low due to insulation of the active site of the enzyme in the 
protein environment and isolation of the enzyme from the electrode surface by its relative 
burial into the bacterial membrane. However, in the case of exoelectrogens e.g. Geobacter, 
the redox enzymes involved in electron transfer are located on the outer surface of the 
bacterial membrane and oriented so that the active site is facing towards to the electrode.
9
  
c-Type cytochromes are ubiquitous redox proteins whose principal biological function 
is electron transfer in cellular respiration, where single or di-heme cytochromes shuttle 
electrons between larger electron transfer proteins. c-Type cytochromes play vital roles in 
mediating electron transfer reactions associated with respiration in nearly all living 
organisms. Geobacter sulfurreducens have a wide diversity of c-type cytochromes exposed 
on the outer surface of the cell (Figure 5).
13
 Although their amino acid sequences differ 
greatly, all c-type cytochromes possess at least one heme that is covalently bound through 
amino acid side-chains of the proteins to position and orientate the heme moiety to facilitate 
efficient reactions.
16
 Geobacter sulfurreducens cells possess an abundance of multi-heme c-
type cytochromes on their outer membrane, in extracellular polymeric structures and along 
pili. One example of such a cytochrome is OmcS, which has a molecular mass of 
approximately 50kDa and is predicted to contain six heme centres.
17
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Figure 5: AFM image of c-type cytochromes in Geobacter sulfurreducens by Dr. Abraham 
Esteve-Núñez, University of Alcalá de Henares.  
 
2) Electron transfer via soluble electron shuttling molecules (redox mediators) 
 Electron shuttles are chemical compounds that stimulate the biodegradation of 
contaminants by facilitating the transfer of electrons to/from bacteria.
18
 These compounds 
assist in microbial energy metabolism primarily as intracellular electron carriers e.g. NAD 
that transfers electrons mainly from the citrate cycle to the respiratory electron-transport 
chain. In general, shuttles facilitate electron transfer between microbes, from electron-
donating substances to microbes and/or from microbes to electron-accepting substances.
19
 
Mediated electron transfer usually proceeds at much faster rates. It relies on the addition of 
naturally occurring redox active species, stable in two redox states, which are able to quickly 
diffuse in and out of the enzymatic channels, hence effectively shuttling electrons to the 
electrode surface.
9
 However, reliance on soluble additives in the anolyte would not be 
compatible for the purpose of wastewater treatment. It is important to realise that added 
mediators, whether or not they are immobilised, are not essential for electron transfer 
between bacteria and an electrode. 
 A diversity of microorganisms e.g. Pseudomonas and Shewanella, have the ability to 
produce electron shuttles to promote electron transfer to electrodes.
20
 Previous studies have 
shown that some microorganisms produce shuttles that promote electron transfer between 
cells and insoluble Fe(III) oxides. Oxidised shuttle molecules are reduced at the outer cell 
surface and the reduced shuttle molecules donate electrons to the electrode. Electrons can hop 
directly from c-type cytochromes to an electrode but this was shown to be possible only when 
anodes were artificially poised at positive potentials significantly higher than those of typical 
MFCs, and the rates of electron transfer were much faster in the presence of a shuttle 
molecule such as flavin.
13
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 The maximum current densities produced by microorganisms that rely on electron 
shuttling to transfer electrons to electrodes are much lower than those for microorganisms 
that are capable of long-range electron transport through thick, conductive biofilms. This is 
because the major limiting factor for electron shuttling is that it relies on diffusion, which is 
slow. The energy investment to produce shuttles is also considerable and this can render the 
shuttling process thermodynamically inefficient or less favourable than direct transfer as used 
by Geobacter species.
13
 Systems that rely on the addition of artificial electron shuttles have 
proven to lack long-term stability and their toxicity to humans greatly limits applications. 
 
3) Long-range electron transport via conductive pili 
 
Figure 6: Geobacter cell with natural microbial nanowires known as pili. (Size of cell: 1μm.)  
 
 Geobacter sulfurreducens have natural microbial nanowires known as pili (Figure 6) 
on their outer surface, which are made of fibrous protein structures.
9
 Microbial nanowires are 
defined as protein filaments produced by microorganisms that are capable of performing 
long-range electron transport in vivo under physiologically relevant conditions.
21
 They are 3-
5nm in width, making them 20,000 times finer than a human hair and up to 10-20μm in 
length.
13, 15, 22
 They offer the possibility of greatly enhancing microbe-electrode interactions 
and play an important role in electronic interactions of microorganisms with inorganic 
electron acceptors in their environment, as well as interspecies electron exchange. Pili have 
been shown to have electronic conductivities in the region of 5mScm
-1
. This is comparable to 
nanostructured films of organic polymers e.g. polyacetylene and polyaniline.
21, 23
 In other 
words, electron conduction along the length of the pili is through conjugated π orbitals of 
pilin constituents, presumably aromatic amino acids.
15
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Pili are capable of long-range (μm to cm) electron transport via a metallic-like 
conductivity, which has not previously been observed in a biological material.
13, 23
 Type IV 
pili in Geobacter sulfurreducens are the only filaments that have been shown to be required 
for extracellular electron transport to extracellular electron acceptors or for conduction of 
electrons through biofilms.
21
  
 
Electron hopping involving cytochromes or metallic-like conduction through pili – which 
mechanism occurs? 
 There is much debate between the groups of Lovley and Tender over which electron 
transfer mechanism actually occurs. The results presented by each of them are currently 
inconclusive. In 2012, Lovley et al.
24
 showed multiple lines of evidence that were consistent 
with long-range electron transport through the biofilms of Geobacter sulfurreducens via 
networks of pili that possess metallic-like conductivity. The reported results refute the 
cytochrome hypothesis discussed above and provide additional data which suggest that 
electron transfer is via a metallic-like conductivity. The results
21, 24
 that supported electron 
transfer via a metallic-like conductivity (i.e. through pili) were:  
1. The highest conductivity for pili was obtained at pH 2, a pH at which c-type 
cytochromes are denatured. 
2. The conductivity of biofilms was found to be 5mScm-1, which is consistent with the 
conductivity of pili, whereas the conductivity due to c-type cytochromes alone was 
2000 times lower at 2.65μScm-1. 
3. Cells at a substantial distance (>50μm) from the anode surface remained 
metabolically active and contributed significantly to current production.  
4. The most abundant cytochromes are localised in the periplasm or in membranes so 
not all hemes are available to participate in extracellular electron exchange. 
5. Known outer-surface cytochromes are multi-heme so the number of cytochromes 
available for electron exchange is much lower than the number of hemes measured. 
6. The only cytochrome known to be associated with pili is OmcS and deletion of OmcS 
caused an increase in biofilm conductivity and current density, not the decrease 
expected if OmcS was important in conferring conductivity required for long-range 
electron transport. The simplest explanation for these observations is that pili deliver 
electrons to OmcS, which transfers them to Fe(III).
25
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7. The average spacing between OmcS molecules was ca. 30nm and spacing between 
OmcS clusters were 100-200nm and these values far exceed the distances of <2nm 
required for electron hopping. The density of the cytochromes is therefore too low and 
spaced too far apart for electron hopping to take place. 
8. OmcZ is the only outer-surface c-type cytochrome known to be necessary for current 
production. OmcZ was found to be specifically localised at the anode-biofilm 
interface, which suggests that it cannot be responsible for conduction of electrons 
through the bulk of the biofilm. 
9. Finally, biofilms were treated with acetyl methionine, which binds to c-type 
cytochromes, making them non-functional. This did not negatively impact on 
conductivity in pili networks. 
 
 The above evidence suggests that c-type cytochromes do not contribute to long-range 
electron transport and the mechanism by which it happens is via a metallic-like conductivity. 
The mechanisms by which OmcZ contributes to electron exchange with electrodes need to be 
further evaluated.  
 
 In contrast to Lovley’s proposals, Tender et al.12 proposed that biofilm anode 
respiration is ultimately controlled by extracellular electron transfer among cytochromes and 
the following is a summary of the points that support their proposal: 
 
1. They found that there was a linear increase in current with the number of c-type 
cytochromes in a Geobacter biofilm anode during biofilm growth. 
2. The hypothesis of metallic-like conduction by pili does not provide explanations for 
the finite thickness of biofilms. 
3. The biofilm anode grows in thickness until either the pH value near the anode surface 
becomes sufficiently low that it inhibits cytochrome function of the innermost cells 
(and thus limiting the ability of all cells in the biofilm to transfer electrons to the 
anode), or until the local concentration of oxidised cytochromes experienced by the 
outermost cells becomes too low to support additional growth. 
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1.3. Fluorescent properties of c-type cytochromes in Geobacter sulfurreducens 
 In 2008, Lovley et al.
26
 reported a novel fluorescence technique for monitoring the 
redox status of c-type cytochromes in Geobacter sulfurreducens. This was developed to 
evaluate the capacity of these cytochromes to store electrons during periods in which an 
external electron acceptor was not available. When cytochromes were in a reduced state and 
excited at a wavelength of 350nm, they fluoresced with maxima at 402 and 437nm. Oxidation 
of the cytochromes resulted in a loss of fluorescence. 
 
1.4. Role of Geobacter and MFCs in bioremediation 
 Microorganisms can aid environmental restoration by oxidising, binding or 
immobilising contaminants. There is significant interest in bioremediation because it 
promises to be simpler, cheaper and more environmentally friendly than non-biological 
options where contaminants are merely dug up and transported elsewhere.
27
 As well as their 
electrogenic properties, Geobacter are also of interest because of their role in environment 
restoration. They are well known for their biodegradation capacities of pollutants such as 
aromatic hydrocarbons, nitroaromatic explosives and even uranium. For example, Geobacter 
species can destroy petroleum contaminants in polluted groundwater by oxidizing these 
compounds to harmless carbon dioxide. 
 
1.4.1. Removal of uranium from contaminated groundwater 
 The addition of an organic electron donor such as acetate to groundwater 
contaminated with uranium can stimulate the growth of Geobacter species, which obtain 
most of their energy from the oxidation of the acetate with the reduction of Fe
3+
 oxides that 
are abundant in most subsurface environments. As U
6+
-containing groundwater enters the 
zone of acetate addition, the Geobacter species also transfer electrons to the soluble U
6+
 
reducing it to the highly insoluble U
4+
.
27, 28
 This method solves the problem of further 
migration of the uranium, which is beneficial but the drawback is that it remains in the 
subsurface. However, if an electrode served as the electron donor, the U
4+
 that is produced 
can precipitate on the electrode surface instead. 
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Gregory and Lovley
29
 showed that under anaerobic conditions, 87% of the uranium 
that had been removed from the contaminated groundwater was recovered from the electrode 
surface after it was pulled from the sediments. U
4+
 was not observed in the solution after 
600hrs when the system was maintained under anaerobic conditions. However, if exposed to 
oxygen, the uranium would be expected to rapidly dissolve. There is a possibility of using 
this system to remove uranium from contaminated groundwater by concentrating it on the 
electrode and removing the electrode from the system. The uranium could then be 
concentrated in an external solution, and the electrode re-used. This method would only be 
feasible if performed under fully anaerobic conditions as intrusion of oxygen into the system 
would cause re-dissolution of the uranium, which would be problematic as it could 
potentially create a spike in chemical concentration.
4, 29
  
 
1.4.2 Geobacter sulfurreducens in MFCs 
 The fact that both biodegradation and electrogenic activities are present in Geobacter 
sulfurreducens makes them the most suitable microorganism for use in MFCs. The low 
electrical output from MFCs needs to be increased before they can be developed further for 
large scale commercial purposes. In an attempt to increase electrical output from MFCs, an 
efficient means of attachment of the bacteria to the electrode is required in the form of a 
molecular wire. As Geobacter sulfurreducens have accessible heme centres on their outer 
membranes, the O’Neil group decided to base the molecular wire design on synthetic 
antimalarial drugs because they are capable of alkylating the porphyrin ring in heme. This 
will be discussed further after an introduction to microbial fuel cells. 
 
1.5. Microbial Fuel Cells (MFCs) 
 Microbial fuel cells (MFCs) are an emerging technology which directly converts 
chemical energy stored in organic matter to electricity. Driven by the increasing concern over 
the energy-climate calamity and environmental pollution, MFCs have been developed rapidly 
over the past decade.
30
 MFCs make it possible to directly utilise bio-electricity from organic 
waste with a higher energy transforming efficiency than other traditional technologies. The 
wide application of MFCs will significantly reduce the energy dependence on fossil fuels as 
well as the problems of climate change and environmental pollution. 
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 Currently, MFCs are in the process of making the challenging step from laboratory to 
practical application. However, it has been argued that a 10-fold increase in the efficiencies 
(compared to current laboratory reactors) is necessary for MFCs to be feasible commercial 
processes.
19
  
 
1.5.1. Introduction to MFCs 
 The first evidence of electricity generation by bacteria in MFCs was reported by 
Potter in 1912.
31
 However, there was little interest in this field until a short revival almost 
half a century later. The main drawbacks at the time were low current generating capacity, a 
need for artificial electron mediators and successful development of other alternative 
technologies such as photovoltaic technology so early MFCs were not considered promising.  
 The greatest environmental challenge is to develop a new energy platform that is 
capable of simultaneously solving energy production and CO2 releases. It is well known that 
microorganisms can produce fuels such as ethanol, methane and hydrogen from organic 
matter. It is less well known that microorganisms can also convert organic matter into 
electricity in devices known as microbial fuel cells.
28
  
 MFC technology currently represents the newest renewable approach for generating 
electricity.
4
 In brief, this is a method of electricity generation from biomass using 
electrogenic bacteria without the need for combustion. MFCs consist of an anode that accepts 
electrons from microorganisms and a cathode that transfers electrons to an electron acceptor. 
This flow of electrons between the electrodes provides current that can be harvested to power 
electronic devices.
22
 Interest in MFCs is increasing as they offer the possibility of harvesting 
electricity from organic waste and they could also fill a niche that is significantly different 
from the better known abiotic hydrogen- and methanol-driven fuel cells. These abiotic cells 
involve the use of fuels that are highly explosive and/or toxic and also require expensive 
catalysts to promote oxidation of the electron donors, whereas naturally occurring 
microorganisms can catalyse the oxidation of the fuels (organic waste) in MFCs.
28
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1.5.2. MFC set-up and operational conditions 
 
Figure 7: Diagram explaining how a MFC functions.
32
  
 
 The MFC is a bio-electrochemical system in which bacteria are used to convert 
organic matter into electricity (Figure 7). Typically, a MFC comprises an anaerobic anode, 
an aerobic cathode, the proton-exchange membrane (PEM) or salt bridge, and the external 
circuit. The anode holds the bacteria and organic matter in an anaerobic environment. The 
cathode holds a conductive saltwater solution. As part of the digestive process (oxidation), 
the bacteria create protons and electrons. The electrons are pulled out of the solution onto the 
anode and are conducted through an external circuit to arrive at the cathode. The protons 
travel through the PEM or salt bridge to meet with the electrons at the cathode. The PEM or 
salt bridge separates the anode and the cathode but protons are able to move through to 
connect them. The salt bridge is a mesh of proteins that allows the protons to move from the 
anode to the cathode but keeps the solutions in the anode and cathode separate. Driven by the 
potential difference between the cathode and the anode, the protons and electrons combine 
with oxygen to create water in the cathode chamber.  
 It is now known that some bacteria can transfer electrons exogeneously (i.e. outside 
the cell) to a terminal electron acceptor such as a metal oxide and it is these bacteria that can 
be used to produce power in a MFC. Bacterial attachment to and the formation of a biofilm 
on the anode surface are essential for the efficient biological transfer of electrons in a MFC.
33
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1.5.3. Mediator and mediator-less MFCs 
 In a mediator MFC, the bacteria are electrochemically inactive. They digest organic 
matter and create electrons but have no mechanism to rid themselves of these electrons so a 
mediator is required. The mediator is an inorganic substance, such as thionine, methyl 
viologen, potassium ferricyanide or methylene blue, which crosses the membrane of the 
bacteria and frees the electrons. The mediator then carries the electrons away from the 
bacteria and deposits them onto the electrode. One disadvantage to the mediator MFC is that 
many of the mediators used are toxic in nature.
34
  
In a mediator-less MFC, the bacteria are electrochemically active and they themselves 
can carry the electrons they create through digestion of organic matter to the electrode. There 
are several factors that are limiting steps for electricity generation, such as fuel oxidation at 
the anode electron transfer from microorganism to the anode, proton transfer through the 
membrane to the cathode and oxygen reduction at the cathode.
34
  
 However, as mediator-less MFCs are a recent development, this process is not yet 
completely understood.
4, 32
 Mediator-less MFCs are considered to be more suitable for 
practical MFCs as sustainable processes since mediators are generally costly.
19
  
 
1.5.4. Wastewater Treatment 
 
Figure 8: Application of MFC technology in wastewater treatment. 
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 Wastewaters are classically processed under anaerobic conditions in order to 
transform organic matter into acetate and short chain organic acids. As shown in Figure 8, 
the acetate is further converted to methane. Although this could be used as an energy source 
in the wastewater treatment plant, it also constitutes a potent greenhouse effect gas whose 
energy absorbed per molecule is 25 times higher than CO2. The ultimate aim of this research 
is to replace this methanogenic stage with an advanced MFC that is able to convert acetate 
into electricity rapidly by means of a highly inter-connected electrogenic biofilm. 
 The next section gives an introduction to malaria and discusses how synthetic 
antimalarial drugs can form the basis of our bi-functional molecular wires and their 
application in microbial fuel cells. 
 
1.6. Introduction to malaria 
 According to the World Malaria Report 2011, there were about 216 million cases of 
malaria and an estimated 655,000 deaths in 2010. Malaria mortality rates have fallen by more 
than 25% globally since 2000 and by 33% in the WHO African Region. Most deaths occur 
among children under the age of 5 in Africa where a child dies every minute from malaria.  
 Malaria is the most important insect-transmitted disease. It is caused by parasites of 
the Plasmodium genus
35
 and four of these species can cause malaria in humans: Plasmodium 
falciparum, Plasmodium vivax, Plasmodium malariae and Plasmodium ovale. Plasmodium 
falciparum and Plasmodium vivax are the most common and Plasmodium falciparum is the 
most deadly, hence a lot of effort has been focused towards designing antimalarial drugs that 
treat falciparum malaria.  
 Malaria is transmitted exclusively through the bites of infected mosquitoes from the 
Anopheles genus, called “malaria vectors”, which bite mainly between dusk and dawn.35, 36 
Symptoms of infection include high fever, shaking, chills, severe anaemia, coma and if left 
untreated, death.
37
 P. falciparum infections are the most prevalent and cause the majority of 
malaria-related mortality in non-immune individuals.
35
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1.6.1. The malaria parasite life cycle 
 
Figure 9: Life cycle of the malaria parasite.
38
  
 The Plasmodium parasite spends its life cycle partly in humans and partly in 
mosquitoes (Figure 9). When an infected female Anopheles mosquito bites a human host to 
take a blood meal to nourish her eggs, it passes cells called sporozoites into the human’s 
bloodstream. These sporozoites travel to the liver where they undergo asexual reproduction to 
form trophozoites, which then mature to produce schizonts. Their nuclei split to form 
thousands of new cells called merozoites. When the liver cells rupture, the merozoites enter 
the bloodstream and infect red blood cells which grow and divide to produce more 
merozoites, eventually causing the red blood cells to rupture. Some of these newly released 
merozoites go on to infect other red blood cells and some develop into sex cells known as 
male and female gametocytes. These gametocytes lie dormant in humans until another 
mosquito bites the infected human, ingesting the gametocytes. In the mosquito’s stomach, the 
gametocytes mature and male and female gametocytes undergo sexual reproduction to form a 
zygote. The zygote multiplies to form sporozoites, which travel to the mosquito’s salivary 
glands. The cycle begins again when this mosquito bites another human. 
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1.6.2. Hemoglobin digestion  
 During the blood stage of the malaria cycle where trophozoites form schizonts, 
Plasmodium falciparum uses hemoglobin in the human host as a food source to provide itself 
with amino acids to build its own proteins.
39
 During the digestion process, a lot of free heme 
(Fe(II)) is released from hemoglobin and this is toxic to malaria parasites.
40
 The free heme is 
autoxidised to hematin(Fe(III)),
41
 which is a dimer formed by covalent bonding between the 
carboxylic acid groups and iron. These dimers interact through hydrogen bonds to form 
crystals of a non-toxic, Fe(III) polymer called hemozoin or ‘malaria pigment’ (Scheme 1). 
 
 
Scheme 1: Detoxification of hemoglobin to hemozoin. 
 
1.7. Antimalarial drugs 
1.7.1. Conventional treatment: Cinchona alkaloids 
 The only two antimalarial classes of medicines used to treat severe malaria come from 
plants: cinchona alkaloids and artemisinin.
42
 In the 16
th
 century, the therapeutic action of the 
bark of the cinchona tree was discovered by natives of Peru.  
 Quinine (Figure 10), the alkaloid from cinchona bark was first isolated in 1834 by 
French chemist, Pelletier and this became the frontline treatment for malaria until the 1930s 
when synthetic antimalarials were developed.
43
 Approximately 300–500 tons of quinine are 
commercially produced each year by extraction of the bark from cinchona species that are 
widely cultivated. About 40% of the quinine goes towards the production of pharmaceuticals, 
while the remaining 60% is used by the food industry as the bitter principle of soft drinks 
such as tonic water.
44
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 From the 1940s to 1990s, chloroquine (Figure 10) was the main treatment for malaria 
worldwide.
45
 However, by the 1970s, it was reported that chloroquine was no longer effective 
in South East Asia, Africa and South America as Plasmodium falciparum had become 
resistant. This level of resistance escalated rapidly within the next ten years so there has been 
increased demand for unrelated classes of antimalarials to reduce the burden of malaria.  
 
Figure 10: Quinoline-based antimalarials. 
 
1.7.2. Artemisinin and analogues 
 The discovery of artemisinin and its derivatives is a milestone in the history of 
antimalarial drug research since the discovery of quinine. After a brief introduction on the 
chemistry and pharmacological aspects of artemisinin, we will focus this section of the 
review on the radical chemistry and alkylation properties of artemisinin and synthetic 
peroxides. It is clear that good knowledge of the mechanism of action of artemisinin allowed 
the rational design of new synthetic antimalarial drugs. 
 
 Artemisinin, a sesquiterpene lactone, was first isolated in 1971 from the Chinese herb, 
artemisia annua.
43
 It was given the name qinghaosu, meaning “blue-green plant extract” but 
the name artemisinin is now commonly used. Artemisia annua has been used for many 
centuries in traditional Chinese medicine as a treatment for fever and malaria. Artemisinin is 
a “new entity” with a structure and mode of action that are unrelated to those of any other 
antimalarial because it differs from the classical quinoline-based drugs, quinine and 
chloroquine. This means that the chances of cross-resistance are unlikely and this is important 
due to the reported high resistance of parasites towards quinoline-based antimalarials.
46
 
Artemisinin has been used successfully in several thousand malaria patients in China, 
including those with chloroquine-sensitive and chloroquine-resistant strains of Plasmodium 
falciparum. Artemisinin is currently the most effective treatment against multi-drug resistant 
Plasmodium species. 
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Figure 11: Artemisinin and its semi-synthetic analogues. 
 
 A series of semi-synthetic first generation analogues (Figure 11) have been made e.g. 
a water soluble derivative, sodium artesunate was prepared to treat advanced cases of malaria 
by intravenous injection. The other analogues listed can all be readily prepared from 
dihydroartemisinin (DHA), which in turn is prepared from borohydride reduction of the ring 
lactone of artemisinin. However, as a drug class, artemisinins suffer from chemical (semi-
synthetic availability, purity, cost and hydrolytic instability of the lactone function), 
biopharmaceutical (poor bioavailability due to poor solubility in both oil and water and 
limiting pharmacokinetics) and treatment (non-compliance with long treatment regimes and 
recrudescence) issues that limit their therapeutic potential.
47
  
 
1.8. How artemisinins work 
1.8.1. Artemisinins as prodrugs 
 It is considered that artemisinins, per se, are not antimalarial but instead act as 
‘prodrugs’, which require the generation of antimalarial-active intermediates after 
encountering ferrous iron.
42
 In the context of artemisinin activation, ferrous iron is found in 
the food vacuole of the parasite, where digestion of hemoglobin takes place and free iron is 
detoxified by deposition in hemozoin. 
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1.8.2. Activation by “free” Fe2+ 
 The Fenton reaction (Scheme 2), which involves reductive cleavage of peroxides by 
ferrous iron to generate alkoxy radicals then carbon-centred radicals, and finally neutral 
products, is well understood. This had been examined in detail before the advent of the 
artemisinins.
42
  
 
Scheme 2: The Fenton reaction.
48, 49
  
 
 Cleavage of the peroxide bond generates two alkoxy radicals, O1 and O2. These 
rapidly rearrange via either hydrogen abstraction or β-scission to form the more stable C-
centred radicals (Figure 12). These alkyl radicals are able to interact with vital parasite 
proteins such as heme, DNA or membranes that ultimately result in parasite death.
50
  
 
Figure 12: Mechanism of action of artemisinin to form C-centred radicals that can either 
alkylate biomolecules or self quench to give antimalarial-inactive products.
42, 50, 51
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1.8.3. Activation by heme-Fe
2+
 
 During the early trophozoite stage in the malaria cycle, the parasite catabolises 
hemoglobin as a source of amino acids in its digestive vacuole to release heme.
52
 Virtually all 
of the heme is converted into hemozoin and very little is degraded by other pathways.
53
 Of 
the total iron present in Plasmodium falciparum trophozoites, approximately 92% is located 
within the food vacuole and 88% of this is in the form of hemozoin. It was established that 
heme has to be in the ferrous state in order to react with artemisinin.  
 In 2001, the first covalent heme-artemisinin adduct produced from the alkylation of 
heme by artemisinin was fully characterised by Robert et al.
54
 In 2002, they found that this 
reaction gave an 85% yield of heme derivatives alkylated at the α-, β- and -meso positions 
by a C-centred radical derived from artemisinin.
39
  
 Work by Posner et al.
55
 in 1994 showed that a C-centred radical was important for 
antimalarial activity by synthesising and testing the in vitro antimalarial activity of mono-
methylated analogues of dihydroartemisinin (Figure 13 and Table 1). This work first 
highlighted the value of mechanistic understanding at the molecular level for the rational 
design of potent antimalarial trioxanes and illustrated how one small stereochemical change 
(diastereomer a Vs. diastereomer b) can be used as a molecular on-off switch for antimalarial 
activity.
55
  
 
Figure 13: Mono-methylated trioxanes derived from dihydroartemisinin. 
 
Compound W-2 Indochina clone  
(IC50 (ng/ml)) 
D-6 African clone  
(IC50 (ng/ml)) 
a 4.5 3.5 
b >500 >500 
artemisinin 8 8 
 
Table 1: In vitro antimalarial activity of trioxanes a and b compared to artemisinin. 
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 IC50 is a measure of the effectiveness of a compound in inhibiting biological or 
biochemical function. It is a quantitative measure that indicates how much of a particular 
drug is needed to inhibit a given biological process by half. In other words, it is the half 
maximal (50%) inhibitory concentration (IC) of a substance; the smaller the IC50 value, the 
more potent the drug. It is most commonly used as a measure of antagonist drug potency in 
pharmacological research. 
 
1.8.4. Fixed-dose Artemisinin Combination Therapy (fACT)  
 Combining artemisinin with another slowly eliminated drug in a tablet is known as 
fixed-dose artemisinin combination therapy (fACT) e.g. Coartem
®
 (artemether/lumefantrine) 
developed by Novartis represents 75% of the ACT market today.
37
 ACTs are now generally 
accepted as the best treatments for uncomplicated falciparum malaria as they are rapidly and 
reliably effective, with efficacies exceeding 95%.
56
  
 The rationale for fACTs is that the short-acting (3 day regimen) but highly potent 
artemisinin derivative delivers a rapid reduction in parasite biomass, with the remaining 
parasites being removed by the less active but more slowly eliminated partner drug that is 
structurally unrelated to artemisinin.
56
 Distinct modes of action of artemisinin derivatives and 
partner drugs should, in theory, enable the combination to kill parasites that manifest 
decreased sensitivity to one agent alone and thus avoid or delay emergence of resistance. 
fACTs are more complicated to produce and can be up to 20 times more expensive 
than monotherapy, which make them unaffordable in vulnerable populations. fACTs could 
make a major contribution to global malaria control but only a minority of people who need 
these drugs actually receive them because cost and access remain formidable obstacles.
56
  
 More than 3 million people have been successfully treated using fACTs, which is a 
tremendous achievement. There are, however, 28 countries that still allow artemisinin 
monotherapy (despite the WHO advising against this) so resistance to fACTs was bound to 
occur. The first signs of emerging resistance to fACT were reported in 2009 in South East 
Asia where the parasite clearance time (PCT) was increased almost two-fold.
37
  
 Current fACT regimens contain between 2.5-4mg/kg of the artemisinin derivative and 
are given daily for three days. They are easy to use and well tolerated with no adverse effects. 
The following fACTs are recommended by the WHO: 
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1. Artemether plus lumefantrine (currently the only internationally licensed ACT. 
Available in Asia and Africa.
57
) 
2. Artesunate plus amodiaquine (cures 70-90% of patients depending on geographic 
location.
42
) 
3. Artesunate plus mefloquine (consistently cures >95% of patients whereas mefloquine 
alone only worked for 50-60% of cases
42
, mainstay of antimalarial drug policy in 
South East Asia but too expensive for the African market.
57
) 
4. Artesunate plus sulfadoxine/pyrimethamine (used in some Asian countries but 
ineffective where sulfadoxine/pyrimethamine has failed as a replacement for 
chloroquine.
57
) 
 
1.9 Drawbacks of artemisinin-based therapy 
1.9.1 Extraction of artemisinin from Artemisia annua 
 The drawback of using semi-synthetic analogues of artemisinin is that their 
production relies on extraction from Artemisia annua and in some countries, it is cultivated 
solely for this purpose but the yield obtained from extraction is only 0.1 - 0.8%. Reliance on 
cultivated Artemisia annua restricts supply of the drug and elevates costs for the patients who 
need it. Total syntheses of artemisinin have been achieved; one example is the route by Avery 
et al.
58
 but it is too laborious (>10 steps) to be considered a viable alternative to extraction for 
supplying a highly cost sensitive market. 
 
1.9.2. Continuous flow synthesis of artemisinin  
 
 
Scheme 3: Reduction of artemisinic acid to dihydroartemisinic acid (DHA). 
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 In 2012, Lévesque and Seeberger
59
 proposed a continuous flow synthesis of 
artemisinin. They found that artemisinic acid, a much less complex molecular precursor can 
also be extracted from Artemisia annua in higher yields or it can be produced in engineered 
yeast. This makes artemisinic acid an ideal starting point for synthetically produced 
artemisinin. After purification, this method yielded 39% of artemisinin from DHA (Scheme 
3), which is approximately 200g produced by the reactor per day. They estimated that 1500 
of their reactors would be enough to meet the 225 million (number of cases of malaria as 
estimated by the WHO in 2009) doses of malaria medication needed per year.   
However, the issues of reliance on natural products, cost and poor biopharmaceutical 
properties still remain and have resulted in complex administration regimens or 
recrudescence. To overcome these limitations, medicinal chemists have developed synthetic 
peroxides that have varying degrees of antimalarial activity.  
  
1.10. Toward synthetic peroxide-containing antimalarial drugs 
 The need for affordable and readily available antimalarial therapies has spurred 
research into alternate methods for their manufacture and also the search for totally synthetic 
molecules that confer antimalarial activity analogous to artemisinin.  
 
1.10.1. Synthetic alternatives to artemisinin    
 
 
Figure 14: Structure of deoxyartemisinin. 
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 The essential part of artemisinin is the peroxide bond in the 1,2,4-trioxane system and 
reduction of this peroxide bridge produces an analogue, deoxyartemisinin (Figure 14), which 
is devoid of antimalarial activity. Therefore, the reactivity of this peroxide function within the 
parasite is the crucial feature for superior pharmacological activity. The high cost of 
artemisinin extraction has driven the development of synthetic antimalarials that incorporate 
the key peroxide pharmacophore. Simpler structures containing this bridge e.g. 1,2,4-
trioxolanes and 1,2,4,5-tetraoxanes, are far more accessible and in excess of 1000 new 
endoperoxides belonging to several classes have now been prepared.
46
 These have provided 
alternative therapeutic possibilities and given medicinal chemists insight to their mode of 
action. 
 
1.11. Main concept behind research and aims of this work 
 The aim of this work is to exploit the ability of synthetic antimalarials (1,2,4-
trioxolanes and 1,2,4,5-tetraoxanes) to alkylate heme and apply them in MFCs. They could 
potentially act as a bi-functional molecular wire by alkylating heme on the outer membrane 
of Geobacter sulfurreducens and simultaneously tethering them to a carbon or gold electrode 
surface via an aryl diazonium or sulfur-based group respectively. This has involved the 
design and synthesis of novel, spiroadamantane peroxide antimalarials, which have 
appropriate functionality on the adamantane moiety. Chapter 2 discusses the mechanism of 
action of 1,2,4-trioxolane antimalarials and our efforts towards dispiro-1,2,4-trioxolane 
molecular wires that are capable of immobilising heme on carbon and gold surfaces. Chapter 
3 discusses our efforts towards bi-functional, dispiro-1,2,4,5-tetraoxane molecular wires, 
including the syntheses of many novel precursors; namely functionalised adamantanone 
derivatives. Chapter 4 briefly introduces the synthesis of β-turn mimetics and chiral enamine 
N-oxides.  
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This chapter contains a separate numbering system for all schemes, tables, figures and 
references. 
 
2.1. Introduction to 1,2,4,-trioxolanes 
2.1.1. Discovery of secondary ozonides as antimalarials 
 There has been increased demand for synthetic cyclic peroxides because they have the 
potential to replace traditional antimalarial remedies. Ozonides are both reactive and unstable 
so they would not be an obvious first choice for a promising antimalarial drug candidate. 
However, Vennerstrom et al. showed that substituted ozonides (1,2,4-trioxolanes) are not 
only chemically stable, but also have potent antimalarial activity.
1
 The drug discovery 
process relied on multi-dimensional lead optimisation made possible by a rapid and recurrent 
combination of antimalarial, physicochemical, metabolism, pharmacokinetic and toxicity data 
to guide the medicinal chemistry and create a lead prototype. 1,2,4-Trioxolanes exhibit 
structural simplicity and are synthetically more accessible and have superior antimalarial 
activity to artemisinin. 
 
Figure 1: General structure of tetra-substituted trioxolanes. 
 
2.2.1 Chemical and metabolic stability 
 Ozonides are formed from the ozonolysis of olefins, which rearrange to secondary 
ozonides or 1,2,4-trioxolanes. The stability of tetra-substituted trioxolanes may be due, in part 
to the lack of α-hydrogen atoms, which prevents heterolytic peroxide fragmentation reactions 
driven by formation of stable carbonyl-containing products.
2
 Tetra-substituted trioxolanes 
have the general structure shown in Figure 1 where the R groups represent combinations of 
ring systems, acyclic systems and functional groups that provide steric hindrance about the 
trioxolane ring, to provide both chemical and metabolic stability.
1
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 Tetra-substituted trioxolanes which possess a spiroadamantane ring are sterically 
hindered on one side of the trioxolane unit. This serves to protect the ring from premature 
chemical and metabolic decomposition in situ. The other side may incorporate a 
spirocyclohexyl ring, preferably functionalised at the 4’-position. This arrangement allows 
for an energetically favourable approach of Fe(II) to a relatively sterically unhindered 
peroxide oxygen atom to give exclusive β-scission of the spiroadamantane ring. Interestingly, 
closely related analogues where the peroxide bridge is too exposed or sterically inaccessible 
to an Fe(II) species are completely antimalarial-inactive (Figure 2). 
 
 
Figure 2: Active and inactive structurally-related trioxolanes. 
 
2.2. Proposed mechanism of action of 1,2,4-trioxolanes 
2.2.1. Iron-mediated degradation 
 Treating the active trioxolane with ferrous acetate as a model for heme indicates that 
the peroxide bond fragments to give an O-centred radical, followed by β-scission to give the 
secondary C-centred radical. This was subsequently trapped by TEMPO to form the 
corresponding aminoxy acid. No products were obtained from the β-scission of the 
spirocyclohexanone, supporting the hypothesis that attack of the Fe(II) species occurs on the 
less-hindered peroxide oxygen (Figure 3). 
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Figure 3: Iron-mediated degradation of trioxolane to form a C-centred radical and subsequent 
trapping with TEMPO.
1, 3
  
 
 It can be seen that analogues resembling the hindered and inactive di-adamantyl 
trioxolane 3 (Figure 2) are prevented from binding to Fe(II) or heme for steric reasons, which 
accounts for their inactivity. Studies by Creek et al.
3
 suggested that polarity can also play a 
major part in the biological activity of these compounds. They found that trioxolanes with a 
heteroatom incorporated in the cyclohexyl ring or a polar substituent at the 4’-position 
rendered the trioxolane chemically more reactive towards iron. As a result, these trioxolanes 
tended to degrade much faster than their non-polar counterparts. They also used Fe(III) in 
their work to determine whether or not it mediated any degradation of the trioxolanes but 
after 24hrs, no degradation had occurred. This indicated that reactions of the trioxolanes 
proceed via Fe(II)-mediated reduction of the peroxide bond and this result is consistent with 
iron-mediated degradations reported for artemisinin. However, it has been found that 
artemisinins are generally less efficient than trioxolanes at alkylating heme in vitro and are 
similarly poor at intercepting radical spin traps such as TEMPO.
4
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2.3. Synthesis of substituted 1,2,4-trioxolanes 
2.3.1. The Griesbaum Co-ozonolysis 
 In 1995, Griesbaum et al.
5
 reported a new type of cross-ozonolysis reaction where an 
O-alkyl ketone oxime was ozonised in the presence of activated carbonyl compounds 
(Scheme 1). They later also found that this method could also be applied efficiently to a 
number of unactivated ketones such as cyclohexanone. 
 
Scheme 1: The Griesbaum Co-ozonolysis. 
 
 If no carbonyl compound is added in the second step, the carbonyl oxide can dimerise 
to form a 1,2,4,5-tetraoxane (Scheme 2). Tetraoxanes will be discussed in detail in Chapter 3. 
 
 
Scheme 2: Dimerisation of carbonyl oxide.  
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 The Griesbaum co-ozonolysis provided for the first time, a widely applicable 
synthesis of both symmetrical and unsymmetrical tetra-substituted ozonides that are 
otherwise generally inaccessible by ozonolysis of a parent alkene or cross-ozonolysis of an 
alkene or enol ether in the presence of carbonyl compounds in solution.
6
 Another useful 
feature is that it avoids the need to synthesise parent tetra-substituted olefins or enol ethers 
and instead requires only the straightforward synthesis of oxime ethers. There is a lot of 
flexibility with this reaction, as a large number of ketones and oxime ether precursors are 
commercially available. If the yields for the co-ozonolysis are low, they can be improved 
dramatically simply by “reversing” the O-methyloxime and ketone.7, 8 This novel procedure 
provides a uniquely convenient method to synthesise spiro- and dispiro- trioxolanes that can 
be purified by crystallisation or flash chromatography. 
 In 1997, Griesbaum et al.
8
 carried out the ozonolyses of O-alkylated ketoximes in the 
presence of carbonyl groups. They showed a two-way approach, routes A and B (Scheme 3), 
which allowed optimisation of ozonide yields by the judicious selection of a pair of substrates 
containing the more reactive carbonyl compound. They did not manage to isolate methyl 
nitrite as a by-product due to its low boiling point of -12
o
C. 
 
 
Scheme 3: Pathways for Griesbaum co-ozonolysis. 
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 The detailed mechanism for the Griesbaum co-ozonolysis has not been well defined 
but the reaction outcome is consistent with the general pathway of the Criegee
9
 mechanism 
for ozonolysis of olefins, especially involving the key carbonyl oxide intermediate. In 1998, 
Geletneky and Berger
10
 showed that when a primary ozonide reacts with a 
17
O-labelled 
aldehyde, the Criegee model incorporates the 
17
O label in the ether linkage of the secondary 
ozonide only (Scheme 4). This was found to be the case for styrene and 
ethylidenecyclohexane from which simple and clear 
17
O-NMR spectra could be obtained as 
they offered no stereochemical complications of cis and trans isomerism of the resulting 
ozonide. 
 
Scheme 4: Criegee mechanism for ozonolysis of olefins using a 
17
O (O*)-labelled aldehyde. 
 
2.3.2. Diastereoselectivity and scope of the Griesbaum co-ozonolysis 
 Vennerstrom et al.
6
 have synthesised a number of trioxolane analogues via the 
Griesbaum co-ozonolysis. They investigated trioxolanes formed from reactions between O-
methyl 2-adamantanone oxime and 4-substituted cyclohexanones. It was found that the 
majority of trioxolane isomers possessed cis configurations, suggesting a preferred axial 
attack of the carbonyl oxide on the cyclohexanone dipolarophiles. 
 Trioxolanes were labelled cis or trans indicating the position of the cyclohexyl-R 
group with respect to the axial peroxide bond (cis indicates that the R group is in the 
equatorial position whereas trans indicates the R group is in the axial position). The general 
result was that large cyclohexyl-R groups (Group I) gave almost exclusively the cis 
diastereoisomer with estimated cis/trans ratios of 20:1. 4’-Substituted cyclohexanones with 
functional groups linked by a single methylene (Group II) gave cis/trans ratios of 5:1. Ester 
and amide groups (Group III) provided cis/trans ratios ranging from 2.5:1 to 5:1 (Figure 4). 
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Figure 4: Diastereoselectivity of the Griesbaum co-ozonolysis. 
 
 These results were attributed to preferred attack of the carbonyl oxide on the axial 
side of the cyclohexanone when the cyclohexyl-R* group increased in size (Figure 5). 
 
 
Figure 5: The stereochemistry of the resulting trioxolane is determined by the nature and size 
of the cyclohexyl-R* substituent at the 4’-position. 
 
2.4. Mechanism of action of 1,2,4-trioxolanes  
 In the same way as artemisinin, synthetic peroxides generate highly reactive C-
centred radicals. There are however, some subtle differences; artemisinin generates both a 
primary and a secondary carbon radical, whereas dispiro-cyclic trioxolanes produce only a 
secondary C-centred radical formed via the primary oxy radical. Once formed, it is proposed 
that these radicals react further by alkylating a nearby substrate.  
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2.4.1. 1,2,4-Trioxolanes in iron-mediated degradation studies 
 As for artemisinin, it was found that Fe(II)-mediated reactivity also applied to 
trioxolanes. Within the study carried out by Creek et al.
3
, in which the iron-mediated 
degradation kinetics of trioxolanes were investigated, some extraordinary reaction rates were 
observed. Some rate constants varied by as much as 1000-fold and they did not directly 
correlate with in vitro antimalarial activity. It is clear that not all trioxolanes that reacted with 
FeSO4 were active antimalarials. However, the ones that did not react with FeSO4 had no 
appreciable antimalarial activity. These results suggested that iron-mediated reactivity is a 
necessary, but insufficient, prerequisite for antimalarial activity. This implied that other 
molecular properties play important roles in the biological mechanism of action and 
experiments involving heme were required for confirmation of this hypothesis. 
 
2.4.2. 1,2,4-Trioxolanes in heme alkylation 
 In 2008, Creek et al.
4
 investigated the Fe(II)-heme mediated reactivity of a series of 
trioxolanes. They compared structurally similar trioxolanes with a wide range of antimalarial 
activities to determine whether or not the reaction with heme showed any correlation with 
antimalarial potency. They found that all of the trioxolanes used in the study reacted with the 
Fe(II) centre of heme (Figure 6) and that these reactions occurred much faster than when 
inorganic Fe(II) salts were used, taking minutes rather than hours to reach completion. The 
extent of heme alkylation also correlated closely with in vitro antimalarial activity of the 
trioxolanes used in this investigation. This suggested that heme alkylation may be related to 
the mechanism of action for trioxolane antimalarials. However, the conditions used in this 
study reflect an extremely simplified system compared to the reaction with biological heme 
within the malaria parasite. Further research was required to correlate bio-mimetic studies 
with the actual environment of parasite-infected red blood cells. 
Chapter 2: Synthetic antimalarials - Dispiro-1,2,4-trioxolanes 
42 
 
 
Figure 6: Proposed mechanism of action of trioxolanes in reaction with Fe(II) heme. Only 
alkylation of β-meso position shown for clarity but there is likely to be a mixture of isomeric 
adducts as with artemisinin.  
 
2.5. Functional group transformations by post-ozonolysis reactions of 1,2,4-trioxolanes 
 Vennerstrom et al. continued to investigate a wide range of post-ozonolysis reactions 
at the 4’-position on the spirocyclohexane. The trioxolanes proved to be quite stable to 
triphenylphosphine, borohydrides, hydrazine, organolithiums, Grignard reagents and aqueous 
potassium hydroxide as illustrated by the synthesis of amine, alcohol, acid, ester, ether, 
sulfide, and heterocycle-functionalised ozonides using a number of different methods.
6
 
Reaction temperatures were kept below 60
o
C to avoid decomposition of the ozonide 
heterocycle into adamantanone lactone and the starting material cyclohexanone via Hock-
type fragmentations (Schemes 5 and 6). 
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Scheme 5: Thermal ozonide decomposition above 60
o
C. 
 
 
Scheme 6: Acid-catalysed Hock-type fragmentation. 
 
2.6. Ozonide drug development 
2.6.1. First generation ozonides 
 The main problems with peroxide drug candidates are attributed to solubility and 
bioavailability. The first prototype trioxolanes were no exception to this; the spiroadamantane 
trioxolane pharmacophore is intrinsically lipophilic and therefore highly susceptible to 
metabolism. Excellent absorption and bioavailability of drugs following oral administration 
requires a fine balance between good aqueous solubility, which is improved for more polar 
structures, and good membrane permeability, which is favoured for less polar compounds. 
However, substitution at the 4’-position of the spirocyclohexane was shown to increase the 
polarity of the trioxolane.
11
 Vennerstrom et al. described the synthesis and antimalarial 
properties of 43 diversely functionalised derivatives of the 1,2,4-trioxolane prototypes with a 
wide spectrum of polarity. They found that more lipophilic trioxolanes had improved oral 
activities compared to their more polar counterparts and trioxolanes with a wide range of 
neutral and basic, but not acidic, functional groups had good antimalarial profiles.
11
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2.6.2. Second generation ozonides 
 Identification of the trioxolane OZ277 (also called arterolane, Figure 7), by 
Vennerstrom et al.
1
 was a significant breakthrough in antimalarial drug development efforts 
during the past decade.  The key pharmacophore of OZ277 is the 1,2,4-trioxolane moiety.  
 
 
 
Figure 7: OZ277, arterolane. 
 
 
 As the trioxolane pharmacophore is inherently lipophilic, the polarity of trioxolanes 
was adjusted by the addition of an amine or amide side chain at the 4’-position of the 
cyclohexyl moiety. OZ277 was shown to have the optimum balance between lipophilicity, 
aqueous solubility, metabolism and potent antimalarial activity and was advanced into “first-
in-man” clinical studies in 2004.1  
 The clinical trials of OZ277 identified some issues with the first generation ozonides. 
The drugs tended to degrade rapidly in rats’ blood in vivo; consequently a higher 
concentration is required to achieve the desired antimalarial effect, proving to be less cost-
effective than desired. It is well known that cleavage of the peroxide bond and subsequent 
formation of free radicals is required for activity; therefore making structural modifications to 
reduce blood instability without sacrificing potency was the next challenge in developing 
second generation analogues. Slight structural modifications resulted in improved properties 
such as improved stability in blood without compromising biological activity; better oral 
bioavailability and excellent prophylactic activity in mice. The latest generation trioxolanes 
are faster acting and some are even showing signs of completely curing malaria in only one 
dose. These are properties that artemisinin and the first generation trioxolanes were lacking. 
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Figure 8: OZ439. This is the next ‘one-shot’ lead drug candidate to be tested and supported 
by MMV, it is currently in early stage clinical trials.
12
 Costing less than $1 per dose to 
produce, OZ439 is finally a promising, cost-effective solution to the burden of malaria. 
 
2.6.3. Metabolites of OZ277 
 In 2008, Vennerstrom et al.
13
 showed that trioxolane OZ277 can be hydroxylated by 
human liver microsomes at the distal bridgehead carbon atoms of the spiroadamantane 
moiety to give two carbinol metabolites that were devoid of antimalarial activity (Figure 9). 
 
 
Figure 9: OZ277 and its hydroxylated metabolites, OZ397 and OZ381. 
 
 The complete lack of antimalarial activity for these metabolites may be an indication 
of the importance of an unsubstituted spiroadamantane ring system to the antimalarial 
properties of the ozonides.  It may be that the steric hindrance provided by the bridgehead 
carbinols in these metabolites prevents efficient alkylation reactions of the spiroadamantane-
derived secondary C-centered radicals from occurring when the ozonide reacts with Fe(II) in 
the parasite. This suggests that any substitution on the adamantane moiety would prevent 
efficient heme alkylation. However, the work presented in this thesis has shown that this is 
not always the case, as discussed in the next sections. 
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2.7. Results and Discussion 
2.7.1. Synthesis of O-methyl oximes 
 The synthesis of 1,2,4-trioxolanes began with the optimisation of conditions for the 
synthesis of the precursors, O-methyl oximes using various ketone substrates (Table 1). 
 
(i) NH2OMe.HCl (1.5eq), pyridine (1.2eq), MeOH, rt, 48hrs. 
 
Entry Ketone Yield (%) 
1 
6 
 
81 
2 
7 
 
56 
3 
   5 
 
70 - 80 
 
Table 1: Synthesis of O-methyl oximes. 
 
 Cyclohexanone 5 was found to give consistently high yields of the corresponding O-
methyl oxime and because it is also the cheapest commercially available ketone of the ones 
surveyed, this was taken forward for trioxolane synthesis.   
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2.7.2. Optimisation of conditions for the synthesis of 1,2,4-trioxolanes 
 O-Methyl 5-hydroxy-2-adamantanone oxime was used in a Griesbaum co-ozonolysis 
reaction with cyclohexanon. This would potentially provide a trioxolane bearing a synthetic 
handle on the adamantyl moiety on which further transformations could be performed. 
However, a very low yield was obtained so this route was abandoned because 5-hydroxy-2-
adamantanone 7 is expensive. We decided to continue trioxolane synthesis using O-methyl 
cyclohexanone oxime 8 (Scheme 7). The conditions for this co-ozonolysis reaction between 
2-adamantanone and O-methyl cyclohexanone oxime were changed slightly each time and 
the resulting yields of trioxolane are summarised in Table 2. 
 
Scheme 7: (i) 2-adamantanone 6 (1.1 equiv), O3, 4:1 pentane/DCM, 5hrs. 
 
Entry Conditions Yield (%) 
1 Bubble O3 into reaction at -78
o
C 16 
2 Cool O3 to -78
o
C before bubbling into reaction 6 
3 Bubble O3 into reaction at 0
o
C 6-9 
4 Bubble O3 into reaction at 0
o
C, anhydrous conditions 9 
 
Table 2: Yields of trioxolane from varying reaction conditions. 
 In general, the yields obtained were very poor under all of the reaction conditions 
used. There was also the problem of the trioxolane product being very non-polar and this 
made it difficult to obtain a mass spectrum because all modes of ionisation failed to ionise the 
molecule. However, further optimisation by a member of the O’Neil group allowed the 
trioxolane to be obtained in higher yields (ca. 40%) when 5-hydroxy-2-adamantanone 7 was 
used as the starting ketone. This meant that a trioxolane that was capable of undergoing 
further transformations had been synthesised successfully. 
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2.7.3. 1,2,4-Trioxolanes for heme alkylation experiments 
 The next targets were trioxolanes for heme alkylation/fluorescence experiments 
involving Geobacter. These trioxolanes had functionality on the cyclohexyl moiety (Scheme 
8) and direct tetraoxane analogues (discussed in Chapter 3) have also been synthesised to 
allow comparison of results. The results from these experiments are currently pending. 
Incorporation of a carboxylic acid group should aid with solubility of the molecule in 
aqueous conditions when used in experiments with Geobacter. 
 
Scheme 8: Synthesis of trioxolanes for heme alkylation experiments. (i) O3, pentane, rt, 5hrs, 
45%. (ii) 15% NaOH, MeOH, rt, 3hrs, then H
+
, 80%. 
 
 The application of trioxolanes in heme alkylation experiments were carried out by the 
group of Dr. Abraham Esteve-Núñez, University of Alcalá de Henares. Fe
2+
-heme groups are 
known to emit blue light under UV (254nm) light excitation. They hypothesised that the 
addition of trioxolanes to reduced cytochromes should allow monitoring of the auto-
fluorescence that originates in the cytochromes of Geobacter. When the bacteria are oxidised 
as a result of heme alkylation, the auto-fluorescence should be lost. As the reaction between 
the trioxolane and heme is oxidative, auto-fluorescence should decrease as the reaction 
progresses. Trioxolane 12 (Scheme 9) and the ketal control 13 (Scheme 9) were used in 
spectrofluorimetric assays to determine if binding of the trioxolane to heme caused the loss of 
auto-fluorescence. 
 
Scheme 9: Trioxolane 12 and ketal control 13 for auto-fluorescence experiments.  
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 Anaerobic cell suspensions of Geobacter sulfurreducens were incubated in sealed 
fluorimeter cuvettes in the presence of different concentrations of the trioxolane in 10% 
DMSO. The results showed that there was indeed a loss of auto-fluorescence after the 
addition of the trioxolane (Figure 10). As expected, the ketal control showed no loss in auto-
fluorescence, which was an indication of it not reacting with heme. 
 
 
Figure 10: Results from auto-fluorescence experiments. 
 
2.7.4. 1,2,4-Trioxolanes with functionality on the adamantane moiety 
 
 According to literature precedent, trioxolanes to date only have functionality at the 4’-
position on the cyclohexyl moiety to tune their physicochemical and pharmacological 
properties. Herein, we report work by the O’Neil group involving the synthesis of novel, 
dispiro-trioxolane molecular wires containing functionality at the 5-position of the 
adamantane moiety that are capable of binding heme to carbon or gold surfaces. In the next 
section, we show that the presence of significant bridgehead substitution on the adamantane 
moiety does not hinder the trioxolane from heme alkylation as thought previously by 
Vennerstrom et al. Trioxolanes bearing functional groups that are capable of binding to 
gold/carbon were synthesized and heme successfully immobilised on the surface. 
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2.7.5. 1,2,4-Trioxolane molecular wires synthesised within the O’Neil group 
1,2,4-Trioxolane molecular wire for immobilising heme on gold 
 We envisaged that a trioxolane bearing a thiol-based group could bind to a gold 
surface. The synthesis of a trioxolane dimer containing a disulfide linkage was carried out in 
the O’Neil group (Scheme 10). It was assumed that the thiol is formed initially and the 
disulfide linkage is thought to have formed as a result of aerobic oxidation. 
 
Scheme 10: Synthesis of trioxolane dimer bearing disulfide linkage 14. (i) 
HCl.NH2CH2CH2SH (0.5eq), EDC.HCl (1.2eq), HOBt (1.2eq), NMM (2.5eq), DMF, 0
o
C-rt, 
12hrs, 60%. 
 
 In the presence of gold, the disulfide linkage should undergo cleavage and the 
resulting thiol bind to the gold surface. The peroxide bond is then available to react with 
reduced heme (Figure 11). These experiments showed that heme was successfully 
immobilised on the gold surface.   
 
Figure 11: Immobilisation of heme on a gold surface by trioxolane dimer 14. 
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1,2,4-Trioxolane molecular wire for immobilising heme on carbon 
 We also envisaged that a trioxolane bearing a diazonium group 15 could be 
selectively reductively coupled to a carbon surface. This would immobilise the trioxolane on 
the surface and the peroxide bond could then react with heme groups, tethering them to the 
surface (Figure 12). This trioxolane 15 was synthesised with a senior member of the O'Neil 
group (Scheme 11). 
 
 
Figure 12: Trioxolane diazonium salt for functionalisation of carbon surfaces. 
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Scheme 11: Synthesis of trioxolane 15 for immobilising heme on carbon surfaces. (i) 100% 
HNO3, rt, 3 days, 52%. (ii) 30% SO3 (8eq), 100% HCO2H (0.5eq), 60
o
C, MeOH, 0
o
C, 3hrs, 
65%. (iii) O-methyl cyclohexanone oxime (1.5eq), O3, pentane, rt, 5hrs, 45%. (iv) 15% 
NaOH, MeOH, 65
o
C, 3hrs, H
+
, 80%. (v) p-phenylenediamine (1eq), EDC.HCl (1.2eq), HOBt 
(1.2eq), NMM (2.5eq), DMF, 0
o
C-rt, 12hrs, 60%. (vi) [NO][BF4] (1eq), DCM, 0
o
C, 60%.  
 
 Typical conditions for diazotisation involve the use of NaNO2, strong acid and water. 
These conditions could cause decomposition of the trioxolane so an alternative milder 
method was sought after, involving the use of nitrosyl tetrafluoroborate. After some 
investigation (Table 3) into the optimum conditions for this reaction, it was found that one 
equivalent of [NO][BF4] in DCM at 0
o
C gave the best yield of diazonium product.  
 
Entry Solvent [NO][BF4] (eq.) Yield (%) 
1 Et2O 1 25 
2 DCM 1 60 
3 DCM 2 Decomposed 
 
Table 3: Optimisation of conditions for diazonium salt formation (step (vi) Scheme 11). 
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 The interesting feature of the diazonium salt formation was that the reaction was self-
indicating. The amine-functionalised trioxolane 18 was a yellow/orange colour and the 
trioxolane diazonium product 15 was purple (Figure 13). 
 
 
 
Figure 13: Diazonium salt formation shows colour change from yellow to purple. 
 
 Due to the unstable nature of the trioxolane bearing the diazonium group, it was only 
synthesised when needed and used immediately, as decomposition occurred when stored at 
room temperature. It was however, stable when stored in the fridge at 2-5
o
C. To avoid the 
risk of decomposition when the diazonium salt was used in electrochemical experiments, a 
trioxolane dimer 19 was synthesised as the more stable alternative (Scheme 12). This dimer 
was then used to successfully immobilise heme on a glassy carbon surface (Figure 14). 
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Scheme 12: Synthesis of trioxolane dimer 19 for immobilisation of heme on carbon surface.         
(i) p-phenylenediamine (0.5eq), EDC.HCl (1.2eq), HOBt (1.2eq), NMM (2.5eq), DMF, 0
o
C, 
3hrs, rt, 16hrs, 66%. 
 
 
Figure 14: Immobilising heme on a glassy carbon surface by a trioxolane dimer bearing an 
amide linkage. 
 
 Having successfully synthesised bi-functional trioxolane-based molecular wires, the 
O’Neil group wanted to expand on this work by designing similar bi-functional, tetraoxane-
based molecular wires. These wires should, in theory, be better heme alkylators than their 
trioxolane counterparts and our efforts towards them are discussed in detail in Chapter 3.  
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This chapter contains a separate numbering system for all schemes, tables, figures and 
references. Numbering of compounds has continued from chapter 2. 
 
3.1. Introduction to 1,2,4,5-tetraoxanes 
 
Figure 1: General structure of tetra-substituted tetraoxanes.  
 
 1,2,4,5-Tetraoxanes (Figure 1) are synthetic cyclic peroxides that have received 
significant attention in the literature. Initially, these compounds were used industrially for the 
production of macrocyclic hydrocarbons and lactones.
1
 They are achiral compounds and can 
be prepared from readily available, inexpensive starting materials in only two synthetic steps. 
This currently represents the shortest sequence reported for the synthesis of non-symmetrical 
tetraoxanes with activity profiles similar to artemisinin.
2
  
 
3.1.1. Stability and reactivity of synthetic endoperoxides: 1,2,4,5-tetraoxanes Vs 1,2,4-
trioxolanes 
 While impressive antimalarial activity profiles have been observed with the 1,2,4-
trioxolane class, the recent development of trioxolane OZ277 (discussed in chapter 2) has 
been hampered as this molecule was found to be unstable in the plasma of malaria patients 
during phase II dose-ranging study,
3
 so a more stable alternative was required. It was found 
that the achiral, 1,2,4,5-tetraoxane template is more stable (both thermodynamically and in 
vivo) than its 1,2,4-trioxolane counterpart (Figure 2). This was confirmed by the observation 
that 3,5-dicyclohexyl trioxolane 1 is inactive and unstable, whereas the analogous tetraoxane 
20 is relatively stable and expresses good antimalarial activity. Unsymmetrical tetraoxanes 
containing a spiroadamantane group 21 were found to give enhanced stability and 
antimalarial activity. 
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Figure 2: Rationale for dispiro-1,2,4,5-tetraoxanes. 
 
 In 1992, Vennerstrom et al.
4
 showed that symmetrical dispiro-1,2,4,5-tetraoxanes 
such as WR148999 (Figure 3) possessed high in vitro antimalarial activity. Despite being 
more potent than artemisinin in vitro, these compounds did not show good activity when 
tested orally as a result of extensive first-pass metabolism rather than solubility-limited 
dissolution.
5
  
 
Figure 3: WR148999. 
 
 In 2008, O’Neill et al.2 explored 1,2,4,5-tetraoxanes that incorporated a 
spiroadamantane group. They designed unsymmetrical dispiro-tetraoxanes, easily prepared 
from inexpensive materials via cyclocondensation of 1,1-dihydroperoxides with various 
ketones. Incorporation of water-soluble and polar functionalities via amide coupling 
produced several simple and achiral analogues. These analogues exhibited remarkable 
antimalarial activities in vitro and preliminary in vivo evaluation demonstrated that they also 
had promising oral activities.
2, 6
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 From a library of over 150 tetraoxanes, RKA182 (Figure 4 and Scheme 1) was 
selected as the candidate for full formal pre-clinical development.
3
 RKA182 has shown 
outstanding in vitro and in vivo activity against Plasmodium falciparum and improved 
pharmacokinetic characteristics compared to other peroxide drugs. 
 
 
 
Figure 4: Structure of RKA182. 
 
 
 RKA182 has excellent in vitro activity against sensitive and resistant strains of 
Plasmodium falciparum and it retains this level of activity in South East Asia, where 
artemisinin combination chemotherapy has failed. The drug candidate has a fast rate of 
parasite kill and superior in vivo activity to artesunate in rodent models of malaria. It also has 
improved stability in the presence of infected red blood cells, when compared to synthetic 
ozonides or semi-synthetic artemisinins. 
 
 
 
 
Scheme 1: Synthesis of RKA182. 
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3.1.2. Mechanistic studies of RKA182 using TEMPO
3
 
 
Scheme 2: TEMPO spin-trapping of C-centred radicals generated following Fe(II) activation. 
 
 To characterise the potential mediators of the antimalarial activity of RKA182, 
mechanistic studies with FeBr2 in THF and TEMPO were performed (Scheme 2). From this 
investigation, both the primary and secondary C-centred radicals were intercepted to give two 
TEMPO adducts. The behaviour of the tetraoxanes reported by O’Neill et al. is distinct from 
1,2,4-trioxolanes, as only the secondary C-centred radical species has been characterised 
from OZ277 and other trioxolanes. Since heme alkylation is believed to play an important 
role in the mechanism of action of endoperoxide antimalarials, the reactivity of tetraoxanes 
with ferrous heme was next investigated (Scheme 3). O’Neill et al. isolated the alkylated 
heme adduct, which confirmed that the mechanism is analogous to that shown by trioxolanes 
and that heme alkylation does indeed play an important role in their antimalarial activity. 
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Scheme 3: Proposed mechanism of action of 1,2,4,5-tetraoxanes. For clarity purposes, only 
the β-regioisomer of the alkylated heme adduct has been shown. 
 
 O’Neill et al. have also compared the reactivity of tetraoxanes with trioxolanes in the 
presence of ferrous iron salts, heme and ferrous iron salts/phospatidylcholine.
7
 This study 
showed that the stability of the two classes of drugs with inorganic Fe(II) was comparable 
when they were substituted with identical side chains on the cyclohexyl ring. O’Neill et al. 
also carried out a modelling study between heme and RKA182 to confirm that the less 
hindered oxygens (O2 and O4) of the peroxide bond co-ordinate to the iron centre in heme 
(Figure 5).
7
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Figure 5: Docking configuration between heme and RKA182.
7
  
 
 The purpose of this was to determine if the regioselectivity of heme alkylation could 
be predicted by docking calculations. In all of the docking conformations studied, the shortest 
distance between iron-heme and RKA182 was found to be with O2 (2.4-2.8Å) for the lowest 
energy conformations. This suggests that there is a preferred co-ordination of iron on the 
sterically less hindered O2 atom of the peroxide bond, confirming regioselectivity observed 
in alkylation experiments and the proposed mechanism of action of tetraoxanes. 
 
3.1.3. Second generation analogues of RKA182 
 
Figure 6: Elimination of the amide linkage provides second generation analogues. 
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 A new series (Figure 6) of analogues was designed by O’Neill et al.8 to eliminate any 
potential metabolic liability due to the amide linkage present in RKA182. They hypothesised 
that by doing this, they would have access to compounds with increased metabolic stability 
and they carried out a study comparing preliminary results of metabolic stability of 
compounds from the new series with RKA182. They found that all of the compounds 
synthesised exhibited remarkable in vitro and in vivo antimalarial activity in the low 
nanomolar range (0.2 - 3.7nM) and several demonstrated promising oral activity. This meant 
that some members of this series are more metabolically stable than RKA182 and these 
compounds are currently under further investigation. 
 
3.2. Molecular wire design 
 The main properties that our molecular wires must possess are functionality that can 
bind to heme centres (provided by the peroxide bond in the tetraoxanes) in the cytochromes 
of bacteria and allow robust attachment to either a carbon or gold surface, while 
simultaneously giving a high rate of electron transfer.  
 The synthetic peroxide antimalarials discussed so far have different functionalities 
incorporated at the 4’-position on the spirocyclohexyl moiety. However, according to the 
proposed mechanism of action of these compounds, it is the adamantane portion of the 
molecule that ends up alkylating the porphyrin ring in ferrous heme. This means that 
connective functionality must be incorporated into the spiroadamantane moiety (ideally at the 
5-position for minimal steric effects) to act as a versatile synthetic handle for further 
transformations. This would create a bi-functional scaffold upon which a molecular wire, as 
shown in Figure 7, can be constructed. 
 
 
Figure 7: Diagram (not drawn to scale) showing components of tetraoxane molecular wire 
and its ability to tether bacteria to carbon/gold surfaces via appropriate functional groups. 
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 We proposed that incorporation of an aromatic ring would increase electrical 
conductivity. The rationale behind using only one aromatic ring is to keep the molecular wire 
short so that tethering bacteria to a surface remains structured, organised and robust as a 
result of minimal flexibility. The design and synthesis of bi-functional tetraoxanes will be 
mainly focused on functional group transformations on the aromatic ring to incorporate 
amine and sulfur-based groups. 
 
3.3. Methods of binding to carbon and gold surfaces 
 A key challenge in molecular electronics is to improve the efficiency of charge 
transfer through target molecules and across interfaces. This is particularly conspicuous for 
protein-based systems since electronic coupling between the protein and the electrode is 
relatively weak. Molecular wiring self-assembly has offered solutions for coupling the 
protein redox centre physically and electronically to the electrode surface.
9
 The O’Neil group 
envisaged that similar chemistry could be applied to bi-functional tetraoxane-based molecular 
wires as discussed in the next sections.  
 
3.3.1. Binding to a carbon surface 
 One option for attachment of the molecular wire to a carbon electrode would involve 
diazonium chemistry as shown by Evrard et al.
10
 where carbon surfaces have been 
functionalised by aromatic azide molecules using “Click” chemistry (Figure 8). 
 
Figure 8: Electroreduction of diazonium salt for covalent immobilisation of phenylazide 
molecule on a carbon electrode surface. 
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 These immobilised azides could then be functionalised with our tetraoxane molecular 
wires (Figure 9), and consequently attaching them to the carbon surface. 
 
Figure 9: Cu(I)-catalysed Huisgen 1,3-dipolar cycloaddition between covalently immobilised 
phenylazide and our tetraoxane molecular wire (“Bacwire”) bearing the corresponding 
ethynyl group. 
 
 The main concern with applying “Click” chemistry to our work is that Cu(I) may 
reduce the peroxide bond of the tetraoxane as well as catalysing the cycloaddition with the 
immobilised azide. In 2009, Robert et al.
11
 reported the Cu(I) activation of artemisinin and 
found that the reactivity of the peroxide bond was similar to that of Fe(II) analogues even 
though the reaction was more sluggish and product distribution slightly different.  
 Pinson and Podvorica
12
 have shown that the electrochemical reduction of aryl 
diazonium salts on carbon leads to the formation of a strong C-C bond between a carbon 
atom from the surface of the solid and a carbon atom from the organic molecule. This 
technique is based on the reductive attachment of diazonium organic residues according to: 
RN2
+
 + e
-
  R + N2 
followed by attachment of the radical formed to the carbon surface, where R is a phenyl 
group substituted with appropriate (thiol or disulfide) functional groups that allow attachment 
to nanoparticles. Similar chemistry was used by Delamar et al.
13
 in 1992 and they found that 
the one-electron reduction of diazonium salts leads to a very robust covalent attachment of 
aryl groups onto a carbon surface. This method was also used by Toupin and Bélanger
14
 in 
2008 where they functionalised the surface of carbon with 4-nitrophenyldiazonium cations. 
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3.3.2. Binding to a gold surface 
 In 2004, Schiffrin et al.
15
 reported the wiring of redox-active molecules to gold 
nanoparticles. Viologen-based dithiols (Figure 10) were self-assembled from solution on 
Au(111) for use as tethers to attach nanoparticles to a conducting substrate.  
 
Figure 10: Viologen-based dithiols. 
 
 The topography, electrical properties and orientation of these molecules were 
investigated by STM, STS and FTIR. Remarkably, it was possible to isolate a single redox-
active molecule in an alkanethiol matrix and by subsequent attachment of a single gold 
nanaoparticle, the electrical properties of the conductivity of single wired molecules could be 
investigated. The aim of this work was to create single molecules that could perform basic 
electronic functions for use in molecular electronic devices and the main requirement was 
stable contacts at both ends of the wire. In 2007, Schiffrin et al.
9
 reported the gold 
nanoparticle-assisted assembly of a heme protein, namely a c-type cytochrome, for 
enhancement of long-range interfacial electron transfer (Figure 11). 
 
Figure 11: Molecular assembly of a c-type cytochrome on a Au(111) surface. 
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 This work was towards improving long-range electronic interactions between the gold 
nanoparticle and the protein molecule for bio-electronics and bio-sensing devices. In addition 
to the thiol groups at one end of the wire, an amine or carboxylic moiety has been 
incorporated at the other extreme for linking to proteins through either covalent or non-
covalent interactions. 
 
3.4. Toward bi-functional 1,2,4,5-tetraoxane molecular wires 
3.4.1. Introduction to 1,1,-dihydroperoxides 
 
 
Figure 12: Structure of 1,1,-dihydroperoxides. 
 
 1,1- or gem-dihydroperoxides (Figure 12) are unstable derivatives of ketones and 
aldehydes and are important intermediates in the synthesis of a number of classes of 
peroxides, including tetraoxanes,
6, 16, 17
 bisperoxyketals
18
 and 1,2,4,5-tetraoxacycloalkanes.
19
 
Dihydroperoxides have also been employed as reagents for nucleophilic epoxidations and 
oxidations,
20
 sulfoxidation of sulfides
21
 and as precursors for the synthesis of dicarboxylic 
acid diesters.
22
 
 
3.4.2. Methods of synthesising 1,1-dihydroperoxides 
 The major pathways for the synthesis of 1,1-dihydroperoxides are: 
1. Ozonolysis of ketone enol ethers or α-olefins in the presence of H2O2; 
2. Reaction of ketals with H2O2 in the presence of tungstic acid or BF3.Et2O; 
3. Peroxidation of ketones using an acidic solvent. 
 
 Drawbacks of these methods include the need for the prior synthesis of starting 
materials, use of highly concentrated H2O2, the need for excess acid, moderate yields and 
limited scope of substrates.  
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 In 2006, Žmitek et al.23 discovered that all of these limitations could be overcome by 
using iodine as a catalyst to synthesise dihydroperoxides directly from the carbonyl 
compounds using commercially available 30% H2O2. As molecular iodine has already proven 
to be a useful Lewis acid catalyst for the activation of carbonyl compounds, they envisaged 
that it would benefit the peroxidation reactions of such compounds. The optimised conditions 
for this straightforward and efficient method for the synthesis of 1,1-dihydroperoxides gave 
yields in the region of 70-90%.  
 In 2007, Das et al.
24
 reported a similar procedure that used CAN in place of iodine 
and they claimed that reaction times were typically reduced from 24hrs to 1hr. However, due 
to the big difference in cost per gram of CAN compared to iodine, we decided to not employ 
this method. Later in 2009, Li et al.
25
 reported a different procedure that involved using PMA 
as the catalyst and ethereal hydrogen peroxide as the solvent for the reaction. They found that 
this method gave nearly quantitative yields of dihydroperoxides for most ketone substrates. 
However, due to the explosive nature of hydrogen peroxide, and the need to use Et2O to 
“wash” it to prepare ethereal hydrogen peroxide, we decided against using this method.   
 
3.4.3. Stability of and side products from 1,1-dihydroperoxides 
 1,1-Dihydroperoxides are very thermally and chemically labile and tend to 
decompose readily at room temperature to give a number of dimeric and trimeric side 
products as shown by 1,1,-dihydroperoxycyclohexane in Scheme 4. 
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Scheme 4: Side products from the decomposition of 1,1-dihydroperoxycyclohexane.
16
 
Structures highlighted in red are the compounds that have been isolated in our work.  
 
 In 2010, Terent’ev et al.26 showed a new property of 1,1-dihydroperoxides; they could 
undergo hydrolysis in the presence of hydrogen peroxide with the removal of hydroperoxide 
groups in acidic media to form the corresponding ketones (Scheme 5). This transformation 
was found to exist as an equilibrium between the dihydroperoxide and the ketone. 
 
 
Scheme 5: Equilibrium between dihydroperoxide and ketone. 
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 They found that the tendency of cyclic peroxides to hydrolyse increases from 6-
membered to 8- and 12-membered rings. The mechanism for this transformation was 
proposed (Scheme 6).  
 
Scheme 6: Proposed mechanism for hydrolysis of 1,1-dihydroperoxides. 
 
3.4.4. Methods of synthesising 1,2,4,5-tetraoxanes 
 A number of useful procedures have been developed for the preparation of 
tetraoxanes. The key steps involve introduction of the peroxide group and where appropriate, 
transformation of hydroperoxide intermediates into cyclic peroxides. Since peroxides, 
especially hydroperoxide intermediates are both thermally and chemically labile, the choice 
of reagents and reaction conditions compatible with them is generally rather limited. This 
restriction poses additional challenges in stereochemical control and subsequent 
functionalisation.  The synthesis of 1,2,4,5-tetraoxanes is dependent on several factors such 
as the structure of the ketone or aldehyde, temperature, solvent, pH, the choice of catalyst, 
concentration of the substrate and also the equilibria between the ketone and the precursors of 
cyclic peroxides. All of these factors result in variable yields being achieved from the 
carbonyl starting materials. Most of them have been investigated during our efforts toward 
tetraoxane molecular wires as examined in detail in the results and discussion section.  
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Scheme 7: Synthesis of 1,2,4,5-tetraoxanes using Re2O7 catalyst. 
 
 The most widely used method of tetraoxane synthesis was developed by Ghorai and 
Dussault in 2009,
27
 which involves the rhenium (VII) oxide catalysed condensation of a 1,1,-
dihydroperoxide with a carbonyl compound in a one- or two-pot procedure (Scheme 7). Due 
to the unstable nature of the dihydroperoxide, the one-pot method is usually preferred as this 
avoids its isolation and risk of decomposition. The mechanism of tetraoxane formation 
undoubtedly begins with the reversible addition of the dihydroperoxide to the ketone (or 
aldehyde). The resulting dihydroperoxide can undergo the desired cyclocondensation to give 
a tetraoxane or alternatively, oligomerisation to give a hexaoxonane
16
 (Figure 13). 
 
 
Figure 13: A hexaoxonane (triperoxide). 
 
 Tetraoxanes can often be contaminated with hexaoxonanes and open-chain 
hydroperoxides. Purification can be achieved by using dimethyl sulphide, or the more 
strongly reducing agent potassium iodide, for selective removal of the more reactive 
hydroperoxides. Heating the mixture in acidic media can aid decomposition of the 
thermodynamically less stable hexaoxonanes to the more water-soluble lactones, which may 
also facilitate the purification process.
16
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 In 2011, a procedure by Yan et al.
28
 reported the use of PMA as the catalyst for 
tetraoxane synthesis with MgSO4 as the drying agent in the reaction (Scheme 8). Both the 
rhenium (VII) oxide and PMA catalysed methods have been applied and optimised in our 
work towards the synthesis of adamantyl-functionalised tetraoxanes. 
 
Scheme 8: Tetraoxane synthesis using phosphomolybdic acid (PMA) catalyst. (i) PMA 
(1mol%), MgSO4 (1.5eq), DCM, rt, 4hrs. 
 
3.5. Results and Discussion 
3.5.1. Synthesis of 1,1-dihydroperoxides : Optimisation of 1,1-dihydroperoxide synthesis 
 Efforts towards tetraoxane synthesis began with optimisation of the synthesis of 1,1-
dihydroperoxides using literature procedures and this was necessary because of their 
inherently unstable and reactive nature. It was important to find a method of synthesis that 
gave consistently good yields. 
 
Entry R= Conditions Yield (%) 
1 H 50% aq. H2O2, HCO2H, 30min, rt. 3 
2 H 50% aq. H2O2, Re2O7 (5mol%), CH3CN, 1hr, rt. 47 
3 H 50% aq. H2O2, I2 (10mol%), CH3CN, 24hrs, rt. 75 
4 CO2Et 50% aq. H2O2, I2 (10mol%), CH3CN, 24hrs, rt. 47 
5 CO2Et 50% aq. H2O2, I2 (10mol%), CH3CN, 3-5 days, rt. 70-80 
 
Table 1: Yields of dihydroperoxides obtained from following literature procedures. 
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 The results are summarised in Table 1. Entry 1 was a procedure reported by Amewu 
et al.
6
 who obtained yields in the region of 70%. It was not surprising when we obtained a 3% 
yield because dihydroperoxides are not at all stable in the presence of acid as discussed in the 
previous section. Using formic acid as the solvent for the reaction would have caused the 
formation of dimeric/trimeric side products and decomposition of the dihydroperoxide 
product back to the starting ketone. Entry 2 was a procedure reported by Ghorai and 
Dussault
29
 and yields obtained were typically >80%. We managed to obtain only 47% yield 
so it was clear that the methods attempted were unreliable and gave inconsistent yields on 
repetition. Entry 3 used a procedure by Žmitek et al.23 and Selvam et al.21 reported a similar 
procedure two years later, which gave 75% yield of 1,1-dihydroperoxycyclohexane 23. 
Yields were reproducible when an ester functionality was present (Entry 5), though they are 
still not as high as the reported 93%. We found that longer reaction times were required to 
achieve higher yields even though the presence of the ester group should, in theory, make the 
carbonyl carbon more electrophilic and hence more reactive. 
 
Scheme 9: Synthesis of dihydroperoxide 25 from 2-adamantanone 6. (i) 50% aq. H2O2, I2 
(10mol%), CH3CN, 24hrs, rt, 57%. 
 
 The synthesis was also carried out starting with 2-adamantanone 6 (Scheme 9) which 
gave a 57% yield of the corresponding dihydroperoxide 25. We decided against using this in 
tetraoxane formation with cyclohexanone as yields of tetraoxane produced were slightly 
lower (20%) than if the dihydroperoxide and carbonyl compounds were “reversed” (25%). 
Another reason is that 2-adamantanone 6 is approximately five times more expensive per 
gram than cyclohexanone 5 so there was no justification in using a more expensive substrate 
that gave lower overall yields. This investigation determined that iodine was the optimum 
catalyst for the synthesis of dihydroperoxides and this was the method of choice throughout 
this work. The authors proposed the following reaction mechanism: 
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Figure 14: Iodine-catalysed synthesis of dihydroperoxides.
23
  
 
3.5.2. Problems caused by the unstable nature of 1,1-dihydroperoxides 
 As discussed, dihydroperoxides are both thermally and chemically labile. It was found 
that on isolation after chromatography, decomposition of the dihydroperoxide back to the 
starting ketone could be seen by TLC after only one day when left to stand at room 
temperature. For this reason, dihydroperoxides were, initially, only synthesised and used 
immediately when needed. It was later found that when stored in the freezer at -18
o
C, 
dihydroperoxides were very stable and no decomposition to the starting ketones was observed 
for over two years. Following this discovery, dihydroperoxides were synthesised on a gram 
scale in batches and stored in the freezer to be used when required. It was found that 1-2g 
was the maximum scale in which the synthesis could be carried out safely and efficiently 
with reproducible yields.  
 
Chapter 3: Synthetic antimalarials - Dispiro-1,2,4,5-tetraoxanes 
76 
 
 On one occasion when the synthesis of 1,1-dihydroperoxycyclohexane was carried 
out on a larger scale using 5g of cyclohexanone, the reaction mixture spontaneously and 
exothermically decomposed in the flask before it could be purified by column 
chromatography. Another possible explanation for not being able to obtain yields higher than 
80% may be due to some decomposition occurring on silica gel. However, 2D TLCs showed 
that there was no decomposition on TLC plates so any decomposition that occurred on the 
column was assumed to be minimal. 
 
3.6. Synthesis of 1,2,4,5-tetraoxanes: Initial work on the synthesis of unfunctionalised 
tetraoxanes 
 Having optimised the synthesis of dihydroperoxides, we proceeded to use them in 
tetraoxane synthesis. The investigation with repeating a literature procedure by Ghorai and 
Dussault that used Re2O7 as a catalyst, to obtain familiarity with the procedure and get an 
indication of what yields to expect. The first reaction involved the condensation of 2-
adamantanone 6 with 1,1-dihydroperoxycyclohexane 23 (Scheme 10). 
 
Scheme 10: Condensation of 2-adamantanone 6 with 1,1-dihydroperoxycyclohexane 23. (i) 
Re2O7 (2mol%), DCM, rt, 1hr, 35%. 
 The literature yield for tetraoxane 21 was reported as 69%. We were unable to obtain 
yields as high as this on repetition and instead found that they were typically <35% and 25% 
would be a better approximation for this reaction. The yields were the same when the DCM 
had been freshly distilled prior to use or used as purchased. The use of molecular sieves in the 
reaction also had no effect on the yield obtained. The reasons for such poor yields are that 
although the ketone is used in slight excess (1.2-1.5eq), during the course of the reaction, 
some dihydroperoxide undoubtedly decomposes back to the starting ketone, some of it 
dimerises to form a symmetrical tetraoxane (can be seen on TLC) and the remainder reacts to 
give the desired tetraoxane product. 
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3.6.1. Tetraoxane synthesis using different samples of Re2O7 
 To confirm that the tetraoxane yields were not dependent on the batch of Re2O7 
catalyst used, we next used two different samples of Re2O7 in the reaction (Scheme 11). 
 
Scheme 11: Tetraoxane formation using different batches of Re2O7 catalyst. 
 
Entry Conditions (i) Result (followed by TLC) 
1 No catalyst No reaction 
2 Usual batch of Re2O7 (pale green) Gone to completion after 1hr 
3 Black Re2O7 (assumed to be inactive) Gone to completion after 4hrs 
 
Table 2: Results from monitoring reactions by TLC. 
 
 We concluded that the colour of the catalyst and its method of storage did not have 
any significant effect on the reaction (Table 2). The black catalyst, which had been stored at 
room temperature in air, was assumed to be inactive. It was in fact still active but less so than 
the usual batch of catalyst that had been stored under inert atmosphere in a desiccator. 
 
 
3.6.2. Attempted synthesis of a tetraoxane for use as a control in heme alkylation 
experiments 
 
 We thought it would be beneficial to synthesise a compound analogous to tetraoxane 
21 that did not have a peroxide bond. This would render it incapable of alkylating heme and 
is therefore able to act as a control (Figure 15) in heme alkylation experiments.  
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Figure 15: Target molecule 26 to be used as a control in heme alkylation experiments. 
 
 In 1973, a procedure reported by Yoon et al.
30
 showed that carboxylic acids could be 
reduced to the corresponding alcohols using BH3.THF. They showed that the reduction of 
phthalic acid using this method gave the diol in 95% yield (Scheme 12). 
 
 
Scheme 12: Reduction of phthalic acid to 1,2-phenylenedimethanol. (i) 2.39M BH3.THF 
(2.3eq), THF, 0
o
C-rt, 6hrs, 95%.  
 
 
 We were optimistic that this method would work with cyclohexane-1,1-dicarboxylic 
acid 27 and subsequent acetal formation with 2-adamantanone 6 would then yield the target 
control molecule 26 (Scheme 13). 
 
 
Scheme 13: Route to target control molecule 26. (i) 1.0M BH3.THF in THF (2.3eq), THF, 
0
o
C-rt, 6hrs (ii) 2-adamantanone 6, p-TSA (10mol%), toluene,  Dean Stark, 24hrs. 
 
 
 Initially, when 2.3 equivalents of BH3.THF were used, no reaction took place so 
another 1 equivalent was added. However, analysis by TLC and 
1
H NMR showed that no 
reaction had taken place. We decided to test this method on the reduction of benzoic acid and 
the reduction of phthalic acid (Scheme 14) to determine whether there was a problem with 
the procedure or if our starting substrate was not tolerated by these reaction conditions.  
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Scheme 14: Reductions of benzoic acid 29 and phthalic acid 31. (i) 1.0M BH3.THF in THF 
(2.3eq), THF, 0
o
C-rt, 6hrs. 
 
 
 The products for both reactions were not isolated but analysis by TLC and 
1
H NMR 
showed that the diol product was clearly present. This result inferred that our substrate could 
not be reduced under these reaction conditions rather than there being an issue with the 
procedure itself or any differences in experimental set-up. We imagine that the most likely 
reason for this reaction not working is that the boron atom in BH3.THF forms a complex 
between the two carboxylic acid groups using its empty p orbital, rendering it inactive.     
 
3.7. Tetraoxane synthesis using camphor and norcamphor 
 Having obtained low yields for adamantyl-derived tetraoxanes, we questioned 
whether or not the same result would be obtained if another bulky/hindered ketone was used 
in place of 2-adamantanone. We predicted that camphor and norcamphor (Figure 16) would 
be good alternatives because in theory, the tetraoxanes from these would form tertiary and 
secondary C-centred radicals respectively when alkylating heme.   
 
 
Figure 16: Structures of camphor and norcamphor. 
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 We first attempted synthesising the dihydroperoxides from camphor and norcamphor 
using iodine catalyst but in both cases, no product was isolated, which is most likely a result 
of decomposition either during the reaction or the purification process. We next attempted 
tetraoxane synthesis using camphor then norcamphor with 1,1-dihydroperoxycyclohexane but 
found that these reactions did not work at all. We were then intrigued by the possibility of 
using functionalised camphor/norcamphor derivatives in tetraoxane synthesis. If successful, 
this would provide an easily accessible route to bi-functional tetraoxanes as 
camphor/norcamphor can be easily functionalised via their corresponding enolates. 
 Tetraoxane synthesis using camphor was unsuccessful so we decided to use 
norcamphor instead, which is less bulky, achiral and very readily functionalised using a 
literature procedure.
31
 Norcamphor was pre-functionalised using different electrophilic 
substrates before it was used in tetraoxane formation (Scheme 15 and Table 3). 
 
Scheme 15: Functionalisation of norcamphor 94 followed by tetraoxane formation. 
 
Entry R =  Step (ii) Yield (%) Step (iii) yield (%) 
1 -CH2Ph 94 22 
2 -CO2H 69 0 
3 -CH2Ph-p-CO2Me 31 0 
 
Table 3: Tetraoxane synthesis using functionalised norcamphor derivatives. (i) LDA (1.1eq), 
THF, 0
o
C, 30min. (ii) Benzyl bromide (1.1eq) or CO2 (excess), THF, -78
o
C, 30min. (iii) 1,1-
Dihydroperoxycyclohexane (1eq), Re2O7 (2mol%), DCM, rt, 1hr. 
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 Norcamphor bearing a benzyl group 95 (Entry 1) gave its corresponding tetraoxane 98 
in 22% yield, which is comparable to the yields obtained from adamantane-derived 
tetraoxanes. The norcamphor substrates bearing acid 96 or ester functionality 97 (Entries 2 
and 3) failed to give any tetraoxane product. It was found that the Baeyer Villiger oxidation 
was also the major competing reaction pathway when norcamphor derivatives were used and 
dimerisation of the dihydroperoxide was taking place. The major product isolated was the 
lactone from oxidation of the starting ketone. For these reasons, we decided to abandon the 
use of norcamphor derivatives as we had encountered the same problems that were 
previously observed with adamantane derivatives. 
 
3.8. Synthesis of cyclohexyl-functionalised tetraoxanes for heme alkylation experiments  
 The syntheses of tetraoxanes bearing functional groups on the cyclohexyl moiety 
were carried out (Scheme 16). These compounds are direct analogues of trioxolanes 10 and 
11 (Chapter 2) synthesised within the O’Neil group. The application of these in heme 
alkylation experiments were to be carried out by the group of Dr. Abraham Esteve-Núñez, 
University of Alcalá de Henares. The results from these experiments are currently pending. 
 
 
Scheme 16: Synthesis of tetraoxanes bearing functionality on the cyclohexyl moiety. (i) 50% 
aq. H2O2 (3eq), I2 (10mol%), CH3CN, rt, 3 days, 71%. (ii) 2-Adamantanone (1.5eq), Re2O7 
(5mol%), DCM, rt, 5hrs, 43%. (iii) 15% aq. NaOH, MeOH, 65
o
C, 5hrs, H
+
, 97%.  
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3.9. Initial work on the synthesis of adamantyl-functionalised tetraoxanes 
 According to the mechanism of action of tetraoxanes, it is the adamantane moiety that 
alkylates the porphyrin ring in heme (Figure 17).   
 
 
Figure 17: Alkylation of porphyrin ring in heme by adamantane moiety of tetraoxane. 
 
 Having successfully carried out the synthesis of an unfunctionalised tetraoxane, we 
next applied the same procedure to several functionalised adamantanones (Scheme 17). They 
each had a functional group at the 5-position of the adamantanone to act as a synthetic handle 
for further transformations.  
 
Scheme 17: Attempted syntheses of adamantyl-functionalised tetraoxanes. (i) 1,1-
dihydroperoxycyclohexane 23 (1eq), Re2O7 (2mol%), DCM, rt, 4hrs.  
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 The Re2O7-catalysed tetraoxane synthesis was carried out using 1,1-
dihydroperoxycyclohexane 23 and four different 5-functionalised adamantanones (1.2-1.5eq). 
All of these reactions either did not give any of the desired tetraoxane products or negligible 
yields. In each case, we instead isolated the tetraoxane from dimerisation of the 
dihydroperoxide, and the lactone from Baeyer Villiger oxidation of the starting ketone as the 
major products (70-90% yield). Only 0.5 equivalents of the dihydroperoxide is required to 
oxidise one equivalent of the ketone to the lactone while one equivalent of dihydroperoxide is 
required to make one equivalent of the desired tetraoxane product. These results suggested 
that when there is an electron-withdrawing group (EWG) bonded directly to the adamantane 
skeleton; the Baeyer Villiger oxidation is favoured over tetraoxane formation.  
 We also attempted tetraoxane formation using 5-hydroxy-2-adamantanone bearing a 
TMS protecting group on the adamantyl alcohol 37 (Scheme 18). However, it was shown by 
1
H NMR and mass spectrometry that these reaction conditions caused the TMS group to fall 
off and no desired tetraoxane product was isolated. 
 
Scheme 18: Attempted tetraoxane formation using TMS-protected 5-hydroxy-2-
adamantanone. (i) Re2O7 (2mol%), DCM, rt, 4hrs, 0%. 
 
3.10. Initial attempts at synthesising functionalised adamantanes and adamantanones 
 We envisaged that the problem with the Baeyer Villiger oxidation taking place 
preferentially could be solved simply by replacing the electron-withdrawing group (EWG) 
with an electron-donating group (EDG). There is no literature precedent for the synthesis of 
such adamantane derivatives so our investigation began with the synthesis of functionalised 
1-bromoadamantane 39 derivatives. 
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3.10.1. SN1 reactions using water as a catalyst
32
 
 Following a literature procedure, water was used as a catalyst in an attempt to arylate 
1-bromoadamantane 39 with toluene (Scheme 19). Unfortunately, under both sets of reaction 
conditions, no desired product was isolated and all starting material was recovered. 
 
Scheme 19: Attempted arylation of 1-bromoadamantane 39 with toluene. (i) Water 
(24mol%), 120
o
C, 24hrs, 0% or dry glassware, N2 atmosphere, 120
o
C, 24hrs, 0%. 
 
3.10.2. Attempted Heck-type coupling reactions with 1-bromoadamantane
33, 34
 
 We next attempted Heck-type coupling reactions on 1-bromoadamantane 39 with 
various substrates (Table 4) but no desired products were isolated under these conditions. 
 
Entry Substrate X Conditions Yield (%) 
1 Styrene Pd/C, DMF, K2CO3, 120
o
C, 24hrs  0 
2 Toluene Pd/C, K2CO3, 120
o
C, 24hrs 0 
3 Toluene Pd(OAc)2, K2CO3, 120
o
C, 24hrs 0 
4 Acrylonitrile Pd(OAc)2, DMF, K2CO3, 145
o
C, 24hrs 0 
 
Table 4: Attempted Heck-type coupling reactions on 1-bromoadamantane 39. 
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3.10.3. Attempted arylation of 5-hydroxy-2-adamantanone using Amberlite

 resin 
 In 2012, Wang et al.
35
 reported the functionalisation of 1-adamantanol derivatives 
using Amberlite resin and different aryl substrates (Scheme 20). Amberlite is a strongly 
acidic cross-linked polystyrene-type sulfonic acid resin which can be recycled. The 
extraordinarily high yields obtained (reported as 98% after recrystallisation) for some of the 
reported compounds made this method appear very promising. 
 
Scheme 20: Arylation of 1-adamantanol derivatives using Amberlite resin. (i) Amberlite 
200, AcOH, 100
o
C, 2hrs, 66-98%.
35
 
 We aimed to find a flexible route towards a range of functionalised adamantanones 
using any aryl substrate, instead of developing a new synthetic route for each target 
compound. The scope of the reaction appeared to be rather limited but reaction times were 
short and yields were high. We therefore applied the Amberlite chemistry in an attempt to 
functionalise 5-hydroxy-2-adamantanone 7. Before the Amberlite could be used, it had to 
be dried. It was first stirred in 20% conc. H2SO4 overnight, washed with water then THF and 
dried under vacuum over P2O5 for 1 day. It was then used in reactions with 5-hydroxy-2-
adamantanone 7 with phenol and trifluorophenylacetamide (Scheme 21). 
 
Scheme 21: Attempted Amberlite catalysed arylation of 5-hydroxy-2-adamantanone. (i) 
Amberlite 200, AcOH, 100oC, 24hrs, 0% desired product, 79% 4-oxoadamantan-1-yl 
acetate 41, 20% phenylacetate 42. 
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 Unfortunately, both of these reactions failed to give any arylated product. We instead 
isolated the esters of both starting materials, which, in hindsight, was not surprising as acetic 
acid was the solvent used for both reactions. 
 
3.11. Friedel Crafts arylations of 1-bromoadamantane and 5-bromo-2-adamantanone 
3.11.1. Friedel Crafts arylation of 1-bromoadamantane 
 In 2004, Su et al.
36
 reported the synthesis of functionalised adamantane derivatives 
using Friedel Crafts chemistry employing FeCl3. We first decided to obtain familiarity with 
and test the scope of this procedure by synthesising several functionalised adamantane 
derivatives. To do this, we carried out Friedel Crafts arylations of 1-bromoadamantane 39, 
which is commercially available, inexpensive and has a similar structure to 5-bromo-2-
adamantanone 36 (Table 5). 
 
Entry R = FeCl3 (eq) Ortho : Para Yield (%) 
1 -Me 0.08 Para only 83 
2 -OMe 0.08 1 : 1.5 5 
3 -Br 0.08 1 : 7 25 
4 -OMe 1.5 Para only 99 
5 -Br 1.5 1 : 5 86 
 
Table 5: Friedel Crafts arylations of 1-bromoadamantane 39. Ratios of regioisomers of the 
product were estimated by 
1
H NMR analysis. 
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 Due to steric considerations in further transformations, we wished to obtain only the 
para-substituted products in these investigations. Entry 1, the Friedel Crafts arylation of 1-
bromoadamantane with toluene, catalysed by FeCl3 was taken from a procedure by Su et al.
36
 
and the yield of 83% was promising, which encouraged us to investigate other aryl substrates. 
When anisole (Entry 2) and bromobenzene (Entry 3) were used, not only did the yields drop 
significantly but the products were isolated as inseparable mixtures of ortho/para isomers. 
This may be caused by the aryl substrate co-ordinating to the catalytic amount of FeCl3, 
which in turn hinders the reaction. However, when 1.5 equivalents of FeCl3 are used, the 
yields increased dramatically (Entries 4 and 5) but the selectivity of the products also 
changed. We currently do not have an explanation for the differences in these results. We 
propose that further work involving a wider range of aryl substrates should be investigated to 
determine the reasons behind the differences in yield and selectivity for this reaction. 
 
3.11.2. Attempted synthesis of 5-bromo-2-adamantanone 
 We next wanted to investigate the Friedel Crafts arylation of 5-bromo-2-
adamantanone 36. This is commercially available but also very expensive and we wanted to 
establish whether or not it could be synthesised from 1-bromoadamantane.  
 In 1968, Geluk and Schlatmann
37
 and then in 1973, Geluk and Keizer
38
 reported the 
oxidation of adamantane 45 to 2-adamantanone 6 using 98% H2SO4, where the intermediate 
was found to be an equilibrium between 1-adamantanol 46 and 2-adamantanol 47 (Scheme 
22). There were two possible reaction pathways observed; the oxidation of 2-adamantanol 
gave 2-adamantanone or a disproportionation reaction gave a mixture of 2-adamantanone 
from oxidation of 2-adamantanol, and adamantane from reduction of adamantanol.  
 
Scheme 22: Oxidation of adamantane 45. (i) 98% H2SO4, 80
o
C, 4hrs, 47%. 
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 We envisaged that the same conditions could be applied to oxidise 1-
bromoadamantane 39 to 5-bromo-2-adamantanone 36 (Scheme 23) where the intermediates 
formed should be an equilibrium between 5-bromo-1-adamantanol and 5-bromo-2-
adamantanol. Unfortunately, this reaction was unsuccessful and gave a black tar-like 
substance. 
 
Scheme 23: Attempted oxidation of 1-bromoadamantane 39 to 5-bromo-2-adamantanone 36. 
(i) 98% H2SO4, 80
o
C, o/n, 0%. 
 
3.11.3. Friedel Crafts arylation of 5-bromo-2-adamantanone 
 With encouraging results from the Friedel Crafts arylation of 1-bromoadamantane 39 
in hand, we next investigated the Friedel Crafts arylations of 5-bromo-2-adamantanone, 
which is more relevant for this work (Scheme 24). 
 
Scheme 24: Synthesis of 5-bromo-2-adamantanone 36. (i) 100% HNO3, 3 days, rt, 52%. (ii) 
48% HBr, , 24hrs, 60%.  
 
 2-Adamantanone 6 (commercially available) was oxidised to 5-hydroxy-2-
adamantanone 7 using 100% nitric acid
39
 by a post-doctoral researcher in the O’Neil group 
on a 25g scale. 5-Hydroxy-2-adamantanone 7 (1-2g was found to be the optimum scale) was 
then brominated by refluxing in hydrobromic acid overnight
40
 to afford 5-bromo-2-
adamantanone 36 in 52% yield. The Friedel Crafts arylation of 5-bromo-2-adamantanone 36 
was then carried out using a variety of aryl substrates (Table 6). 
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Entry R = FeCl3 (eq.) Ortho : Para :  Meta Yield (%) 
1 -Me 0.08 - Not isolated 
2 -Me 0.22 - Not isolated 
3 -Me 1.0 - Not isolated 
4 -Me 1.5 1 : 10 : 0 93 
5 -OMe 1.5 2.6 : 1 : 0 27 (p) 67 (o) 
6 -Br 1.5 Para only 76 
 
Table 6: Optimisation of conditions for Friedel Crafts arylation of 5-bromo-2-adamantanone. 
 We began the investigation by using literature conditions reported for the arylation of 
1-bromoadamantane with 0.08 equivalents FeCl3 (Entry 1). On monitoring by TLC, this led 
to incomplete conversion of starting material and the same result was observed on increasing 
to 0.22 equivalents and 1.0 equivalent (Entries 2 and 3). When 1.5 equivalents of FeCl3 was 
used (Entry 4), the reaction went to completion but the product was formed as a mixture of 
ortho/para isomers that were inseparable by column chromatography. By using a more 
electron rich aryl substrate, anisole (Entry 5), we managed to obtain a mixture of isomers that 
were separable by column chromatography. However, the desired para-substituted product 49 
was the minor isomer at only 27% yield. When bromobenzene was used (Entry 6), the 
product 50 was obtained as the para isomer only in a good yield. This was a critical result as 
we now had an adamantanone derivative with suitable functionality at the 5-position that 
could be used in tetraoxane synthesis. 
 Having used the same substrates for Friedel Crafts arylation of 1-bromoadamantane 
39 and 5-bromo-2-adamantanone 36, we noticed a dramatic change in selectivity that was 
dependent on the presence of the ketone (comparing Entries 4 and 5, Table 5 with Entries 5 
and 6, Table 6) having kept the reaction conditions the same. We have yet to establish a 
plausible explanation for this observation. 
 
Chapter 3: Synthetic antimalarials - Dispiro-1,2,4,5-tetraoxanes 
90 
 
3.11.4. Testing the scope of the Friedel Crafts arylation of 5-bromo-2-adamantanone 
 To investigate the scope of the optimised conditions for the Friedel Crafts arylation, 
we carried out this reaction using a range of solid and liquid aryl substrates (Table 7). Having 
only used liquid aryl substrates as the solvent for reaction so far, we hoped that the scope 
would also include solid aryl substrates. We aimed to find at least one arylated adamantanone 
was capable of undergoing further transformations and could also be obtained in good yield. 
 
 
Entry R = Solvent Ortho : Para : Meta Yield (%) 
1 -CH2Br  51 - - Polymerised 
2 -NH2  52 - - No reaction 
3 -NHBoc  53 CHCl3/DCM - Decomposed 
4 -NHCOCH3  54 CHCl3/DCM - No reaction 
5 -NHCOCF3  55 CHCl3/DCM - No reaction 
6 -OH
36
  56 - - Decomposed 
7 -CH=CH2  57 - - Polymerised 
8 -CO2Me  58 - Meta only 65 
9 -OPh  59 - Para only 30 
10 -H  60 - - 69 
11 -OPh-p-CCH  61 - - Decomposed 
 
Table 7: Scope of optimised Friedel Crafts arylation. 
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 The general result was that most aryl substrates decomposed, polymerised or did not 
react at all under these conditions. The ones that did react (Entries 8-10) gave single isomers 
of the arylated products. It appears that only liquid aryl substrates that can be used as the 
solvent at reflux temperatures will afford arylated adamantanones (either as mixtures of 
isomers or single isomers) using this method. There has been great difficulty in finding a 
suitable solvent to use in this reaction with solid aryl substrates. Both chloroform and DCM 
were tried but these have boiling points that are far below the temperatures required for the 
Friedel Crafts arylation to take place. The choice of solvents that are high boiling but at the 
same time will not interfere with the Friedel Crafts reaction is very limited. 5-Phenyl-2-
adamantanone 60 (Entry10) was obtained in 69% yield. Nitration of the phenyl ring was 
attempted using NO2BF4 in DCM at 0
o
C but no reaction occurred. Theoretically, this would 
have been the most direct route to an amine-functionalised adamantanone derivative, capable 
of further transformations. However, as benzene is required for the synthesis of 5-phenyl-2-
adamantanone 60, we did not deem this to be a long term feasible route towards large scale 
production of bi-functional molecular wires.  
3.11.5. Solvent screen for Friedel Crafts reaction using a solid aryl substrate 
 We next carried out a solvent screen (Table 8) in an attempt to find one suitable for 
use with acetanilide, a solid aryl substrate, in the Friedel Crafts reaction. 
 
Entry Solvent T (
o
C) 
1 DCM 40 
2 CHCl3 80 
3 1,2-Dichloroethane 85 
4 DMF 130 
 
Table 8: Solvent screening for Friedel Crafts reaction using acetanilide as the solid aryl 
substrate. (i) FeCl3 (1.5eq), solvent, T
o
C, 24hrs, 0%. 
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 Of all the solvents that were screened (Entries 1-4), no desired product could be 
isolated because no reaction occurred. We therefore decided to not pursue this any further 
and continue by taking forward the suitable arylated products (Entry 6, Table 5 and Entries 
8-10, Table 6) for tetraoxane synthesis. 
 
3.11.6. Attempted silyl protection of aniline before Friedel Crafts arylation 
 The simplest route to a suitable compound for aryl diazonium formation would be to 
functionalise adamantanone 6 with aniline 62 or an aniline derivative, which can then be used 
in tetraoxane formation. The reaction was unsuccessful when aniline was used directly in the 
Friedel Crafts arylation so we next decided to protect the aniline with a hindered silyl group 
first before attempting the arylation again (Scheme 25). However, crude 
1
H NMR of the 
reaction mixture showed that only aniline was present. It is thought that the silyl protecting 
group was hydrolysed during the course of the reaction or when exposed to air at the end.  
 
Scheme 25: Attempted silyl protection of aniline 62. (i) NEt3 (2eq), dry DCM, rt, 2hrs, 0%.
41
 
 
3.12. Synthesis of 5-(4-bromophenyl)adamantan-2-one starting from 5-hydroxy-2-
adamantanone 
 Before moving on to tetraoxane synthesis, we wanted to reduce the number of steps 
towards functionalised adamantanones. A route to 5-(4-bromophenyl)adamantan-2-one 50 
starting from 5-hydroxy-2-adamantanone 7 was sought after. This would eliminate the need 
to synthesise 5-bromo-2-adamantanone 36 first and hence reduce the amount of material lost. 
We envisaged that an acid would protonate the alcohol in 5-hydroxy-2-adamantanone 7 to 
give water as a leaving group and generate a tertiary carbocation that could react with 
bromobenzene. Several acids were screened in the optimisation stage (Table 9). 
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Entry Acid (1eq) Yield (%) 
1 p-TSA 0 
2 Conc. H2SO4 0 
3 TFA
42
 0 
4 TfOH
43
 59  
 
Table 9: Synthesis of 5-(4-bromophenyl)adamantan-2-one 50 from 5-hydroxy-2-
adamantanone 7 in one step. (i) Acid (1eq), bromobenzene, , 1-20hrs. 
 
 Triflic acid (Entry 4) was found to be the optimum choice, giving 5-(4-
bromophenyl)adamantan-2-one 50 in 59% in one step starting from 5-hydroxy-2-
adamantanone 7. When the synthesis was carried out in two steps previously, starting with 
bromination of 5-hydroxy-2-adamantanone 7 and subsequent Friedel Crafts arylation of 5-
bromo-2-adamantanone 36, the yield over both steps was only 40%.   
 
3.12.1. Testing the scope of the adamantyl arylation using triflic acid 
 Having had success with synthesising 5-(4-bromophenyl)adamantan-2-one 50 using 
triflic acid, we wanted to determine the scope of this method when carried out in a 
chlorinated solvent (Scheme 26).  
 
Scheme 26: Attempted triflic acid catalysed arylation of 5-hydroxy-2-adamantanone 7. (i) 
TfOH (1eq), benzyl bromide/aniline/allyl bromide (1.5eq), CHCl3, 70
o
C, 24hrs, 0%.  
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 We attempted the arylation using benzyl bromide and then aniline in chloroform but 
unfortunately, both reactions failed to give any product. In the case of benzyl bromide, we 
believe that the benzylic cation may have formed in preference to the tertiary cation of 2-
adamantanone, preventing the desired arylation reaction from taking place.  
 In the case of aniline, we assumed that the reflux temperature of the solvent was not 
high enough to allow the reaction to proceed, which was the same problem in the Friedel 
Crafts arylations. Under the strongly acidic conditions, it is very likely that aniline was 
simply protonated by the acid, rendering it unreactive. The reason for no reaction taking place 
with allyl bromide could be due to temperatures not being high enough or allyl bromide itself 
being rather unreactive.  
 
3.13. Synthesis of novel adamantyl-functionalised tetraoxanes 
 The functionalised adamantanones from the optimised Friedel Crafts arylation that 
gave single isomers of the products were taken forward for tetraoxane synthesis using Re2O7 
catalyst (Table 10). 
 
Entry R
1
 = R
2
 = Yield (%) 
1 -H    6 -CO2Et    24 43    33 
2 -H    6 -H    23 25-35    21 
3 -Ph-p-Me    48 -CO2Et    24 38 (mixture o/p isomers)    64 
4 -Ph-p-Br    50 -CO2Et    24 24    65 
5 -Ph-p-Br    50 -H    23 9    66 
6 -Ph-m-CO2Me    58 -CO2Et    24 14    67 
7 -Ph-m-CO2Me    58 -H    23 8    68 
8 -Ph-p-OPh    59 -H    23 8    69 
 
Table 10: Yields of adamantyl-functionalised tetraoxanes, synthesised using 1 equivalent of 
the dihydroperoxide and 1.2 equivalents of the adamantanone derivative. 
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 These results suggested that tetraoxane yields are significantly higher when there was 
no functionality on the adamantyl skeleton (Entries 1 and 2). When there was an electron 
withdrawing group present with a phenyl ring acting as an electron-rich “spacer group”, 
tetraoxane yields decreased to as low as 8% (Entries 5-8). With entry 4 giving the highest 
yield for the adamantyl-functionalised tetraoxanes in this investigation, we strived to further 
increase the yield by slightly altering the reaction conditions used in the Re2O7-catalysed 
reaction (Table 11).  
 
Entry DHP (mg) Conditions A (%) B (%) C (%) D (%) 
1 25 rt, 4hrs 35 - - - 
2 200 rt, 4hrs 24 10 3 53 
3 200 0
o
C 2hrs, rt 2hrs 34 35 3 25 
 
Table 11: Yields of bromophenyl-tetraoxane and side products. 
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3.14. Experiments to determine if concentration of dihydroperoxide affected tetraoxane 
yields 
 Having found that temperature has some effect on the yield of tetraoxane obtained, we 
next investigated the effect of concentration of the starting dihydroperoxide (Table 12). 
 
Entry Mass of 24 (mg) DCM (ml) Conc
n
 of DHP (mg/ml) Yield of 65 (%) 
1 30 15 2 42 
2 40 20 2 35 
3 200 25 8 24 
4 200 100 2 24 
 
Table 12: Yields of tetraoxane from varying concentrations of dihydroperoxide. 
 
 Entries 1, 2 and 4 used 2mg of dihydroperoxide per millilitre of DCM and the yields 
all varied due to differences in scale of the reactions carried out and errors associated with 
smaller scale reactions. Entry 3 used 8mg of dihydroperoxide per millilitre of DCM and the 
yield obtained was the same as in entry 4, on the same scale. This result confirmed that the 
concentration of the starting dihydroperoxide does not affect the yield of tetraoxane obtained.  
 
3.15. PMA-catalysed tetraoxane formation 
 This prompted us to search for a better method of tetraoxane synthesis. A procedure 
from 2011 by Yan et al.
28
 used PMA catalyst for tetraoxane formation in DCM with MgSO4 
as the drying agent (Scheme 8). We next compared yields of tetraoxanes obtained from the 
Re2O7-catalysed method with those from the PMA-catalysed method (Table 13).  
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Entry R
1
 R
2
 Catalyst DHP (eq.) Yield (%) 
1 -H    6 -CO2Et    24 Re2O7 1 43    33 
2 -H    6 -CO2Et    24 PMA 1 85 (lit. 91)    33 
3 -H    6 -CO2Et    24 PMA 2 73    33 
4 -Ph-p-Br    50 -CO2Et    24 Re2O7 1 24    65 
5 -Ph-p-Br    50 -CO2Et    24 PMA 1 37    65 
6 -Ph-p-Br    50 -CO2Et    24 PMA 2 42    65 
7 -Ph-m-CO2Me    58    -H    23 Re2O7 1 8    68 
8 -Ph-m-CO2Me    58 -H    23 PMA 1 14    68 
9 -Ph-m-CO2Me    58 -H    23 PMA 2 22    68 
 
Table 13: Comparison of tetraoxane yields obtained with Re2O7 and PMA catalysts.  
 
 Entries 1, 4 and 7 are results from Table 10. Entries 2, 5 and 8 used 1 equivalent of 
dihydroperoxide, 1.2 equivalents of functionalised adamantanone and PMA catalyst in DCM 
with MgSO4 as a drying agent. In all cases, the yields obtained from the PMA-catalysed 
reactions were far superior to those from the Re2O7-catalysed reactions and for entry 2; we 
managed to obtain a yield of 85%, which is very close to the literature yield of 91%.  
 Entries 3, 6 and 9 involved the same reaction conditions as before, but an excess of 
dihydroperoxide was used. When TLC analysis showed that the first equivalent had all 
reacted, a second equivalent was added. This was to compensate for any 
decomposition/dimerisation that had taken place with the first equivalent.  
 For entry 3, the use of excess dihydroperoxide caused a slight drop in tetraoxane yield 
but for entries 6 and 9, yields were increased slightly. However, the yields of the adamantyl-
functionalised tetraoxanes were still not as high as desired because the Baeyer Villiger 
oxidation (though now somewhat suppressed compared with the Re2O7-catalysed reactions) 
was still taking place. 
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3.15.1. Solvent screening for PMA-catalysed tetraoxane formation 
 Having found that PMA was a better catalyst for tetraoxane fomation than Re2O7, we 
next decided to carry out a solvent screening with the aim of finding one that suppressed the 
Baeyer Villiger oxidation side reaction and produced equally high yields of the tetraoxane as 
when DCM is used (Table 14).  
 
Entry Solvent Yield of tetraoxane 33 (%) 
1 DCM 85 
2 Et2O 40 
3 CHCl3 30 
4 MeOH 0 
5 Toluene 40 
6 DCM/Hexane (1:10) 50 
 
Table 14: Solvent screening for PMA-catalysed tetraoxane formation. (i) PMA (2mol%), 
MgSO4 (1.5eq), solvent, rt, 4hrs. 
 
 The results showed no correlation between yield and polarity of solvent. The huge 
difference between yields obtained in DCM and CHCl3 (Entries 1 and 3) does not explain 
why one chlorinated solvent is preferred over the other. A mixture of solvent using a 
minimum amount of DCM in hexane (Entry 6) gave an intermediate yield, which also 
suggests that solvent polarity has no effect. These results are currently inconclusive and 
further work involving more solvents or solvent mixtures are required to determine if any 
trends can be seen.  
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3.16. Further transformations on adamantyl-functionalised tetraoxanes – organolithium 
chemistry  
 We continued our investigation by taking tetraoxane 65 and carrying out further 
transformations in an attempt to incorporate an amine group that could then be converted to a 
diazonium group for attachment to a carbon surface. We began our studies with 
organometallic chemistry. We envisaged that lithium-bromine exchange could be carried out 
on tetraoxane 65 (Scheme 27) and the resulting organolithium intermediate 70 could then be 
trapped out with a suitable electrophile to give the desired functionalised tetraoxane 71. 
 
 
Scheme 27: Lithium-bromine exchange with bromophenyl-functionalised tetraoxane 65. 
 However, according to literature precedent, this chemistry has never been applied to 
tetraoxanes and there were a few issues regarding possible side reactions that needed to be 
addressed before continuing (Figure 18).  
 
Figure 18: Possible side reactions when carrying out lithium-bromine exchange. 
 Firstly, it was not known whether the peroxide bond in the tetraoxane was stable to 
organolithiums and how likely it was for fragmentation to occur if lithium co-ordinated to the 
oxygen(s). Secondly, the ester group at the 4’-position of the cyclohexyl moiety could hinder 
lithium-bromine exchange by reacting with the organolithium reagent itself.  
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3.16.1. Experiments to determine stability of tetraoxane in the presence of nBuLi 
 Lithium-bromine exchange experiments were carried out on the bromophenyl-
functionalised tetraoxane 65 in THF at -78
o
C using freshly titrated nBuLi and the reactions 
were monitored by TLC until no more starting material could be seen (Table 15).  
 
Entry nBuLi (eq.) Result of lithium-bromine exchange 
1 1.0 Does not reach completion. 
2 1.5 Does not reach completion. 
3 2.0 Reaches completion but some fragmentation also seen. 
4 3.0 Further fragmentation. 
 
Table 15: Results from lithium-bromine exchange experiments using freshly titrated nBuLi. 
 
 There was great difficulty in finding the exact number of equivalents of nBuLi to use 
that would allow lithium-bromine exchange to reach completion but at the same time, would 
not cause any fragmentation to take place. However, it is important to note that in all cases, 
1
H NMR spectra showed that the ester group on the tetraoxane remained intact, which 
confirmed that it does not interfere with lithium-bromine exchange and the reactivity of 
tetraoxanes towards organolithiums is affected by involvement of the peroxide bond. 
 
3.16.2. Lithium-bromine exchange experiments involving electrophiles 
 We decided to use 2 equivalents of nBuLi in lithium-bromine exchange reactions that 
also involved electrophiles; CO2 and benzophenone, to determine the extent to which the 
intermediate debrominated  species 70 reacted (Scheme 28).  
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Scheme 28: Lithium-bromine exchange followed by reaction with electrophile. (i) nBuLi 
(2eq), THF, -78
o
C, 20min, (ii) CO2 (excess) or benzophenone (1 eq), -78
o
C, 45min, H
+
, 0%.  
 
 TLC analysis for both reactions showed that lithium-bromine exchange had gone to 
completion, but a lot of fragmentation had also occurred. Separation of the components by 
column chromatography allowed us to obtain mass spectra for each, which confirmed that no 
desired product was present. From these results, we concluded that: 
1. The peroxide bond in the tetraoxane is (to some extent) co-ordinating to the 
organolithium and hindering/preventing lithium-bromine exchange from taking place. 
2. nBuLi is far too reactive to use in these experiments and could be forming polymeric 
aggregates, which would prevent lithium-bromine exchange from taking place. 
3. Although nBuLi was freshly titrated before use each time, the titres varied by more 
than 0.01M, which meant that the concentration was never known precisely. As a 
result of this, there was difficulty in finding the number of equivalents of nBuLi 
required for lithium-bromine exchange without causing fragmentation of the 
tetraoxane, which suggests that a milder reagent should be used. 
4. There was difficulty in finding a suitable electrophile to trap out the intermediate 
organolithium species with (if any of it had formed) under these reaction conditions. 
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3.16.3. Experiments using iPrMgCl in place of nBuLi 
 We next used chemistry developed by Knochel,
44
 employing a Grignard reagent, 
iPrMgCl. This is a milder and less reactive reagent than nBuLi and we predicted that it would 
allow magnesium-bromine exchange to take place but not cause too much fragmentation of 
the tetraoxane. We performed two experiments, one at -78
o
C and another at room 
temperature. One equivalent of iPrMgCl was added to the tetraoxane and allowed to stir at 
the specified temperature for 2hrs with monitoring by TLC (Scheme 29). 
 
Scheme 29: Attempted magnesium-bromine exchange on tetraoxane 65. (i) iPrMgCl (1eq), 
THF, -78
o
C or rt, 2hrs.
44
  
 
 The results of these experiments showed that no reaction had taken place at either 
temperature. We assumed that iPrMgCl, being less reactive than nBuLi, may have either 
completely co-ordinated to the peroxide bridge of the tetraoxane or formed 
dimeric/polymeric aggregates and had not reacted at all. 
 
3.16.4. Experiment using a “TurboGrignard”: iPrMgCl.LiCl44 
 Knochel had a solution to this problem of aggregation by using lithium salts. The 
Grignard reagent forms a complex with the lithium salt. This helps break up any aggregation 
and allows reaction with an electrophile to take place (Scheme 30). The resulting 
“TurboGrignard” is more reactive towards electrophiles than the standard Grignard reagent. 
 
Scheme 30: Lithium chloride breaks up polymeric aggregates formed by Grignard reagent. 
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 Magnesium-bromine exchange was attempted on tetraoxane 65 using the 
“TurboGrignard” (Scheme 31) but unfortunately, monitoring by TLC showed that no 
reaction had taken place. 
 
Scheme 31: Attempted magnesium-bromine exchange using the “TurboGrignard”. (i) 
iPrMgCl.LiCl (1eq), THF, -15
o
C, 20mins, 0%. 
 
 As it appeared that aggregation and co-ordination to the peroxide bond of the 
tetraoxane was the main cause of unsuccessful reactions, we predicted that a more hindered 
“TurboGrignard” reagent would solve both of these problems.  
 
3.16.5. Experiment using a “TurboGrignard”: TMPMgCl.LiCl45 
 One of Knochel’s more hindered “TurboGrignard” reagents was synthesised from 
TMP and iPrMgCl.LiCl (Scheme 32). The “TurboGrignard” was then added to the tetraoxane 
65 in THF and allowed to stir at room temperature. Once again, monitoring by TLC showed 
that no reaction had taken place after one day. 
 
 
Scheme 32: Synthesis of TMPMgCl.LiCl. (i) THF, rt, 24hrs. 
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3.17. Attempted electrophilic amination on bromophenyl-functionalised tetraoxane 
 Having had very little success in using organometallic chemistry to further 
functionalise our tetraoxane, we decided to try a different approach. The next method that 
was attempted to incorporate amine functionality in our tetraoxane was a modified 
electrophilic amination. This involved methoxyamine with organolithium compounds or 
Grignard reagents and was first developed by Schverdina and Kotscheschkow in 1938 then 
later modified by Beak and Kokko in the 1980s (Schemes 33 and 34).  
 
 
Scheme 33: Electrophilic amination using methoxyamine and organometallic reagents.
46
  
 
 
Scheme 34: Modified electrophilic amination.
47, 48
  
 
 However, this was unsuccessful when the reaction was carried out using the 
bromophenyl-functionalised tetraoxane 65. The reason for this was that only MeONH2.HCl is 
commercially available and making the free-base was not achievable as the solvent required 
for the procedure was DCM, which has the same boiling point as MeONH2 so separation of 
the two components would not have been possible. In an attempt to overcome this problem, 
two equivalents of nBuLi were added to MeONH2.HCl in an attempt to “free-base” it to make 
the lithium-methoxyamine species in situ before addition of the tetraoxane. Regrettably, it 
remained insoluble in THF even after sonication so this was not investigated any further. 
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3.18. Attempted aminations using Pd chemistry  
 Having had no success with further transformations on the bromophenyl-tetraoxane, 
we decided to try and first functionalise the synthetically more accessible and higher yielding 
precursor, 5-(4-bromophenyl)adamantan-2-one then carry out tetraoxane formation 
afterwards. We began our investigation with Pd-catalysed aminations, developed by 
Buchwald. We first used benzophenone imine (Scheme 35) as a surrogate for ammonia. 
Benzophenone imine degraded on TLC, which initially gave the impression that the reaction 
had proceeded but NMR analysis confirmed that no reaction had taken place. 
 
Scheme 35: Attempted amination of 5-(4-bromophenyl)adamantan-2-one 50 using 
benzophenone imine. (i) Pd2(dba)3 (1mol%), NaO
t
Bu, BINAP, toluene, 80
o
C, 24hrs.
49
  
 
 We next attempted an amination using ammonia (Scheme 36) but once again, only 
starting material was obtained.   
 
Scheme 36: Attempted amination of 5-(4-bromophenyl)adamantan-2-one 50. (i) Pd2(dba)3 
(1mol%), Ligand (5mol%), 0.5M NH3 in dioxane (5eq), NaO
t
Bu, 1,4-dioxane, 80
o
C, 24hrs.
50
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 Both reactions attempted used the literature conditions and they failed to work on our 
bulky substrate. It would have been very difficult (costly and time consuming) to find the 
optimal combination of Pd source, ligand, base, solvent and temperature that would allow our 
substrate to react in good yield so we decided not to pursue this any further. 
3.19. Attempted amination using Cu2O catalyst  
 We next attempted a copper-catalysed amination (Scheme 37) using aqueous 
ammonia. This did not proceed as expected because the mixture turned a blue colour, an 
indication that the copper catalyst had formed a tetra-amine complex, [Cu(NH3)4(H2O)2], 
rendering it inactive. 
 
Scheme 37: Attempted Cu-catalysed amination of 5-(4-bromophenyl)adamantan-2-one 50.         
(i) aq. NH3, Cu2O (5mol%), 1:1 H2O:NMP, 80
o
C, 24hrs.
51
 
3.20. Attempted Suzuki cross coupling reaction 
 We next carried out a Suzuki cross coupling reaction on 5-(4-
bromophenyl)adamantan-2-one using phenylboronic acid (Scheme 38). This reaction did not 
produce any desired product 76 and instead, 1,1’-biphenyl 77 was isolated in 10% yield with 
the majority of the starting ketone 50. 
 
Scheme 38: Attempted Suzuki cross coupling. (i) Pd(OAc)2 (5mol%), K2CO3, acetone/water 
10:1, 60
o
C, 4hrs, 0%.
52
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3.21. Attempted Sonogashira cross coupling reactions
53
  
 We next attempted a Sonogashira cross coupling reaction on 5-(4-
bromophenyl)adamantan-2-one 50 using phenylacetylene (Scheme 39). After leaving the 
reaction overnight, TLC analysis showed that only starting material was present. 
 
Scheme 39: Attempted Sonogashira cross coupling. (i) PdCl2(PPh3)2 (5mol%), CuI (3mol%), 
iPr2NH, 80
o
C, o/n. 
 
 There was a possibility that the presence of the ketone was somewhat hindering the 
reaction. To confirm whether or not this was the case; we decided to protect the ketone to 
determine if the reaction gave the same result as above and indeed it did (Scheme 40). From 
this, we could conclude that it was not an electronic effect hindering the reaction and may 
possibly be due to steric bulk of the adamantyl skeleton. 
 
Scheme 40: Protection of ketone followed by attempted Sonogashira coupling. (i) p-TSA 
(10mol%), ethylene glycol, toluene,  Dean Stark, 24hrs, 89%. (ii) PdCl2(PPh3)2 (5mol%), 
CuI (3mol%), iPr2NH, 80
o
C, o/n, 0%. 
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3.22. Attempted lithium-bromine exchange on 5-(4-bromophenyl)spiro[adamantane-
2,2'-[1,3]dioxolane] 
 We next attempted lithium-bromine exchange on the protected ketone, 5-(4-
bromophenyl)spiro[adamantane-2,2'-[1,3]dioxolane] 79 using one equivalent of nBuLi and 
trapped out the organolithium intermediate using benzyl bromide (Scheme 41). Mass 
spectrometry confirmed that this reaction was unsuccessful. It was assumed that benzyl 
bromide was not a good enough electrophile to use in this reaction. 
 
Scheme 41: Attempted lithium-bromine exchange and subsequent trapping with benzyl 
bromide. (i) nBuLi (1eq), -78
o
C, 30mins. (ii) Benzyl bromide (1eq), -78
o
C, 30mins, 0%. 
 
 We carried out lithium-bromine exchange again using freshly distilled benzaldehyde 
(more reactive than benzyl bromide) as the electrophile (Scheme 42). However, mass 
spectrometry confirmed that this reaction had also failed to give any desired product.  
 
Scheme 42: Attempted lithium-bromine exchange and subsequent trapping with 
benzaldehyde. (i) nBuLi (1eq), -78
o
C, 30mins. (ii) Benzaldehyde (1eq), -78
o
C, 30mins, 0%. 
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3.23. Synthesis of tetraoxanes with meta-substituted aromatic rings 
 Having had no success in carrying out further transformations on the bromophenyl-
tetraoxane 65 and 5-(4-bromophenyl)adamantan-2-one 50, we decided to not continue with 
these substrates and use a different functionalised adamantanone from our Friedel Crafts 
optimisation reactions.  
 We envisaged that the optimal choice was methyl 3-(4-oxoadamantan-1-yl)benzoate 
58. As this possessed an ester group on the meta-position of the aromatic ring, we predicted 
that there would not be a great deal of difference in terms of steric crowding compared with 
having functionality at the para-position. This would also solve the problem of obtaining 
functionalised adamantanones as inseparable mixtures of ortho/para isomers and avoid the 
use of organometallic or palladium chemistry for further functionalisation. As ester groups 
are strongly deactivating, the Friedel Crafts arylation of 5-bromo-2-adamantanone 36 with 
methyl benzoate required longer reaction times and higher temperatures than its electron rich 
counterparts. The yields also tended to vary on repetition (Scheme 43).  
 
Scheme 43: Friedel Crafts arylation of 5-bromoadamantan-2-one 36 using methyl benzoate. 
(i) FeCl3 (1.5eq), PhCO2Me, 170
o
C, 3 days, 45-65%. 
 
   We next carried out base hydrolysis of the ester to give the corresponding carboxylic 
acid 84 (Scheme 44). This opened up the possibility of an amide coupling reaction with 
phenylenediamine. The product from this could then be used in tetraoxane formation and 
subsequent synthesis of the aryl diazonium (or vice versa) would generate a suitable 
compound for binding to a carbon surface. 
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Scheme 44: Base hydrolysis of methyl 3-(4-oxoadamantan-1-yl)benzoate. (i) 15% aq. NaOH, 
MeOH, 65
o
C, 6hrs, H
+
, 66%. 
 
3.23.1. Tetraoxane formation using adamantanones bearing meta-substituted aromatic 
rings 
 Tetraoxane formation using adamantanone derivatives 58 and 84 was carried out 
(Table 16). 
 
Entry R =  Yield (%) 
1 -CO2Me   58 14   67 
2 -CO2H   84 73 (inseparable mixture with SM)   85     
 
Table 16: Synthesis of functionalised tetraoxanes. (i) Re2O7 (6mol%), DCM, rt, 4hrs. 
 We used the dihydroperoxide bearing an ethyl ester as we anticipated that it could be 
later hydrolysed to a carboxylic acid, making the tetraoxane more soluble in aqueous 
conditions when used in experiments with Geobacter. Entry 1 showed that tetraoxane 
formation took place but only in 14% yield. When the functional group was a carboxylic acid 
(Entry 2), tetraoxane formation took place (confirmed by mass spectrometry) but it could 
only be isolated as an inseparable mixture with the carboxylic acid starting material 84. The 
ratio of these could not be determined by 
1
H NMR.  
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 As we were unable to selectively hydrolyse the methyl ester in the presence of the 
ethyl ester in the tetraoxane formed in entry 1, we decided to continue our investigation with 
the tetraoxane that had no functionality on the cyclohexyl moiety 68 (Entry 7, Table 10 
earlier). This meant that we could not incorporate a carboxylic acid group for solubility 
purposes but we first wanted to establish whether or not further transformations could be 
carried out on tetraoxanes without fragmentation taking place. As the trioxolanes synthesised 
by the O’Neil group (chapter 2) did not have any functionality on the cyclohexyl moiety and 
were used successfully in heme alkylation experiments, we were positive that this would also 
be the case for tetraoxanes. 
 
3.23.2. Ester hydrolysis and subsequent amide coupling to incorporate a NH2 group 
 With the intention of making a tetraoxane functionalised with a diazonium, ester 
hydrolysis and subsequent amide coupling was carried out on tetraoxane 68 (Scheme 45). 
 
 
Scheme 45: Further functionalisation on tetraoxane 68. (i) aq. NaOH, MeOH, 65
o
C, 4hrs, 
H3O
+
, 100%. (ii) EDC.HCl (1.2eq), NMM (2.5eq), HOBt (1.2eq), DMF, 0
o
C, 24hrs, p-
phenylenediamine (1eq), rt, 24hrs, 12%. (iii) [NO][BF4] (1eq), DCM, 0
o
C, o/n.  
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 The amide coupling (step (ii)) did not give a very good yield. These were conditions 
that had previously been used for amide coupling with a trioxolane functionalised with a 
carboxylic acid group at the 5-position of the adamantane moiety.
54
 The tetraoxane bearing 
the carboxylic acid on an aromatic ring may have hindered this reaction to some degree. Only 
4mg of the coupled tetraoxane product was isolated, which made it difficult to characterise by 
NMR as the sample was very dilute and hence gave very weak signals in the spectrum. 
However, mass spectrometry confirmed that it had been synthesised successfully with a 
molecular ion peak at 513.2 [M+Na]
+
. 
 
3.23.3. Attempted amide coupling to incorporate a thiol group 
 We also attempted amide coupling with the acid-functionalised tetraoxane 86 using 
cysteamine hydrochloride, which would incorporate a thiol group that is capable of binding to 
a gold surface (Scheme 46). However, this reaction failed to give any desired product. We 
concluded that the conditions used for the amide coupling required further optimisation. 
 
Scheme 46: Attempted amide coupling with cysteamine hydrochloride. (i) EDC.HCl (1.2eq), 
NMM (2.5eq), HOBt (1.2eq), DMF, 0
o
C-rt, o/n, HSCH2CH2NH3Cl (1eq), rt, o/n, 0%. 
 
3.23.4. Solvent screening for amide coupling on tetraoxane  
 We next carried out a solvent screen (Scheme 47 and Table 17) in an attempt to find 
a better solvent for the amide coupling reaction.   
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Scheme 47:  Amide coupling on tetraoxane. (i) EDC.HCl (1.2eq), NMM (2.5eq), HOBt 
(1.2eq), DMF, 0
o
C, 24hrs, p-phenylenediamine (1eq), rt, 24hrs. 
 
 
Entry Solvent Yield (%) 
1 DCM 12 
2 DMF 0 
3 Water 0 
 
Table 17: Solvent screen for amide coupling. 
 
 As the reaction was unsuccessful in both DMF and water, we decided to “reverse” the 
steps by carrying out amide coupling with the acid-functionalised adamantanone 84 first 
followed by tetraoxane formation with the product 90 (Scheme 48). 
 
Scheme 48: Amide coupling on carboxylic acid-functionalised adamantanone 84 and 
subsequent tetraoxane formation. (i) EDC.HCl (1.2eq), NMM (2.5eq), HOBt (1.2eq), DMF, 
0
o
C, 24hrs, p-phenylenediamine (1eq), rt, 24hrs, 34%. (ii) PMA (18mol%), 1,1-
dihydroperoxycycohexane (2eq), MgSO4 (2eq), DCM, rt, 4hrs, 0%.  
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 The amide coupling step gave a higher yield of 34% when performed on the acid-
functionalised adamantanone 84 compared with the acid-functionalised tetraoxane 86. 
Unfortunately, the amide coupled product 90 failed to react in the tetraoxane formation step 
and we believe the reason for this was its steric bulk. 
 
3.24. Synthesis of adamantanones functionalised with thiophene and thiophene 
derivatives 
 Having had little success with synthesising tetraoxanes functionalised with benzene 
derivatives, we then explored other aromatic compounds that could replace benzene but were 
still electrically conductive. We next turned our attention to thiophene because it is less 
aromatic and in theory, should be more reactive than benzene. 
 
3.24.1. Attempted synthesis of adamantanone functionalised with thiophene 
 Our investigation began with using thiophene in the optimised Friedel Crafts arylation 
(Scheme 49). We envisaged that the thiophene ring could be functionalised by selective 
deprotonation at the 5-position using nBuLi, followed by addition of a suitable electrophile. 
 
Scheme 49: Attempted Friedel Crafts arylation of 5-bromo-2-adamantanone 36 using 
thiophene. (i) FeCl3 (1.5eq), thiophene, 75
o
C, 20hrs, 0%. 
 
 Mass spectrometry for the compound isolated from this reaction showed a molecular 
ion peak that was 50 mass units higher than the expected mass. This did not agree with the 
expected mass for when the adamantanone is functionalised with a thiophene dimer. We do 
not yet have an explanation for this result. 
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3.24.2. Attempted synthesis of adamantanone functionalised with ethyl 2-
thiophenecarboxylate 
 We next attempted Friedel Crafts arylation using ethyl 2-thiophenecarboxylate 
(Scheme 50). We anticipated that a pre-functionalised thiophene would give a product that 
was more readily ionised and hence easier to characterise by mass spectrometry. 
 
Scheme 50: Attempted Friedel Crafts arylation of 5-bromo-2-adamantanone 36 using ethyl 2-
thiophenecarboxylate as the solvent for reaction. (i) FeCl3 (1.5eq), ethyl 2-
thiophenecarboxylate, 80
o
C, 20hrs, 0%. 
 
 
1
H NMR for the compound isolated from this reaction showed that there was a 
mixture of isomers and TLC showed that they both had the same Rf. However, mass 
spectrometry showed a molecular ion peak that was 30 mass units higher than the expected 
mass. We do not yet have an explanation for this result.  
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3.25. Conclusions and Further Work 
 In summary, the synthesis and optimisation of many novel 5-functionalised 2-
adamantanones has been achieved using liquid aryl substrates possessing high boiling points. 
Further study in finding a suitable solvent for this reaction to allow the use of solid aryl 
substrates is still required.  
 The Baeyer Villiger oxidation side reaction in the tetraoxane formation step has been 
somewhat suppressed after optimisation of the conditions (PMA Vs. Re2O7) used for 
tetraoxane formation. However, tetraoxane yields are still not satisfactory so an extensive 
solvent screen for this reaction is required to find a suitable solvent/mixture of solvents that 
would, ideally, prevent the Baeyer Villiger oxidation from taking place. Many novel 
tetraoxanes bearing different functional groups on the adamantyl moiety have been 
successfully synthesised. The antimalarial activity of these could also be tested because to 
date; no adamantyl-functionalised tetraoxanes have been reported in the literature. It would 
be interesting to determine whether or not they have superior activity to those synthesised by 
the O’Neill group, where they only have functionality on the cyclohexyl moiety. 
 The synthesis of a tetraoxane with suitable functionality for aryl diazonium formation 
has been achieved but only in 12% yield and this provided enough material for 
characterisation only. Optimisation of the conditions for the amide coupling step is required 
as it appears that these conditions only work well for aliphatic carboxylic acids (trioxolane 
12) but not aromatic carboxylic acids (tetraoxane 86). An alternative method would be to use 
the corresponding acid chloride (more reactive) instead of the carboxylic acid in the amide 
coupling step but the stability of the tetraoxane in the presence of reagents such as SOCl2 
needs to be determined.  
 Once a robust synthetic route has been found, these bi-functional tetraoxane 
molecular wires can be used in heme alkylation experiments involving Geobacter and the 
results from these can be compared with the trioxolane molecular wires. 
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This chapter contains a separate numbering system for all schemes, figures and references. 
Numbering of compounds has continued from chapter 3. 
 
4.1. Introduction to amino acids and proteins 
 Amino acids play central roles both as building blocks of proteins and as 
intermediates in metabolism. They have a unique chemical structure with a backbone 
consisting of H2N-CRH-CO2H where R is a side group. There are 20 genetically coded amino 
acids in nature i.e. 20 R groups and they can exist as two enantiomers at the α-centre, D and 
L; all conveying a vast array of chemical versatility. The L enantiomer appears in nature and 
is easily distinguished from the D enantiomer as it possesses an up-facing R group.  
 
4.1.1. Primary structure of proteins 
 The precise amino acid content, and the sequence of those amino acids, of a specific 
protein, is determined by the sequence of the bases in the gene that encodes that protein to 
give the primary structure. The chemical properties of the amino acids of proteins determine 
the biological activity of the protein. In addition, proteins contain within their amino acid 
sequences the necessary information to determine how that protein will fold into a 3D 
structure, and the stability of the resulting structure. The field of protein folding and stability 
has been a critically important area of research for years, and remains today one of the great 
unsolved mysteries.
1
  
 
4.1.2. Secondary structure of proteins: α-helix and β-sheet 
 The secondary structure is the specific geometric shape caused by intramolecular and 
intermolecular hydrogen bonding of primarily amide groups.
2 There are two main secondary 
structures of proteins in nature; α-helices and β-sheets.  
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 In the α-helix, the polypeptide chain is coiled tightly like a spring. The backbone of 
the peptide forms the inner part of the coil while the side chains (R groups) extend outward 
from the coil. The helix is stabilized by hydrogen bonding between the N-H of one amino 
acid and the C=O on the 4th amino acid away from it. One "turn" of the coil requires 3.6 
amino acid units.
2
 The helix can be either right-handed or left-handed in the sense of threads 
on a screw. The naturally occurring α-helices found in proteins are all right-handed. 
 In the β-pleated sheet, individual protein chains are aligned side-by-side with every 
other protein chain aligned in an opposite direction. The protein chains are held together by 
intermolecular hydrogen bonding between amide groups of two separate chains. The 
hydrogen on the amide of one protein chain is hydrogen bonded to the amide oxygen of the 
neighbouring protein chain. The pleated sheet effect arises from the fact that the amide 
structure is planar while the "bends" occur at the carbon containing the side chain.  
 β-sheets come in two forms as the chains can run anti-parallel or parallel to one 
another (Figure 1). In both of these, there is an average of one hydrogen bond for each pair 
of amino acid residues and both require a “turn”. The parallel turn is much longer than the 
anti-parallel turn and the anti-parallel turns are known as β-turns or “reverse” turns. 
 
 
Figure 1: Parallel and anti-parallel β-sheets. 
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4.2. Introduction to β-turns 
 A turn is defined as a site where the polypeptide chain reverses its overall direction. 
The term β has a more restricted definition and describes a turn of four residues and γ 
describes a turn of three residues.
3, 4
 The β-turn is one of the three major motifs of peptide 
and protein secondary structure.
5
 β-Turns play a key role in many biological molecular 
recognition events including interactions between antigens and antibodies, peptide hormones 
and their receptors and regulatory enzymes and their corresponding substrates. The idea that 
turns have functions related to their structural characteristics appears throughout the 
literature.
4
 Turns are intrinsically polar structures with backbone groups that pack closely 
together and side chains that project outward. Such an array of atoms may constitute a site for 
molecular recognition e.g. antibody recognition. In peptides, turns are the conformations of 
choice for simultaneously optimising both backbone-chain compactness (intramolecular non-
bonded contacts) and side chain clustering (to facilitate intermolecular recognition).  
 The formation of a β-turn requires four consecutive amino acids with a hydrogen 
bond joining the C=O of the first residue (i) with the N-H of the last residue (i+3) to give a 10 
atom loop (Figure 2). This steric arrangement requires that any hydrogen bond involving the 
remaining two residues (i+2, i+3) be formed with partners outside the turn. 
 
 
Figure 2: The β-turn motif.6  
 
 An isolated β-turn is already highly polar due to these unpaired N-H and C=O groups. 
In the context of a protein, polarity is further enhanced because turn formation is promoted at 
chain sites where the average linear hydrophobicity is locally minimal. Hence, turns are 
almost always situated at the molecular surface in contact with solvent water. 
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4.3. Introduction to protein β-turn mimetics 
 A β-turn mimetic is a synthetic variant of a β-turn that has a non-peptidic backbone 
but retains the functional groups of the peptide in their correct active conformations to act on 
a receptor. An important structural feature of many peptides and proteins is the β-turn motif 
and it may well be crucial in receptor interactions that ultimately lead to biological activity.
7
 
Peptides and proteins play a vital role in the control and modulation of virtually all biological 
processes regulating biological functions by acting as hormones, enzymes, receptors and 
inhibitors.
7
  
 The understanding of the relationship between protein and peptide structure and their 
biological function has dramatically increased as a result of the growth in the fields of 
molecular biology, peptide synthesis, structure elucidation and molecular modelling. This 
recent progress in the synthesis and screening of huge peptide libraries has focused attention 
on small peptides as important lead structures for the development of potential therapeutic 
agents. Peptides themselves cannot be used as therapeutic candidates due to poor receptor 
selectivity, unfavourable absorption properties, metabolic instability and lack of oral 
bioavailability.
6
 Hence there has been much interest in establishing general synthetic 
strategies for converting these potent peptides into peptidomimetics that may overcome the 
pharmacokinetic limitations of the peptides themselves.  
 In order to attain high affinity and selective binding to a targeted receptor, a β-turn 
mimetic must reproduce both the functionality and orientation of the side chains of the 
receptor-bound peptide ligand. The inherent diversity in β-turn structure and difficulties in 
identifying the key residues responsible for binding has made the design of β-turn mimetics 
quite challenging.  
 
4.3.1. Design of peptidomimetics 
 The design of peptidomimetics may be based on a particular protein structural motif 
and the β-turn offers the significant advantage that it is compact and of such a size that it can 
be readily mimicked by a small organic molecule. To successfully mimic even a small helix 
would require molecules significantly larger than steroids.
7
  
  
Chapter 4: Synthesis of β-turn mimetics and chiral enamine N-oxides  
126 
 
 It would be advantageous to have a rigid molecule that could mimic any β-turn 
structure and position the four side chains (i, i+1, i+2, i+3 residues) in their proper orientation 
as determined by x-ray crystallography of β-turn sequences in known proteins.7 A great deal 
of effort has therefore been focused on the design of small constrained mimetics of turn 
structure in order to provide a better understanding of the molecular basis of peptide and 
protein interactions in addition to providing potent and specific therapeutic agents.
8
 These 
efforts have met with only limited success due to difficulties in identifying the key turn 
residues and the relative orientations of those residues in the receptor-bound conformation. 
To date, peptide mimetics have already been reported to show biological activity although 
they were found by serendipity. Examples include opiate analgesics and antagonists for β-
endorphins,
9
 benzodiazepines as cholecystokinin (CCK) antagonists
10
 and substituted 
imidazoles as angiotensin II receptor antagonists.
11
 These all involved synthetic 
modifications to the peptides to produce suitable drug targets. 
 The difficulties in identifying the optimal structure for a given turn mimetic could be 
circumvented by the synthesis and screening of a combinatorial library of β-turn mimetics 
which include all possible side-chain combinations as well as multiple relative orientations of 
the side chains. In 1994, Virgilio and Ellman
8
 reported a general method for the solid-phase 
synthesis of β-turn mimetics that incorporated a variety of side-chain functionality and 
demonstrated the simultaneous synthesis of multiple turn derivatives (Figure 3).  
 
 
Figure 3: A β-turn mimetic with different backbone linkages. 
 
 The different backbone linkages determine the flexibility of the mimetic and the 
relative orientations of the side chains e.g. to provide 9- or 10-membered rings, as well as by 
preparing different combinations of the absolute configurations at each of the stereocentres 
introduced by the i+1 and i+2 side chains. 
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4.3.2. β-Turn mimetic classification 
 Turn mimetics can be classified into two distinct groups; internal and external.
6
 
Internal mimetics are constructed upon skeletons that lie within the pseudo 10-membered ring 
framework of the turn motif, and place an emphasis on side chain presentation as displayed 
by the structure reported by Kahn
12
 (Figure 4). 
 
 
Figure 4: An example of internal turn mimetics. 
 
 The external mimetics are often constructed on dipeptide isostere skeletons that do not 
display side chain functionality at the central i+1 and i+2 positions. These structures reduce 
the conformational flexibility of a peptide with a rigidified skeleton that lies outside of the 
turn’s general framework, and are primarily employed to orient the surrounding peptide chain 
into a turn conformation. Figure 5 developed by Freidinger
13
 is a notable example. 
 
 
Figure 5: An example of external turn mimetics. 
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 One problem with the synthesis of β-turn mimetics is steric crowding around side 
chains i+2 and i+3. Some methods have been developed to overcome this issue; including the 
addition of smaller R groups such as glycine, inverting the stereochemistry from L to D, or 
cyclising R
2
 onto the next amino group. This can be done using proline efficiently; hence β-
turn mimetics from proline derivatives are the main focus of the work in this chapter. 
Molecular modelling has strongly suggested that two novel morpholine templates (Figure 6) 
will behave as β-turn mimetics so we intended to base our β-turn mimetics on this structure.  
 
 
Figure 6: β-Turn mimetics with a fused morpholine template.  
 
4.4. Proposed route to β-turn mimetics based on a fused morpholine skeleton 
 The O'Neil group proposed a route for the synthesis of a fused morpholine template 
(Scheme 1). The reaction of S-prolinol 99 with acrylonitrile followed by O-allylation gives 
the tertiary amine 101. Selective oxidation of this tertiary amine gives the N-oxide 102 which 
undergoes Cope elimination to give the hydroxylamine 103. Stirring the hydroxylamine 103 
under a nitrogen atmosphere in CDCl3 should give the fused morpholine N-oxide 104 as a 
single diastereoisomer.  
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Scheme 1: Route to β-turn mimetics. (i) Acrylonitrile, MeOH (ii) Allyl bromide, NaH, THF 
(iii) m-CPBA, DCM (iv) Cope elimination (v) Reverse-Cope cyclisation.
14
  
 
  We then aspired to couple the final N-oxide 104 with an isocyanide 107 derived from 
an amino acid (Schemes 2 and 3).  
 
 
Scheme 2: Synthesis of isocyanide 107 from L-phenylalanine methyl ester hydrochloride 
105. (i) Acetic formic anhydride (ii) Triphosgene, NEt3, DCM. 
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Scheme 3: Coupling of N-oxide 104 with isocyanide 107, a new variant of the 
Ugi/Polonovski reaction. (i) TFAA, DCM (ii) NaOMe, THF. 
 
4.5. Introduction to chiral enamine N-oxides 
 A large number of chiral ligands based on amines have been reported over the years 
but there have been virtually no examples of asymmetric synthesis using homochiral tertiary 
amine N-oxides, despite the excellent metal-binding properties of this functional group. 
 
Figure 7: Structure of S-Proline. 
 
 Proline derived amine oxides have been extensively studied by the O'Neil group. A 
variety of chiral N-oxide derivatives of proline are capable of catalysing a wide range 
synthetically useful transformations such as the borane reduction of ketones (Scheme 4), 
giving products with high e.e.
15
 The e.e. of the products were determined by converting them 
to their trifluoroacetates and analysing by chiral GC. The amine oxides were found to be 
stable and simple to prepare and could be recovered from the reaction mixture in >90% yield. 
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Scheme 4: Borane reduction of ketones catalysed by amine N-oxides. (i) BH3SMe2, Ligand, 
Solvent, 5mins.
16
 
 
 On the other hand, enamine N-oxides are virtually unknown and there are only a 
limited number of literature examples describing their synthesis. So far, there have been two 
methods described; the first is the elimination of HX from a suitably β-functionalised tertiary 
amine N-oxide e.g. quinuclidine enamine N-oxide (Figure 8).
17
  
 
Figure 8: Quinuclidine enamine N-oxide. 
 
 The second method developed by Woodward involves the aminolysis of epoxides 
followed by chlorination, N-oxidation and dehydrochlorination (Scheme 5).
18
 
 
Scheme 5: Preparation of enamine N-oxides by Woodward.
18
 
 
  The O'Neil group have since developed a short and highly efficient route to chiral 
enamine N-oxides. The reverse-Cope cycloaddition of chiral prolinol derived hydroxylamines 
to activated acetylenes gave single diastereomeric enamine N-oxides where the N-oxide was 
hydrogen-bonded to the side chain hydroxyl group (Scheme 6).   
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Scheme 6: Addition of prolinol-derived hydroxylamines to activated acetylenes. 
 
4.6. Results and Discussion 
4.6.1. Route to β-turn mimetics using a modified Ugi/Polonovski reaction  
 The synthesis began with the straightforward cyanoethylation of S-prolinol 99 
(Scheme 7). S-Prolinol 99 and excess acrylonitrile were stirred in methanol at room 
temperature overnight to give the cyanoethyl-protected product 100 in high yield. On 
repetition, it was found that reaction times did not need to be as long as 16hrs (1-4hrs was 
sufficient for the reaction to reach completion) and in some cases, the crude product was pure 
enough to use without purification by column chromatography. 
 
 
Scheme 7: Cyanoethylation of S-prolinol 99. (i) Acrylonitrile (1.2eq), MeOH, rt, o/n, 87%. 
 
 The next step involved the O-allylation of the cyanoethyl-protected prolinol 100 
(Scheme 8). This reaction did not proceed to give as high a yield as expected. We presumed 
that this was because the sodium hydride, a very fine solid dispersed in mineral oil, was used 
without pre-washing with hexanes. On repetition, yields obtained were in the region of 75% 
when the sodium hydride was washed immediately before use in the reaction.  
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Scheme 8: O-Allylation of cyanoethyl-protected prolinol 100. (i) NaH (1.1eq), THF, 0
o
C, 
40mins, allyl bromide (1.5eq), TBAI (cat.), rt, o/n, 56%. 
 
 The O-allylated product 101 was then oxidised to the corresponding hydroxylamine 
using m-CPBA (Scheme 9).  
 
Scheme 9: Oxidation of prolinol derivative 101 using m-CPBA followed by Cope elimination 
to give hydroxylamine 103. (i) m-CPBA (1.1eq), K2CO3 (1.5eq), DCM, -78
o
C, 3hrs, rt, o/n. 
 
 The hydroxylamine could not be isolated in pure form as it underwent reverse Cope 
cyclisation slowly at room temperature (Scheme 10). Subsequent refluxing in methanol gave 
the cyclised product as a mixture of diastereoisomers in 13% yield. It was later found that 
simply stirring in CDCl3 under a N2 atmosphere at room temperature gave the cyclised 
product as a single diastereoisomer 104A in 25% yield over 2 steps starting from 101. 
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Scheme 10: Reverse-Cope cyclisation. (i) MeOH, N2, , 3 days, 13%, 4:3 (A:B) or CDCl3, 
N2, rt, 4 days, 25% over 2 steps, 1:0 (A:B).  
 
 
Figure 9: 
1
H NMR showing characteristic doublet peak(s) corresponding to -CH3 on 
morpholine ring. Single diastereoisomer formed in CDCl3 (A) and a mixture of 
diastereoisomers formed in MeOH (B).   
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 A prolinol-derived N-oxide with a simpler structure 111 was synthesised (Scheme 11) 
with the intention of coupling this with an isocyanide to test the feasibility of the reaction. N-
oxide 111 exhibited long term stability when stored at room temperature. 
 
 
Scheme 11: Synthesis of (1R, 2S)-1-benzyl-2-(hydroxymethyl)pyrrolidine-1-oxide 111. (i) 
Benzyl bromide (1.4eq), K2CO3 (1.03eq), N2, toluene, 110
o
C, 21hrs, 56%. (ii) m-CPBA 
1.1eq), K2CO3 (1.5eq), DCM, N2, -78
o
C, 2hrs, rt, o/n, 70%. 
 
4.6.2. Synthesis of β-turn mimetics using a reverse-Cope cyclisation 
 Having successfully synthesised a fused morpholine template (104A, Scheme 10), we 
were encouraged to investigate similar analogues possessing a side chain on the morpholine 
ring that was capable of undergoing further transformations, with the intention of 
incorporating an alkyne ester substrate at this position.  
 The tetrahydropyranyl derivative of propargyl alcohol 112 was deprotonated using 
ethylmagnesium bromide and the resulting acetylenic anion trapped out with freshly distilled 
methyl chloroformate (Scheme 12). 
 
 
 
Scheme 12: (i) EtMgBr (1.0M in THF, 1.1eq), THF, -78
o
C, 30mins, ClCO2Me (1.1eq), THF, 
-78
o
C-rt, o/n, 25%. 
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On repetition, this afforded the alkyne ester product in only 25% yield. Having 
separated all the components in the crude reaction mixture by column chromatography, it was 
found that half of the starting tetrahydropyranyl derivative was left unreacted. It was 
suspected that the cause of this was the concentration of the ethylmagnesium bromide 
solution, as supplied by Sigma Aldrich was not 1.0M as labelled. For this reason, freshly 
titrated nBuLi was used in place of ethylmagnesium bromide but this gave only 14% yield of 
product. It was assumed that the intermediate alkoxide formed from methyl chloroformate is 
better stabilised by a magnesium bromide cation than it is by a lithium cation. Without further 
optimisation of the conditions for deprotonation, the alkyne ester was deprotected under 
mildly acidic conditions (Scheme 13).  
 
 
 
 
Scheme 13: Deprotection of alkyne ester derivative 113. (i) p-TSA (10mol%), 
MeOH, rt, 4hrs, 100%. 
 
Due to concerns about its stability on silica gel, the crude alcohol 114 was then used 
immediately to make the corresponding mesylate (Scheme 14).  
 
 
 
Scheme 14: Mesyl chloride (1.1eq), NEt3 (1.5eq), dry DCM, N2 atmosphere, -40
o
C-rt, 
2hrs, 73%. 
 
Due to the unstable nature of the mesylate 115 at room temperature, it was used 
immediately in separate coupling reactions with cyanoethylprolinol 100 at 0
o
C and -40
o
C to 
yield the resulting coupled product in 5% and 7% isolated yields respectively (Scheme 15). 
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Scheme 15: Coupling mesylate with cyanoethylprolinol. (i)  NaH (1.1eq), THF, 0
o
C or -
40
o
C, 30mins, mesylate 115 (1.5eq), TBAI (cat.), 0
o
C or -40
o
C - rt, o/n. 
 
 Mass spectrometry confirmed the presence of the desired product with a molecular 
ion peak at 252.2 [M+H]
+
 but 
1
H NMR showed that the prolinol ring protons were not 
present. It was concluded that the desired product had been formed but only as a very minor 
product in the reaction (not detectable by NMR) and this could not be determined 
quantitatively by mass spectrometry. We proposed that the major possible product from this 
coupling reaction could be addition of the prolinol alkoxide derivative into the triple bond 
instead of displacing the mesylate group (Figure 9) but mass spectrometry did not show a 
peak for this product. 
 
 
 
Figure 10: Possible side product resulting from alkoxide attacking alkyne.  
 
Another prolinol derivative synthesised by a member of the O’Neil group was 
successfully used in the reverse-Cope cyclisation (Scheme 16). The N-oxide was rigorously 
dried in a vacuum desiccator over P2O5 where it changed from a yellow to dark green and 
eventually a black, viscous oil, an indication that decomposition had occurred.     
 
 
Chapter 4: Synthesis of β-turn mimetics and chiral enamine N-oxides  
138 
 
 
 
Scheme 16: Oxidation of the TBDMS prolinol derivative to corresponding hydroxylamine 
followed by reverse-Cope cyclisation. (i) m-CPBA (1.1eq), K2CO3 (1.5eq), DCM, N2, -78
o
C, 
18hrs (ii) CDCl3 (10ml), N2, rt, 5 days, 31% over 2 steps. 
 
4.6.3. Synthesis of chiral enamine N-oxides 
 We next focused on the synthesis of chiral enamine N-oxides using diphenylprolinol 
hydroxylamine 123 in reactions with activated alkynes. We began with the commercially 
available propiolamide 125 as the alkyne substrate (Scheme 17).  
 
 
 
 
Scheme 17: Synthesis of a chiral enamine N-oxide. (i) CDCl3, N2, rt, 3 days, 83%. 
 
 
 The yield of 83% encouraged us to use other alkyne substrates bearing electron 
withdrawing groups. We envisaged that cyanoacetylene 127 and propiolaldehyde 129 would 
furnish similar yields. Both of these alkyne substrates were synthesised and used immediately 
in the coupling reactions with diphenylprolinol hydroxylamine. 
 The synthesis of cyanoacetylene 127 involved the dry distillation of propiolamide 125 
under reduced pressure (Scheme 18). However, the reaction of cyanoacteylene 127 with 
diphenylprolinol hydroxylamine 123 was unsuccessful at -78
o
C (no reaction or very slow at 
low temperature) but due to the volatile nature of cyanoacetylene, this reaction was not 
feasible at room temperature.    
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Scheme 18: Synthesis of cyanoacetylene 127 via dry distillation of propiolamide 125. 
Cyanoacetylene collected at -78
o
C. (i) Sand, P2O5 (1.5eq), 140
o
C, 20mmHg. 
 
 Propiolaldehyde 129 was synthesised via the Jones oxidation of propargyl alcohol in 
moderate yield (67%) after a short path distillation (Scheme 19). The reaction of 
propiolaldehyde 129 with diphenylprolinol hydroxylamine 123 was attempted but we 
encountered the same problem of volatility as previously observed with cyanoacetylene.   
 
 
 
Scheme 19: Synthesis of propiolaldehyde. (i) Jones’ reagent, butanone, 0oC, 30mins, 67%. 
 
 The reaction was also attempted using 3-butyn-2-one as the alkyne substrate. This 
was carried out twice, using one and then three equivalents of 3-buytn-2-one (Scheme 20). 
However, on both occasions, there was no product seen by 
1
H NMR after purification by 
column chromatography or mass spectrometry. It appeared that decomposition had taken 
place as the ring protons were not present in the 
1
H NMR and TLC showed multiple 
components. 
 
Scheme 20: Coupling diphenylprolinol hydroxylamine with 3-buytn-2-one. (i) CDCl3, N2, rt, 
7 days, 0%.  
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4.7. Conclusions and Further Work 
 The yield and ratio of diastereoisomers for the product from reverse-Cope cyclisation 
was found to be inconsistent with the literature when MeOH was the solvent for the 
reaction.
14
 This needs to be repeated to determine reproducibility of the yields. The coupling 
of isocyanide 107 with N-oxide 104A from reverse-Cope cyclisation (attempted once within 
the O'Neil group but unsuccessful) and benzyl-protected prolinol N-oxide 111 is still required 
to determine the feasibility of the modified Ugi/Polonovski reaction. Once an efficient and 
reliable synthesis has been established, the resulting β-turn mimetics can be screened for 
biological activity.  
 The synthesis of an alkyne bearing ester and mesylate functionality 115 for use in the 
synthesis of a β-turn mimetic using a  reverse-Cope cyclisation was found to be unsuccessful 
due to its tendency to decompose at room temperature. Alternative syntheses of this alkyne 
are required. 
 The synthesis of a novel, chiral enamine N-oxide 126 has been successfully carried 
out by coupling diphenylprolinol hydroxylamine 123 with propiolamide 125. Similar 
coupling reactions using activated alkyne substrates, cyanoacetylene 127 and propiolaldehyde 
130 were attempted but were found to be unsuccessful due to their volatile nature. The chiral 
enamine N-oxides synthesised within the O'Neil group can, in future, be screened as ligands 
for catalysis.  
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5.1. General Information 
 
5.1.1. Purification of chemicals 
All chemicals and solvents were used as purchased without further purification unless 
otherwise stated. Re2O7 was stored under N2 in a desiccator containing self indicating silica 
gel. Diisopropylamine was freshly distilled over CaH2 and stored under N2 prior to use. 
 
5.1.2. Purification of solvents 
THF was freshly distilled from Na/benzophenone under an inert atmosphere of N2 prior to 
use. DCM was freshly distilled from CaH2 under an inert atmosphere of N2 prior to use. All 
other solvents were purified by standard methods.  See W. L. F. Armarego and C. L. L. Chai, 
“Purification of Laboratory Chemicals”, 5th Edition, Butterworth-Heinemann Publications, 
2003. DMF and 1,4,-dioxane were purchased from Sigma Aldrich in 100ml bottles and used 
without further purification. Petroleum ether (40-60
o
C) was used for flash column 
chromatography. 
 
5.1.3. Titration of nBuLi 
nBuLi was purchased from Sigma Aldrich in 100ml bottles as a 1.6M solution in hexanes.  
The precise molarity was determined by titration against a solution of N-benzylbenzamide in 
THF at -45
o
C to a blue endpoint.
1
  
 
5.1.4. Purification of m-CPBA 
m-CPBA (ca. 50% pure as supplied by Sigma Aldrich) was purified prior to use. Di-sodium 
hydrogen phosphate dihydrate (2.66g, 15mmol), and sodium di-hydrogen phosphate (0.52g, 
4.33mmol) were dissolved in distilled water (500ml). m-CPBA (13g) was added to DCM 
(150ml), the insoluble white solid was filtered off and the filtrate washed with the buffer (3 x 
150ml). The organic extracts were dried (MgSO4) and the solvent removed under reduced 
pressure, furnishing m-CPBA (ca. 90-100% pure), which was dried in a vacuum desiccator 
over P2O5 for 1 day. The product was obtained as a white flocculent solid (ca. 7g).
2
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5.1.5. Preparation of glassware 
For anhydrous reactions, all syringes, needles, flasks, condensers and stirrer bars were flame 
dried prior to use. All were cooled in a desiccator containing self indicating silica gel, fitted 
with a septum and flushed with N2 prior to use. All anhydrous reactions were performed 
under a small positive pressure of nitrogen. 
 
5.1.6. Other apparatus 
Ozone (3-4% in a stream of O2) was generated via a Wallace and Tiernan B. A. 023012 
ozonizer. Sonication of reaction flasks were performed with a Camlab Transsonic T 460/H 
sonic bath. 
 
5.1.7. Chromatography 
Thin layer chromatography was carried out on Merck silica gel 60 F-254 aluminium-backed 
plates. Compounds were visualised by exposure to iodine mixed with silica gel, treatment 
with potassium permanganate (1% w/v in water) or an acidic, ethanolic solution of p-
anisaldehyde. Flash column chromatography was performed using silica gel, pore size 60Å 
from Sigma Aldrich, using a compressed air line to apply a positive pressure to the column. 
 
5.1.8. Characterisation of compounds 
1
H (400MHz) and 
13
C (100MHz) NMR spectra were recorded on a Bruker AMX400 
machine. Chemical shifts () are recorded in ppm downfield from an internal standard of 
TMS, using CDCl3 as solvent. Multiplicities are quoted as: singlet (s), doublet (d), triplet (t), 
doublet of doublets (dd), doublet of triplets (dt), multiplet (m). Coupling constants are in Hz.  
Mass spectra were recorded on TRIO-1000 and Micromass LCT mass spectrometers using 
chemical ionisation (CI) in ammonia as the reagent gas or electrospray ionisation (ESI) in 
MeOH. Elemental analyses were carried out in the University of Liverpool Chemistry 
Department microanalysis laboratory. IR spectra were recorded in the range 4000-600 cm
-1
 
using a JASCO FT/IR 4200 spectrometer. Melting points were performed on a Gallenkamp 
melting point apparatus in degrees Celsius and are uncorrected.  
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5.2. Individual Experimental Procedures 
 
Synthesis of 1,2,4-trioxolanes and 1,2,4,5-tetraoxanes 
 
Synthesis of O-methyl 2-adamantanone oxime 6a
3 
 
 To a stirred solution of 2-adamantanone 6 (1.00g, 6.66mmol) in MeOH (20ml), was 
added pyridine (1ml, 12.40mmol) and methoxyamine hydrochloride (0.84g, 10.00mmol). The 
reaction was stirred at room temperature under a N2 atmosphere for 48hrs, concentrated under 
reduced pressure to yield a yellow residue, and diluted with DCM (20ml) and water (20ml). 
The organic layer was separated and the crude product extracted with DCM (2 x 20ml). The 
combined organic extracts were washed with 1M HCl (2 x 20ml), brine (20ml) and dried 
(MgSO4). The solvent was removed under reduced pressure to afford O-methyl 2-
adamantanone oxime 6a (0.96g, 81%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  3.85-3.81 (3H, s, CH3), 2.57-2.52 (2H, s, 2 x CHC=N), 2.10-
1.78 (12H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  167.2 (C=N), 61.4 (CH3), 38.0, 36.9, 29.9, 28.2. 
m.p 112-114
o
C 
IR (neat)/cm
-1
: 2915 (C-H alkyl), 2852, 1718 (C=N), 1452, 1049, 892. 
LRMS (CI); 180.2 [M+H]
+
, 150.2 [M-OMe]
+
. 
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Synthesis of O-methyl 5-hydroxy-2-adamantanone oxime 7a 
 
 To a stirred solution of 5-hydroxy-2-adamantanone 7 (1.00g, 6.02mmol) in MeOH 
(20ml), was added pyridine (1ml, 12.40mmol) and methoxyamine hydrochloride (0.75g, 
8.98mmol). The reaction was stirred at room temperature under a N2 atmosphere for 48hrs, 
concentrated under reduced pressure to yield a cloudy residue, and diluted with DCM (40ml) 
and water (30ml). The organic layer was separated and the crude product extracted with 
DCM (30ml). The combined organic extracts were washed with 1M HCl (2 x 20ml), brine 
(20ml) and dried (MgSO4). The solvent was removed under reduced pressure to afford O-
methyl 5-hydroxy-2-adamantanone oxime 7a (0.66g, 56%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  3.85-3.80 (3H, s, CH3), 3.65-3.60 (1H, br s, OH), 2.73-2.69 
(1H, s, CHC=N), 2.31-2.25 (1H, s, CHC=N), 1.90-1.72 (11H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  164.5 (C=N), 68.2 (C-OH), 61.5 (CH3), 45.9, 44.6, 37.9, 36.7, 
30.9. 
C11H17NO2 requires C 67.66 %, H 8.78 %, N 7.17 % found C 67.77 %, H 8.85 %, N 7.07 %. 
IR (neat)/cm
-1
: 3149 (br, OH), 2965 (C-H), 1606 (C=N), 1056 (C-O). 
LRMS (CI); 196.1 [M+H]
+
. 
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Synthesis of O-methyl cyclohexanone oxime 8
3
 
 
 To a stirred solution of cyclohexanone 5 (2.2ml, 21.2mmol) in MeOH (20ml), was 
added pyridine (2ml, 24.8mmol, 1.2eq) and NH2OMe.HCl (2.56g, 30.6mmol, 1.4eq). The 
reaction was stirred at room temperature under a N2 atmosphere for 48hrs, concentrated under 
reduced pressure and diluted with DCM (50ml) and water (50ml). The product was extracted 
with DCM (2 x 50ml). The combined organic extracts were washed with 1M HCl (2 x 50ml) 
and brine (30ml), and dried (MgSO4). The solvent was removed under reduced pressure to 
afford O-methyl cyclohexanone oxime 8 (2.17g, 80%) as a colourless oil. 
1
H NMR (400MHz, CDCl3)  3.82-3.80 (3H, s, CH3), 2.46-2.42 (2H, m, CH2), 2.21-2.17 
(2H, m, CH2), 1.68-1.56 (6H, m, 3 x CH2). 
13
C NMR (100MHz, CDCl3)  160.7 (C=N), 61.4 (CH3), 32.6, 27.4, 26.2, 26.1, 25.6. 
IR (neat)/cm
-1
: 2935 (C-H alkyl), 1733 (C=N), 1448 (C-O), 1051 (C-O) 
LRMS (CI); 144.2 [M+NH4]
+
. 
 
 
Synthesis of adamantane-2-spiro-3’-1’,2’,4’-trioxaspiro[4.5]decane 23 
 
 Ozone (3-4% in a stream of O2) was bubbled into a solution of O-methyl 
cyclohexanone oxime 8 (0.20g, 1.56mmol) and 2-adamantanone 6 (0.26g, 1.74mmol, 1.1eq) 
in n-pentane (60ml) and DCM (15ml) at -78
o
C. The reaction was stirred for 5hrs and 
quenched by flushing with N2 for 5mins until the blue colour disappeared to leave behind a 
colourless solution. The solvent was removed under reduced pressure and the residue purified 
by flash column chromatography using EtOAc/n-Hex (eluting with 10:90) to afford the 
product 2 (0.67g, 16%) as a colourless solid. 
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1
H NMR (400MHz, CDCl3)  2.11-1.32 (24H, m, adamantyl/cyclohexyl H) 
13
C NMR (100MHz, CDCl3)  110.2 (quaternary C), 110.1 (quaternary C), 39.7, 31.2, 30.4, 
30.2, 25.8, 23.0, 22.9.  
IR (neat)/cm
-1
: 2942 (C-H alkyl), 1060 (C-O), 914 (O-O). 
 
Synthesis of 5-hydroxy-adamantane-2-spiro-3’-1’,2’,4’-trioxaspiro[4.5]decane 7b 
 
 Ozone (3-4% in a stream of O2) was bubbled into a solution of O-methyl 
cyclohexanone oxime 8 (0.21g, 1.61mmol) and 5-hydroxy-2-adamantanone 7 (0.29g, 
1.72mmol, 1.1eq) in n-pentane (60ml) and DCM (15ml) at -78
o
C. The reaction was left for 
5hrs and quenched by flushing with N2 for 5mins until the blue colour disappeared to leave 
behind a colourless solution. The solvent was removed under reduced pressure and the 
residue purified by flash column chromatography using EtOAc/n-Hex (eluting with 10:90) to 
afford the product 7b (47mg, 10%) as a colourless solid. 
1
H NMR (400MHz, CDCl3)  1.91-1.80 (10H, m), 1.61-1.40 (9H, m), 1.5-1.20 (4H, m). 
13
C NMR (100MHz, CDCl3)  111.7 (quaternary C), 111.5 (quaternary C), 32.1, 30.2, 25.7, 
23.1, 21.4. 
IR (neat)/cm
-1
: 3405 (OH), 2942 (C-H), 1060 (C-O), 914 (O-O).  
 
 
Synthesis of 5-adamantane-2-spiro-1’ 2’ 4’-trioxaspiro[4.5]decane methyl ester 17 
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 Ozone (3-4% in a stream of O2) was bubbled through DCM at -78
o
C then into a 
solution of O-methyl cyclohexanone oxime 8 (0.55g, 4.34mmol, 1.25eq) and 5-
carbomethoxy-2-adamantanone 16 (0.72g, 3.46mmol, 1eq) in n-pentane (60ml) at room 
temperature. After 3hrs, excess ozone in the reaction mixture was quenched by flushing with 
N2 for 5mins. Ozone was bubbled through a second batch of O-methyl cyclohexanone oxime 
(0.14g, 1.11mmol, 1.29eq) and 5-carbomethoxy-2-adamantanone (0.18g, 0.86mmol, 1eq) in 
n-pentane (60ml) at room temperature. After 3hrs, excess zone was quenched by flushing 
with N2 for 5mins. The flask containing DCM was saturated with ozone and had turned blue. 
This was quenched by flushing with N2 for 35mins to leave behind a colourless solution. 
Both reaction mixtures were combined and the crude product adsorbed onto silica and 
purified by flash column chromatography using EtOAc/petroleum ether (eluting with 2:98) to 
afford the product 17 (0.69g, 50%) as a colourless oil. Ratio of diastereoisomers 1:1.3.  
 
1
H NMR (400MHz, CDCl3)  3.67-3.66 (3H, s, OCH3), 3.65-3.64 (3H, s, OCH3), 2.25-1.35 
(46H, m, adamantyl/cyclohexyl H). 
13
C NMR (100MHz, CDCl3)  177.7(3) (C=O), 177.6(3) (C=O), 110.5(1) (quaternary C), 
110.4(8) (quaternary C), 109.7(0) (quaternary C), 109.6(6) (quaternary C), 52.1 (OCH3), 
40.3, 39.9, 38.6, 36.7, 36.5, 36.4, 36.2, 35.1, 34.1, 34.0, 29.5, 28.1, 27.0, 26.6, 25.3, 24.2. 
C18H26O5 requires C 67.06 %, H 8.13 % found C 67.15 %, H 8.13 %. 
IR (neat)/cm
-1
: 2935 (C-H alkyl), 1727 (C=O), 1241 (C-O), 1091 (O-O). 
  
HRMS (ESI); 345.1679 [M+Na]
+
, C18H26O5Na requires 345.1678. 
 
Synthesis of 5-adamantane-2-spiro-1’ 2’ 4’-trioxaspiro[4.5]decane carboxylic acid 12 
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 To a solution of 5-adamantane-2-spiro-1’ 2’ 4’-trioxaspiro[4.5]decane methyl ester 17 
(0.41g, 1.28mmol) in MeOH (5ml) was added 15% aq. NaOH (5ml). The mixture was stirred 
at 65
o
C for 2hrs and acidified to pH 2 using 2M HCl (10ml). The product was extracted with 
DCM (3 x 30ml), the combined organic extracts were dried (MgSO4) and the solvent 
removed under reduced pressure to afford the product 12 (0.31g, 79%) as a colourless solid.  
 
1
H NMR (400MHz, CDCl3)  2.36-1.32 (48H, m, adamantyl/cyclohexyl H). 
13
C NMR (100MHz, CDCl3)  183.4(2) (C=O), 183.2(8) (C=O), 110.3(8) (quaternary C), 
110.3(6) (quaternary C), 109.7(8) (quaternary C), 109.7(4) (quaternary C), 42.4, 40.0, 39.7, 
38.4, 38.3, 36.4, 36.3(2), 36.2(6), 36.1(7) 35.1, 34.0, 33.9, 27.4, 26.9, 26.5, 25.3, 24.3.  
m.p 130-132
o
C 
 
C17H24O5 requires C 66.21 %, H 7.84 % found C 66.28 %, H 7.93 %. 
 
IR (neat)/cm
-1
: 2935 (C-H), 1689, (C=O), 1114 (C-O), 941 (O-O). 
 
HRMS (ESI); 331.1520 [M+Na]
+
, C17H24O5Na requires 331.1521. 
 
 
Synthesis of trioxolane dimer 19 
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 To a stirred solution of 5-adamantane-2-spiro-1’ 2’ 4’-trioxaspiro[4.5]decane 
carboxylic acid 12 (95mg, 0.31mmol) in DMF (2.5ml) was added EDC.HCl (95mg, 
0.50mmol, 1.6eq), HOBt (50mg, 0.37mmol, 1.2eq), and NMM (0.07ml, 0.064g, 0.64mmol, 
2.06eq) at 0
o
C. The mixture was allowed to activate for 3hrs under a N2 atmosphere. p-
Phenylenediamine (17.5mg, 0.16mmol, 0.52eq) and NMM (0.03ml, 0.028g, 0.27mmol, 
0.87eq) were added and the mixture was allowed to warm to room temperature overnight 
before being diluted with Et2O (30ml) and washed with water (2 x 30ml). The combined 
aqueous phases were extracted with Et2O (2 x 30ml). The combined organic extracts were 
washed with water (2 x 40ml), dried (MgSO4) and the solvent removed under reduced 
pressure. The crude product was adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/petroleum ether (eluting with 20:80) to afford the product 19 
(26mg, 12%) as a pale, straw coloured solid. The mono-coupled trioxolane (65mg, 32%) was 
also isolated as an orange oil.  
 
1
H NMR (400MHz, CDCl3)  7.72-7.69 (1H, m, NH), 7.55-7.52 (1H, m, NH), 7.48-7.44 (2H, 
d, CH aromatic), 7.25-7.21 (2H, d, CH aromatic), 2.30-0.85 (46H, m, adamantyl/cyclohexyl 
H). 
13
C NMR (100MHz, CDCl3)  174.8 (C=O), 134.1 (aromatic C), 128.8 (aromatic C), 120.5 
(quaternary C), 109.9 (quaternary C), 40.2, 38.3, 34.7, 33.6, 29.7, 28.9, 26.3, 24.9, 23.7.   
C40H52N2O8 requires C 69.74 %, H 7.61 %, N 4.07 found C 70.55 %, H 8.33 %, N 3.05 %. 
 
IR (neat)/cm
-1
: 3328 (N-H), 2933 (C-H), 1644 (C=O amide), 1536 (C=C aromatic), 1240 (C-
O), 941 (O-O). 
 
HRMS (ESI);  711.3600 [M+Na]
+
, C40H52N2O8Na requires 711.3621. 
 
 
Synthesis of 1,1-dihydroperoxycyclohexane 23
4
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 To a stirred solution of I2 (0.25g, 0.97mmol, 10mol%) in CH3CN (20ml) was added 
cyclohexanone 5 (1.0ml, 9.66mmol) and 50% aq. H2O2 (1.7ml, 29.9mmol, 3.1eq) in CH3CN 
(10ml). The reaction mixture was stirred at room temperature for 24hrs. The solvent was 
removed under reduced pressure, water (30ml) was added and the product extracted with 
Et2O (5 x 30ml). The combined organic extracts were dried (Na2SO4), and the solvent 
removed under reduced pressure. The crude product was adsorbed onto silica gel and purified 
by flash column chromatography using EtOAc/n-Hex (eluting with 10:90) to afford pure 1,1-
dihydroperoxycyclohexane 23 (1.10g, 77%)  as a colourless oil. 
 
1
H NMR (400MHz, CDCl3)  8.80-8.72 (2H, s, 2 x OOH), 1.87-1.81 (4H, t, J = 5.9 Hz, 2 x 
CH2), 1.62-1.55 (4H, m, 2 x CH2), 1.50-1.42 (2H, m, CH2). 
13
C NMR (100MHz, CDCl3)  111.3 (quaternary C), 29.9, 25.7, 22.8. 
C6H12O4 requires C 48.64 %, H 8.16 % found C 48.43 %, H 8.41 %. 
IR (neat)/cm
-1
: 3448 (OOH), 3181 (OH), 2937 (C-H alkyl), 1741, 1349 (C-O), 927 (O-O). 
  
LRMS (CI); 132.1 [M-OH]
+
, 116.1 [M-2OH]
+
. 
 
Side product: 1,1'-peroxybis(1-hydroperoxycyclohexane) 23a 
 
1
H NMR (400MHz, CDCl3)  9.55 (2H, s, 2 x OOH), 1.93-1.80 (8H, m, 8 x H-3), 1.64-1.55 
(8H, m, 8 x H-2), 1.51-1.40 (4H, m, 4 x H-4). 
13
C NMR (100MHz, CDCl3)  111.2 (2 x C-1), 29.8 (4 x C-2), 25.3 (4 x C-3), 22.5 (2 x C-4). 
C12H22O6 requires C 54.94 %, H 8.45 % found C 54.92 %, H 8.41 %. 
 
IR (neat)/cm
-1
: 3438 (OOH), 2937 (C-H alkyl), 1060 (C-O), 936 (O-O). 
 
HRMS (ESI); 285.1315 [M+Na]
+
, C12H22O6Na requires 285.1314. 
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Synthesis of adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-cyclohexane 215 
 
 
 To a stirred solution of 1,1-dihydroperoxycyclohexane 23 (0.30mg, 2.00mmol) and 
Re2O7 (24.3mg, 0.05mmol, 2.5mol%) in DCM (20ml) was added 2-adamantanone 6 (0.46g, 
3.03mmol, 1.5eq) in DCM (20ml). The reaction mixture was stirred at room temperature for 
4hrs. The crude product was adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/n-Hex (eluting with 2:98) to afford the product 21 (0.20g, 
35%) as a colourless solid.  
 
1
H NMR (400MHz, CDCl3)  2.30-1.25 (m, adamantyl/cyclohexyl H) 
13
C NMR (100MHz, CDCl3)  110.7 (quaternary C), 108.4 (quaternary C), 37.4, 33.6, 27.5, 
25.8. 
m.p 78-80
o
C 
C16H24O4 requires C 68.54 %, H 8.63 % found C 68.63 %, H 8.68 %. 
IR (neat)/cm
-1
: 2933 (C-H), 1448 (C-O), 1060 (C-O), 923 (O-O). 
 
Synthesis of 5-hydroxy-adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-
cyclohexane 7c 
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 To a solution of 1,1-dihydroperoxycyclohexane 23 (160mg, 1.09mmol) and Re2O7 
(15.8mg, 0.03mmol, 3.0mol%) in DCM (20ml) was added 5-hydroxy-2-adamantanone 7 
(270mg, 1.62mmol, 1.5eq) in DCM (20ml). The reaction mixture was stirred at room 
temperature overnight. The crude product was adsorbed onto silica gel and purified by flash 
column chromatography using EtOAc/n-Hex (eluting with 2:98) to afford the product 7c 
(52mg, 16%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  2.29-1.25 (m, adamantyl/cyclohexyl H). 
13
C NMR (100MHz, CDCl3)  110.7 (quaternary C), 108.5 (quaternary C), 108.4 (C-OH), 
37.4, 33.7, 32.2, 30.1, 27.5, 25.8, 22.6. 
IR (neat)/cm
-1
: 2919 (OH), 2854 (C-H alkyl), 1060 (C-O), 995 (O-O). 
HRMS (ESI): 351.1796 [(M+CH3OH)+Na]
+
, C17H28O6Na requires 351.1784. 
 
Synthesis of (dihydroperoxymethyl)benzene 30b 
 
 To a stirred solution of I2 (1.25g, 4.93mmol, 10mol%) in CH3CN (30ml) was added 
freshly distilled benzaldehyde 30a (5.0ml, 49.1mmol) and 50% aq. H2O2 (8.50ml, 
149.6mmol, 3.1eq) followed by CH3CN (20ml). The reaction mixture was stirred at room 
temperature for 20hrs. The solvent was removed under reduced pressure, water (50ml) was 
added and the product extracted with Et2O (6 x 50ml). The combined organic extracts were 
dried (Na2SO4) and evaporated under reduced pressure. The crude product was adsorbed onto 
silica gel and purified by flash column chromatography using EtOAc/n-Hex (eluting with 
10:90) to afford the product 30b (1.86g, 24%) as a yellow oil. 
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1
H NMR (400MHz, CDCl3)  9.60-9.30 (2H, br s, 2 x OOH), 7.50-7.30 (5H, m, aromatic H), 
6.40-6.30 (1H, br s, CH). 
13
C NMR (100MHz, CDCl3)  130.2 (quaternary C), 129.3, 128.9, 127.4, 110.5 (CH). 
C7H8O4 requires C 53.84 %, H 5.16 % found C 54.70 %, H 5.34 %. 
 
IR (neat)/cm
-1
: 3134 (OOH), 2843 (C-H aryl), 1683 (C=C), 1454, 1187 (C-O), 935 (O-O).  
 
LRMS (CI); 124.1 [M-OOH]
+
. 
 
 
Synthesis of 5-adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-methylbenzene 
30c
5
 
 
 To a stirred solution of 2-adamantanone 6 (0.44g, 2.90mmol, 1.5eq) and Re2O7 
(60mg, 0.12mmol, 6mol%) in DCM (20ml) was added (dihydroperoxymethyl)benzene 30b 
(0.30g, 1.92mmol) in DCM (10ml). After stirring at room temperature for 1.5hrs, the crude 
product was adsorbed onto silica gel and purified by flash column chromatography using 
EtOAc/n-Hex (eluting with 2:98) to afford the product 30c (0.23g, 41%) as a colourless solid. 
1
H NMR (400MHz, CDCl3)  7.42 (5H, m, Ar H), 6.68 (1H, s, benzylic CH), 2.18-1.63 (14H, 
m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  132.1, 131.4, 129.0, 127.9, 111.2 (quaternary C), 108.1 
(quaternary C), 37.4, 34.9, 31.3, 27.5. 
m.p 63-65
o
C 
C17H20O4 requires C 70.81 %, H 6.99 % found C 71.05 %, H 6.99 %. 
IR (neat)/cm
-1
: 2978 (C-H aryl), 2929 (C-H alkyl), 1687 (C=C), 1454 (C-O), 1294 (C-O), 707 
(O-O). 
HRMS (ESI); 311.1262 [M+Na]
+
,
 
C17H20O4Na requires 311.1259. 
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Synthesis of ethyl 4,4-dihydroperoxycyclohexanecarboxylate 24  
 
 
 
 To a solution of I2 (47mg, 0.19mmol, 9mol%) in CH3CN (10ml) was added ethyl 4-
oxocyclohexanecarboxylate 22 (0.28ml, 300mg, 1.76mmol) in CH3CN (10ml) and 50% aq. 
H2O2 (0.30ml, 5.27mmol, 3eq). The mixture was stirred at room temperature for 4 days. Most 
of the solvent was removed under reduced pressure, water (30ml) was added and the product 
extracted with DCM (6 x 30ml). The combined organic extracts were dried (Na2SO4) and the 
solvent removed under reduced pressure. The crude product was adsorbed onto silica gel and 
purified by flash column chromatography using EtOAc/petroleum ether (eluting with 20:80) 
to afford the product 24 (344mg, 88%) as a colourless oil. 
 
1
H NMR (400MHz, CDCl3)  9.10-8.95 (2H, br s, 2 x OOH), 4.20-4.10 (2H, q, J=7.1 Hz, 
CH2CH3), 2.45-2.36  (1H, m, J=3.7, 8.0 Hz, CHCO2Et), 2.27-2.19 (2H, dt, J=3.7, 13.9 Hz, 2 
x CH), 1.96-1.88 (2H, dt, J=3.7, 13.9 Hz, 2 x CH), 1.82-1.71 (2H, m, 2 x CH), 1.65-1.56 (2H, 
m, 2 x CH), 1.26 (3H, t, J=7.1 Hz, CH3). 
13
C NMR (100MHz, CDCl3)  176.3 (C=O), 110.0 (C-(OOH)2), 61.2 (CH2CH3), 42.2 (CH), 
28.6 (2 x CH2), 25.1 (2 x CH2), 14.6 (CH3). 
C9H16O6 requires C 49.08 %, H 7.32 % found C 48.33 %, H 7.65 %. 
 
IR (neat)/cm
-1
: 3421 (O-H), 2942 (C-H), 1708 (C=O), 1446 (O-O), 1060 (C-O). 
 
LRMS (CI); 188.2 [(M-OOH)+H]
+
.  
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Synthesis of adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-cyclohexane-4”-
ethyl carboxylate 33 
 
 
 
Method 1 
 To a solution of 2-adamantanone 6 (110mg, 0.73mmol, 1.6eq) and Re2O7 (5mg, 
0.01mmol, 2mol%) in DCM (15ml) was added ethyl 4,4-
dihydroperoxycyclohexanecarboxylate 24 (105mg, 0.47mmol, 1eq) in DCM (15ml). The 
mixture was stirred at room temperature for 16hrs. The crude product was adsorbed onto 
silica gel and purified by flash column chromatography using EtOAc/petroleum ether (eluting 
with 5:95) to afford the product 33 (122mg, 50%) as a colourless solid. 
 
Method 2 
 To a solution of 2-adamantanone 6 (105mg, 0.70mmol, 1.5eq) in DCM (10ml) was 
added MgSO4 (99mg, 0.82mmol, 1.7eq) and PMA (16mg, 9.1μmol, 2mol%). The mixture 
was stirred at room temperature for 20mins. Ethyl 4,4-dihydroperoxycyclohexanecarboxylate 
24 (104mg, 0.47mmol, 1eq) in DCM (10ml) was added drop-wise over 10mins and the 
mixture was stirred at room temperature for 3hrs. The crude product was adsorbed onto silica 
gel and purified by flash column chromatography using EtOAc/petroleum ether (eluting with 
5:95) to afford the product 33 (142mg, 85%) as a colourless solid. In CHCl3, 40% yield was 
obtained and in Et2O, 30% yield was obtained. 
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Method 3 
 
 To a solution of 2-adamantanone 6 (111mg, 0.74mmol, 1.6eq) was added MgSO4 
(99mg, 0.82mmol, 1.9eq) and PMA (14mg, 8μmol, 2mol%). The mixture was stirred at room 
temperature for 20mins. A solution of ethyl 4,4-dihydroperoxycyclohexanecarboxylate 24 
(96mg, 0.44mmol, 1eq) in DCM (5ml) was added drop-wise over 5mins and the mixture was 
stirred at room temperature until TLC showed that the dihydroperoxide had all reacted (2hrs). 
Ethyl 4,4-dihydroperoxycyclohexanecarboxylate 24 (112mg, 0.51mmol, 1.2eq) in DCM 
(5ml) was added and the mixture left to stir at room temperature for 4hrs. The crude product 
was adsorbed onto silica gel and purified by flash column chromatography using 
EtOAc/petroleum ether (eluting with 5:95) to afford the product 33 (190mg, 73%) as a 
colourless solid.  
 
 
1
H NMR (400MHz, CDCl3)  4.13 (2H, q, J=7.1 Hz, CH2CH3), 2.10-1.55 (23H, m, 
adamantyl/cyclohexyl H), 1.25 (3H, t, J=7.1 Hz, CH2CH3). 
13
C NMR (100MHz, CDCl3)  175.0 (C=O), 110.9 (quaternary C), 107.6 (quaternary C), 60.8 
(CH2CH3), 47.4 (CHCO2Et), 42.0 (CH2 bridgehead), 39.6 (2 x CH), 37.3 (2 x CH), 33.5 (4 x 
CH2), 27.8 (2 x CH2 cyclohexyl), 27.4 (2 x CH2 cyclohexyl), 14.1 (CH3).  
m.p 78-80
o
C 
C19H28O6 requires C 64.75 %, H 8.01 % found C 64.72 %, H 8.22 %.  
IR (neat)/cm
-1
: 2935 (C-H), 1732 (C=O), 1442 (O-O), 1060 (C-O).  
HRMS (ESI); 375.1783 [M+Na]
+
,
 
C19H28O6Na requires 375.1784. 
 
Synthesis of adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’spiro-1”-cyclohexane-4”-
carboxylic acid 34 
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 To a solution of adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-
cyclohexane-4”-ethyl carboxylate 33 (70mg, 0.20mmol) in MeOH (10ml) was added 15% aq. 
NaOH (10ml). The mixture was stirred at room temperature overnight and then acidified to 
pH 2 using 30% aq. HCl (10ml). The product was extracted with DCM (3 x 40ml). The 
combined organic extracts were dried (MgSO4) and the solvent evaporated under reduced 
pressure to afford the product 34 (63mg, 97%) as a colourless solid.  
 
1
H NMR (400MHz, CDCl3)  3.20-1.25 (24H, m, adamantyl/cyclohexyl H). 
13
C NMR (100MHz, CDCl3)  189.9 (C=O), 111.0 (quaternary C), 107.4 (quaternary C), 
41.5, 39.7, 37.3, 33.5, 27.4. 
m.p 156-158
o
C 
 
C17H24O6 requires C 62.95 %, H 7.46 % found C 63.47 %, H 7.58 %. 
 
IR (neat)/cm
-1
: 2931 (C-H), 1685 (C=O), 1446 (O-O), 1060 (C-O). 
 
HRMS (ESI); 347.1473 [M+Na]
+
,
 
C17H24O6Na requires 347.1471. 
 
Synthesis of 1-(4-tolyl)adamantane 40
6
 
 
 
 
 1-Bromoadamantane 39 (103mg, 0.48mmol) and FeCl3 (9mg, 0.06mmol, 12mol%) 
was added to toluene (5ml). The reaction mixture turned a red/brown colour and was stirred 
at 140
o
C under a N2 atmosphere for 23hrs. After cooling to room temperature, the reaction 
mixture was washed with 2M HCl (50ml) and the product extracted with DCM (3 x 40ml). 
The combined organic extracts were dried (MgSO4) and the crude product adsorbed onto 
silica gel and purified by flash column chromatography using petroleum ether (100%) to 
afford the product 40 (90mg, 83%) as a colourless solid. 
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1
H NMR (400MHz, CDCl3)  7.28-7.25 (2H, d, J=8.1 Hz, 2 x aromatic H), 7.14-7.12 (2H, d, 
J=8.1 Hz, 2 x aromatic H), 2.32 (3H, s, CH3), 2.09 (3H, br s, 3 x CH), 1.90 (6H, s, 3 x CH2), 
1.80-1.73 (6H, m, 3 x CH2). 
13
C NMR (100MHz, CDCl3)  148.9 (quaternary aromatic C), 135.3 (quaternary aromatic C), 
129.2 (2 x aromatic C), 125.1 (2 x aromatic C), 43.7, 37.2, 36.2 (quaternary adamantyl C), 
29.4, 21.3 (CH3). 
m.p 83-85
o
C 
 
C17H22 requires C 90.20 %, H 9.80 % found C 89.73 %, H 10.08 %. 
 
IR (neat)/cm
-1
: 2908 (C-H aryl), 2850 (C-H alkyl), 1511 (C=C). 
 
LRMS (CI): 226.2 [M+H]
+
.  
 
 
Synthesis of 1-(4-methoxyphenyl)adamantane 43 
 
 
 
 1-Bromoadamantane 39 (108mg, 0.50mmol) and FeCl3 (111mg, 0.68mmol) were 
added to anisole (5ml). The reaction mixture turned a red/brown colour and was stirred at 
155
o
C under a N2 atmosphere for 21hrs. After cooling to room temperature, the reaction 
mixture was washed with 2M HCl (50ml) and the product extracted with DCM (3 x 40ml). 
The combined organic extracts were dried (MgSO4) and the crude product adsorbed onto 
silica gel and purified by flash column chromatography using EtOAc/petroleum ether (eluting 
with 4:96) to afford the product 43 (120mg, 99%) as a colourless solid. 
 
 
1
H NMR (400MHz, CDCl3)  7.30-7.27 (2H, d, J=8.9 Hz, 2 x aromatic CH), 6.88-6.83 (2H, 
d, J=8.9 Hz, 2 x aromatic CH), 3.79 (3H, s, OCH3), 2.10-2.05 (3H, br s, 3 x adamantyl CH), 
1.90-1.87 (6H, br d, 3 x adamantyl CH2), 1.81-1.69 (6H, br m, 3 x adamantyl CH2). 
Chapter 5: Experimental Procedures  
162 
 
13
C NMR (100MHz, CDCl3)  157.7 (C-OCH3), 144.1 (quaternary aromatic C), 126.2 (2 x 
aromatic C), 113.8 (2 x aromatic C), 55.6 (OCH3), 43.8 (quaternary adamantyl C), 37.2, 35.9, 
29.4. 
m.p 70-72
o
C 
 
C17H22O requires C 84.25 %, H 9.15 % found C 84.07 %, H 9.37 %. 
 
IR (neat)/cm
-1
: 2912 (C-H aryl), 2850 (C-H alkyl), 1511 (C=C), 1180 (C-O). 
 
LRMS (CI): 242.0 [M+H]
+
. 
 
Synthesis of 5-bromo-2-adamantanone 36
7
 
 
 5-Hydroxy-2-adamantanone 7 (0.80g, 4.83mmol) was added to 48% aq. HBr (50ml) 
and stirred at 124
o
C for 24hrs. After cooling to room temperature, the reaction mixture was 
added to water (125ml) and the product extracted with Et2O (4 x 40ml). The combined 
organic extracts were washed with brine (40ml), dried (MgSO4) and the solvent evaporated 
under reduced pressure to afford the product 36 (0.62g, 56%) as a pale orange solid.  
1
H NMR (400MHz, CDCl3)  2.67-2.50 (8H, m, 4 x CH2), 2.26 (1H, br s, CH), 2.13-1.94 
(4H, m). 
13
C NMR (100MHz, CDCl3)  215.0 (C=O), 60.3 (C-Br), 49.5 (2 x CH2 next to C-Br), 49.4 
(2 x CH next to C=O), 48.2 (CH2CBr), 37.9 (2 x CH2), 31.7 (CH). 
m.p 143-146
o
C 
 
C10H13BrO requires C 52.42 %, H 5.72 % found C 53.07 %, H 5.84 %. 
 
IR (neat)/cm
-1
: 2927 (C-H), 1724 (C=O), 651 (C-Br). 
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HRMS (ESI); 229.0218 [M+H]
+
,
 
C10H13O
79
Br requires 229.0223 and 231.0196 [M+H]
+
, 
C10H13O 
81
Br requires 231.0203. 
 
 
Synthesis of 5-(o/p-tolyl)adamantan-2-one 48 
 
 
 
 5-Bromo-2-adamantanone 36 (110mg, 0.48mmol) and FeCl3 (116mg, 0.72mmol) 
were added to toluene (5ml) and stirred at 125
o
C under a N2 atmosphere for 24hrs. After 
cooling to room temperature, the reaction mixture was washed with 2M HCl (40ml) and the 
product extracted with DCM (3 x 40ml). The combined organic extracts were dried (MgSO4) 
and the crude product adsorbed onto silica gel and purified by flash column chromatography 
using EtOAc/petroleum ether (eluting with 10:90) to afford the product 48 (103mg, 89%, 
ratio of regioisomers 1:10, ortho:para) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.25-7.23 (2H, d, J=8.20 Hz, 2 x aromatic H), 7.16-7.13 (2H, 
d, J=8.20 Hz, 2 x aromatic H), 2.69-2.64 (2H, br s, 2 x CHC=O), 2.43-2.02 (14H, m, 
adamantyl H).  
13
C NMR (100MHz, CDCl3)  200.6 (C=O), 145.5 (quaternary aromatic C), 136.2 
(quaternary aromatic C), 129.5 (2 x aromatic C), 126.0 (2 x aromatic C), 47.1 (CH2), 44.9 (2 
x CHC=O), 43.1 (2 x CH2), 38.9 (2 x CH2 bridgehead), 36.2 (quaternary C), 28.6 (CH), 21.2 
(CH3). 
m.p 52-54
o
C 
C17H20O requires C 84.96 %, H 8.39 % found C 84.67 %, H 8.23 %. 
IR (neat)/cm
-1
: 2927 (C-H aryl), 2824 (C-H alkyl), 1720 (C=O), 1454 (C=C). 
LRMS (CI): 241.3 [M+H]
+
, 258.3 [M+NH4]
+
. 
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Synthesis of 5-(o/p-tolyl)adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”- 
cyclohexane 48a 
 
 
 
 To a solution of 5-(o/p-tolyl)adamantan-2-one 48 (71mg, 0.30mmol, 1.1eq) and 
Re2O7 (12mg, 0.02mmol, 6mol%) in DCM (10ml) was added 1,1-dihydroperoxycyclohexane 
23 (44mg, 0.29mmol) in DCM (10ml). The mixture was stirred at room temperature for 4hrs. 
The crude product was adsorbed onto silica gel and purified by flash column chromatography 
using EtOAc/petroleum ether (eluting with 10:90) to afford the product 48a (13mg, 12%) as a 
colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.25-7.22 (2H, d, J=8.09 Hz, 2 x aromatic H), 7.14-7.10 (2H, 
d, J=8.09 Hz, 2 x aromatic H), 2.35-1.40 (26H, m, adamantyl/cyclohexyl H).  
13
C NMR (100MHz, CDCl3)  146.9 (quaternary aromatic C), 135.7 (CCH3), 129.3 (2 x 
aromatic C), 125.2 (2 x aromatic C), 110.2 (quaternary C), 108.6 (quaternary C), 42.7 (CH2), 
39.3 (quaternary C), 35.8 (2 x CH2), 32.9 (2 x CH2 bridgehead), 32.7 (2 x CH), 30.1 (CH), 
28.2 (2 x CH2), 25.8 (CH2), 22.4 (2 x CH2), 21.3 (CH3).    
m.p 67-70
o
C 
C23H30O4 requires C 74.56 %, H 8.16 % found C 70.57 %, H 8.45 %. 
IR (neat)/cm
-1
: 2935 (C-H), 2881 (C-H), 1446 (C=C), 1068 (C-O), 921 (O-O). 
HRMS (ESI): 393.2038 [M+Na]
+
, C23H30O4Na requires 393.2042. 
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Synthesis of 5-(4-methoxyphenyl)adamantan-2-one 49 
 
 
 
 5-Bromo-2-adamantanone 36 (102mg, 0.45mmol) and FeCl3 (106mg, 0.65mmol) 
were added to anisole (5ml). The red/brown reaction mixture was stirred at 155
o
C under N2 
for 23hrs. After cooling to room temperature, the reaction mixture was washed with 2M HCl 
(40ml) and the product extracted with DCM (3 x 30ml). The combined organic extracts were 
dried (MgSO4) and the crude product adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/petroleum ether (eluting with 10:90) to afford the product 49 
(30mg, 27%, para and 74mg, 65%, ortho) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.28-7.25 (2H, d, J=8.9 Hz, 2 x aromatic H), 6.89-6.86 (2H, d, 
J=8.9 Hz, 2 x aromatic H), 3.80 (3H, s, OCH3), 2.67-2.63 (br s, 2 x CH next to C=O), 2.30-
2.03 (11H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  218.5 (C=O), 158.3 (C-OMe), 140.6 (quaternary aromatic C), 
126.2 (2 x aromatic C), 114.1 (2 x aromatic C), 55.7 (OCH3), 47.1 (quaternary adamantyl C), 
45.0 (2 x CH next to C=O), 42.6 (2 x CH2), 38.9 (2 x CH2), 35.9 (CH2), 28.6 (CH). 
m.p 60-64
o
C 
C17H20O2 requires C 79.65 %, H 7.86 % found C 78.83 %, H 7.78 %. 
IR (neat)/cm
-1
: 2927 (C-H), 1720 (C=O), 1515 (C=C), 1060 (C-O). 
HRMS (ESI): 279.1362 [M+Na]
+
, C17H20O2Na requires 279.1361. 
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Synthesis of 5-phenyladamantan-2-one 60 
 
 
 Benzene (2ml) was added to 5-bromo-2-adamantanone 36 (32mg, 0.14mmol) and 
FeCl3 (38mg, 0.23mmol, 1.6eq) and stirred at 70
o
C under N2 for 30hrs. After cooling to room 
temperature, the reaction mixture was washed with 2M HCl (30ml), the product extracted 
with DCM (2 x 20ml), dried (MgSO4) and the solvent removed under reduced pressure to 
afford the product 60 (22mg, 69%) as a brown, sticky solid. 
 
1
H NMR (400MHz, CDCl3)  7.37-7.33 (4H, m, 4 x aromatic H), 7.24-7.20 (1H, m, aromatic 
H), 2.70-2.65 (2H, br s, 2 x CH=CO), 2.46-1.95 (11H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  200.8 (C=O), 137.8 (quaternary aromatic C), 128.8 (2 x 
aromatic C), 126.6. (2 x aromatic C), 125.2 (aromatic C), 48.4 (CH2), 47.1 (2 x CHC=O), 
42.4 (2 x CH2), 38.9 (2 x CH2 bridgehead), 36.5 (quaternary C), 28.6 (CH). 
IR (neat)/cm
-1
: 2919 (C-H), 2854 (C-H), 1716 (C=O). 
 
LRMS (CI); 244.1 [M+NH4]
+
. 
 
Synthesis of 5-(4-phenoxyphenyl)adamantan-2-one 59 
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 5-Bromo-2-adamantanone 36 (50mg, 0.22mmol) and FeCl3 (60mg, 0.37mmol, 1.7eq) 
was added to diphenylether (2ml) and stirred at 155
o
C under N2 for 24hrs. After cooling to 
room temperature, the reaction mixture was washed with 2M HCl (40ml) and the product 
extracted with DCM (3 x 40ml). The combined organic extracts were dried (MgSO4) and the 
crude product adsorbed onto silica gel and purified by flash column chromatography using 
EtOAc/petroleum ether (eluting with 10:90) to afford the product 59 (20mg, 29%) as a sticky, 
orange solid. 
 
1
H NMR (400MHz, CDCl3)  7.36-7.28 (4H, m, aromatic H), 7.12-7.07 (1H, m, aromatic H), 
7.02-6.94 (4H, m, aromatic H), 2.70-2.65 (2H, br s, 2 x CH next to C=O), 2.30-2.02 (11H, m, 
adamantyl H). 
13
C NMR (100MHz, CDCl3)  218.3 (C=O), 157.7 (quaternary aromatic C), 155.9 
(quaternary aromatic C), 143.3 (quaternary aromatic C), 130.1 (2 x aromatic C), 126.5 (2 x 
aromatic C), 123.6 (aromatic C), 119.3 (2 x aromatic C), 119.0 (2 x aromatic C), 47.1 (CH2 
adamantyl), 45.0 (2 x CH next to C=O), 42.6 (2 x CH2 adamantyl), 38.9 (2 x CH2 
adamantyl), 36.1 (quaternary adamantyl C), 28.6 (adamantyl CH). 
C22H22O2 requires C 82.99 %, H 6.96 % found C 80.12 %, H 6.61 %. 
 
IR (neat)/cm
-1
: 2927 (C-H), 1720 (C=O), 1589 (C=C), 1234 (C-O). 
 
HRMS (ESI): 341.1505 [M+Na]
+
, C22H22O2Na requires 341.1517. 
 
Synthesis of 5-(4-phenoxyphenyl)adamantyl-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-
1”- cyclohexane 69 
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 To a solution of 5-(4-phenoxyphenyl)adamantan-2-one 59 (41mg, 0.13mmol, 1.0eq) 
and Re2O7 (23mg, 0.05mmol, 38mol%) in DCM (10ml) was added 1,1-
dihydroperoxycyclohexane (21mg, 0.14mmol) in DCM (10ml). The mixture was stirred at 
room temperature for 3hrs. The crude product was adsorbed onto silica gel and purified by 
flash column chromatography using EtOAc/petroleum ether (eluting with 8:92) to afford the 
product 69 (5mg, 8%) as a colourless semi-solid. 
 
1
H NMR (400MHz, CDCl3)  7.35-7.28 (4H, m, aromatic H), 7.11-7.06 (1H, m, aromatic H), 
7.02-6.93 (4H, m, aromatic H), 2.35-1.41 (23H, m, adamantyl/cyclohexyl H).  
13
C NMR (100MHz, CDCl3)  167.1 (aromatic C-O), 155.3 (aromatic C-O), 140.4 
(quaternary aromatic C), 130.1 (2 x aromatic C), 126.6 (2 x aromatic C), 123.4 (2 x aromatic 
C), 119.1 (aromatic C), 118.9 (2 x aromatic C), 110.1 (quaternary C), 108.6 (quaternary C), 
42.9 (CH2), 39.3 (quaternary C), 35.8 (2 x CH2), 32.7 (2 x CH2 bridgehead), 32.2 (2 x CH), 
30.0 (CH), 28.2 (2 x CH2), 25.8 (CH2), 22.5 (2 x CH2). 
IR (neat)/cm
-1
: 2957 (C-H), 1604 (C=C aromatic), 1241 (C-O), 904 (O-O). 
 
HRMS (ESI): 471.2139 [M+Na]
+
,
 
C28H32O5Na requires 471.2147. 
 
Synthesis of 5-(4-bromophenyl)adamantan-2-one 50 
 
 
Method 1 – starting from 5-bromo-2-adamantanone 
 
 5-Bromo-2-adamantanone 36 (78mg, 0.34mmol) and FeCl3 (92mg, 0.57mmol, 1.7eq) 
were added to bromobenzene (5ml) and stirred at 130
o
C under N2 for 24hrs. The reaction 
mixture was washed with 2M HCl (50ml) and the product extracted with DCM (3 x 40ml). 
The combined organic extracts were dried (MgSO4) and the crude product adsorbed onto 
silica gel and purified by flash column chromatography using EtOAc/petroleum ether (eluting 
with 10:90) to afford the product 50 (79mg, 76%) as a pale orange solid. 
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Method 2 – starting from 5-hydroxy-2-adamantanone 
 
 To a stirred solution of 5-hydroxy-2-adamantanone 7 (48mg, 0.29mmol) in 
bromobenzene (10ml) was added TfOH (0.03ml, 0.34mmol, 1.2eq) slowly drop-wise 
(caution: fumes on addition). The yellow-ish reaction mixture was left to stir at room 
temperature for 5mins. The reaction was then heated at 130
o
C for 1hr and a colour change 
from yellow to orange to brown was observed. After cooling to room temperature, the 
reaction mixture was quenched (slow addition) with aq. NaHCO3 (10ml) at 0
o
C and the 
product extracted with Et2O (2 x 30ml). The combined organic extracts were dried (Na2SO4) 
and the crude product adsorbed onto silica gel and purified by flash column chromatography 
using EtOAc/petroleum ether (eluting with 10:90) to afford the product 50 (52mg, 59%) as a 
pale orange solid.  
 
1
H NMR (400MHz, CDCl3)  7.46-7.43 (2H, d, J=8.8 Hz, 2 x aromatic H), 7.23-7.20 (2H, d, 
J=8.8 Hz, 2 x aromatic H), 2.67 (2H, br s, 2 x CH next to C=O), 2.31-2.02 (11H, m, 
adamantyl H). 
13
C NMR (100MHz, CDCl3)  217.9 (C=O), 147.4 (quaternary aromatic C), 131.9 (2 x 
aromatic C), 127.1 (2 x aromatic C), 120.5 (C-Br), 46.9 (2 x CH next to C=O), 44.6, 42.3, 
38.8, 36.3, 28.5. 
m.p 120-122
o
C 
 
C16H17BrO requires C 62.96 %, H 5.61 % found C 62.74 %, H 5.44 %. 
 
IR (neat)/cm
-1
: 2927 (C-H aryl), 2857 (C-H alkyl), 1716 (C=O), 1492 (C=C), 628 (C-Br). 
   
HRMS (ESI); 327.0366 [M+Na]
+
,
 
C16H17ONa
79
Br requires 327.0360 and 329.0355 [M+Na]
+
,
 
C16H17ONa
81
Br requires 329.0340. 
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Synthesis of 5-(4-bromophenyl)adamantane-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-
1”- cyclohexane-4”-ethyl carboxylate 65 
 
 
 
 
Method 1 
 To a solution of 5-(4-bromophenyl)adamantan-2-one 50 (320mg, 1.05mmol, 1.1eq) 
and Re2O7 (26mg, 0.05mmol, 6mol%) in DCM (15ml) was added ethyl 4,4- 
dihydroperoxycyclohexanecarboxylate 24 (210mg, 0.96mmol, 1eq) in DCM (15ml). The 
mixture was stirred at room temperature for 4hrs. The crude product was adsorbed onto silica 
gel and purified by flash column chromatography using EtOAc/petroleum ether (eluting with 
8:92) to afford the product 65 (120g, 24%) as a colourless solid. 
 
Method 2 
 To a solution of 5-(4-bromophenyl)adamantan-2-one 50 (83mg, 0.27mmol, 1.1eq) 
was added MgSO4 (59mg, 0.50mmol 2eq) and PMA (9mg, 5μmol, 2mol%) and stirred at 
room temperature for 20mins. Ethyl 4,4-dihydroperoxycyclohexanecarboxylate 24 (54mg, 
0.25mmol, 1eq) in DCM (5ml) was added drop-wise over 10mins and the mixture stirred at 
room temperature for 4hrs. The crude product was adsorbed onto silica gel and purified by 
flash column chromatography using EtOAc/petroleum ether (eluting with 8:92) to afford the 
product 65 (46mg, 37%) as a colourless solid.   
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Method 3 
 To a solution of 5-(4-bromophenyl)adamantan-2-one 50 (77mg, 0.25mmol, 1.07eq) 
was added MgSO4 (53mg, 0.44mmol, 1.8eq) and PMA (18mg, 10μmol, 4mol%) and stirred 
at room temperature for 20mins. Ethyl 4,4-dihydroperoxycyclohexanecarboxylate 24 (52mg, 
0.24mmol, 1eq) in DCM (5ml) was added drop-wise over 5mins and the mixture stirred at 
room temperature until TLC showed that all of the dihydroperoxide had reacted (2hrs). Ethyl 
4,4-dihydroperoxycyclohexanecarboxylate 24 (54mg, 0.25mmol, 1eq) in DCM (5ml) was 
added and the mixture was left to stir at room temperature for 4hrs. The crude product was 
adsorbed onto silica gel and purified by flash column chromatography using 
EtOAc/petroleum ether (eluting with 8:92) to afford the product 65 (54mg, 42%) as a 
colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.43-7.40 (2H, d, J=8.6 Hz, 2 x aromatic H), 7.23-7.19 (2H, d, 
J=8.6 Hz, 2 x aromatic H), 4.17-4.11 (2H, q, J=7.1 Hz, CH2CH3), 2.45-1.50 (22H, m, 
adamantyl/cyclohexyl H), 1.27-1.23 (3H, t, J=7.1 Hz, CH2CH3).  
13
C NMR (100MHz, CDCl3)  175.0 (C=O), 148.7 (quaternary aromatic C), 131.6 (2 x 
aromatic C), 127.2 (2 x aromatic C), 120.1 (C-Br), 110.2 (quaternary C), 107.8 (quaternary 
C), 60.9 (O-CH2CH3), 42.5 (C-CO2Et), 42.0, 41.9, 39.0, 36.0, 32.5, 28.0, 14.6 (O-CH2CH3). 
m.p 102-105
o
C 
C25H31BrO6 requires C 59.18 %, H 6.16 % found C 59.05 %, H 6.05 %. 
IR (neat)/cm
-1
: 2938 (C-H aryl), 2861 (C-H alkyl), 1724 (C=O), 1450 (O-O), 1056 (C-O). 
HRMS (ESI); 529.1185 [M+Na]
+
,
 
C25H31O6Na
79
Br requires 529.1202 and 531.1159 
[M+Na]
+
, C25H31O6Na
81
Br requires 531.1181. 
 
 
Synthesis of 2,2,2-trifluoro-N-phenylacetamide 62a
8
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 To a stirred solution of aniline 62 (0.35ml, 3.83mmol) in dry DCM (15ml) was added 
TFAA (1.50ml, 10.60mmol, 2.8eq) and the reaction mixture changed from colourless to pink. 
NEt3 (3.50ml, 25.00mmol, 6.5eq) was added slowly drop-wise over 10mins (caution: fumes 
on addition) and the reaction mixture changed from pink to yellow. After stirring at room 
temperature for 4hrs, water (30ml) was added and the product extracted with DCM (3 x 
30ml). The combined organic extracts were dried (MgSO4) and the crude product adsorbed 
onto silica gel and purified by flash column chromatography using EtOAc/petroleum ether 
(eluting with 8:92) to afford the product 62a (0.53g, 73%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.59-7.55 (2H, d, J=7.9 Hz, 2 x aromatic H), 7.43-7.38 (2H, t, 
J=15.9, 7.9 Hz, 2 x aromatic H), 7.27-7.25 (1H, m, aromatic H).  
13
C NMR (100MHz, CDCl3)  155.0 (C=O), 135.4 (C-NH), 129.8 (2 x aromatic C), 126.8 
(aromatic C), 120.9 (2 x aromatic C), 117.5 (CF3). 
m.p 78-80
o
C 
 
IR (neat)/cm
-1
: 3320 (N-H), 2972 (C-H aryl), 1700 (C=O), 1546 (C=C).  
 
LRMS (CI); 189.2 [M+H]
+
,
 
207.2 [M+NH4]
+
. 
 
Synthesis of 5-(4-bromophenyl)spiro[adamantane-2,2'-[1,3]dioxolane] 79 
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 To a stirred solution of 5-(4-bromophenyl)adamantan-2-one 50 (254mg, 0.83mmol) 
and p-toluenesulfonic acid (62mg, 0.36mmol) in toluene (30ml) was added ethylene glycol 
(0.1ml, 1.8mmol, 2.2eq) and the resulting mixture was refluxed in a Dean Stark apparatus for 
24hrs. The reaction mixture was allowed to cool to room temperature, 20% aq. K2CO3 (50ml) 
was added and the product extracted with toluene (2 x 40ml). The combined organic extracts 
were dried (Na2SO4) and the crude product adsorbed onto silica gel and purified by flash 
column chromatography using EtOAc/petroleum ether (eluting with 8:92) to afford the 
product 79 (260mg, 89%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.25-7.22 (2H, d, J=8.7 Hz, 2 x aromatic H), 7.07-7.04 (2H, d, 
J=8.7 Hz, 2 x aromatic H), 3.80 (4H, s, 2 x CH2), 2.05-2.00 (2H, d, 2 x CH next to C-O), 
1.87-1.45 (11H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  149.5 (quaternary aromatic C), 131.5 (2 x aromatic C), 127.3 
(quaternary C), 119.8 (2 x aromatic C), 111.1 (C-Br), 64.8 (2 x CH2), 42.7 (CH2), 40.9 (2 x 
CH next to C-O), 37.2 (quaternary aliphatic C), 36.0 (2 x CH2), 34.3 (2 x CH2), 27.8 (CH). 
m.p 63-65
o
C 
 
C18H21BrO2 requires C 61.90 %, H 6.06 % found C 61.77 %, H 5.98 %. 
 
IR (neat)/cm
-1
: 2911 (C-H alkyl), 1621 (C=C aromatic), 1126 (C=O), 674 (C-Br).  
 
HRMS (ESI); 349.0798 [M+H]
+
,
 
C18H22O2
79
Br requires 349.0803 and 351.0784 [M+H]
+
,
 
C18H22O2
81
Br requires 351.0783. 
 
 
Synthesis of methyl 3-(4-oxoadamantan-1-yl)benzoate 58 
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 Methyl benzoate (2ml, 2.20mmol) was added to 5-bromo-2-adamantanone 36 (50mg, 
0.22mmol) and FeCl3 (54mg, 0.32mmol, 1.5eq) and stirred at 170
o
C under N2 for 3 days. 
After cooling to room temperature, the reaction mixture was washed with 2M HCl (40ml) 
and the product extracted with DCM (3 x 40ml). The combined organic extracts were dried 
(MgSO4) and the crude product adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/petroleum ether (eluting with 10:90) to afford the product 58 
(28mg, 45%) as a colourless, sticky semi-solid. 
 
1
H NMR (400MHz, CDCl3)  8.07-8.04 (1H, br m, aromatic H), 7.93-7.88 (1H, br m, 
aromatic H), 7.65-7.60 (1H, m, aromatic H), 7.56-7.53 (1H, m, aromatic H), 3.94 (3H, s, 
OCH3), 2.71-2.69 (2H, br s, 2 x CH next to C=O), 2.30-2.05 (11H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  218.1 (C=O ketone), 167.6 (C=O ester), 148.7 (quaternary 
aromatic C), 134.1 (aromatic C), 130.7 (aromatic C), 128.9 (aromatic C), 127.9 (aromatic C), 
126.6 (aromatic C), 52.6 (OCH3), 47.0, 44.6, 42.4, 38.8, 36.6 (quaternary adamantyl C), 28.5. 
C18H20O3 requires C 76.03 %, H 7.09 % found C 76.11 %, H 6.97 %. 
 
HRMS (ESI); 307.1318 [M+Na]
+
,
 
C18H21O3Na requires 307.1310 and 285.1487 [M+H]
+
,
 
C18H21O3 requires 285.1491. 
 
 
Synthesis of 3-(4-oxoadamantan-1-yl)benzoic acid 84 
 
 
 
 To a solution of methyl 3-(4-oxoadamantan-1-yl)benzoate 58 (125mg, 0.44mmol) in 
MeOH (5ml) was added 15% aq. NaOH (5ml). The mixture was stirred at 65
o
C for 6hrs and 
then acidified to pH 2 using 2M HCl (15ml). The product was extracted with DCM (3 x 
20ml). The combined organic extracts were dried (MgSO4) and the solvent evaporated under 
reduced pressure to afford the product 84 (80mg, 66%) as a colourless solid.  
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1
H NMR (400MHz, CDCl3)  8.15-8.07 (1H, m, aromatic H), 8.01-7.97 (1H, m, aromatic H), 
7.65-7.60 (1H, m, aromatic H), 7.51-7.44 (1H, m, aromatic H), 2.73-2.68 (2H, br s, 2 x CH 
next to C=O), 2.35-2.05 (12H, m, adamantyl H). 
13
C NMR (100MHz, CDCl3)  218.2 (C=O ketone), 172.2 (C=O acid), 148.9 (quaternary 
aromatic C), 134.2 (aromatic C), 130.6 (quaternary aromatic C), 128.9 (aromatic C), 128.6 
(aromatic C), 127.2 (aromatic C), 47.0, 44.6, 42.4, 38.8, 36.6 (quaternary adamantyl C), 28.5. 
m.p 204-206
o
C 
 
C17H18O3 requires C 75.53 %, H 6.71 % found C 73.07 %, H 6.41 %. 
 
IR (neat)/cm
-1
: 3000 (OH), 2927 (C-H), 1715, (C=O), 1735 (C=O), 1650 (C=C). 
 
LRMS (CI); 288.3 [M+NH4]
+
. 
 
 
Synthesis of methyl 3-(4-oxoadamantan-1-yl)benzoate-2-spiro-3’-1’,2’,4’,5’-tetraoxane-
6’-spiro-1”- cyclohexane-4”-ethyl carboxylate 67 
 
 
 
 To a solution of methyl 3-(4-oxoadamantan-1-yl)benzoate 58 (83mg, 0.29mmol, 
1.04eq) and Re2O7 (44mg, 0.09mmol, 32mol%) in DCM (10ml) was added ethyl 4,4- 
dihydroperoxycyclohexanecarboxylate 24 (63mg, 0.28mmol) in DCM (10ml). The mixture 
was stirred at room temperature for 4hrs. The crude product was adsorbed onto silica gel and 
purified by flash column chromatography using EtOAc/petroleum ether (eluting with 8:92) to 
afford the product 67 (19mg, 14%) as a colourless, sticky semi-solid. 
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1
H NMR (400MHz, CDCl3)  8.03-8.01 (1H, br m, aromatic H), 7.89-7.85 (1H, br m, 
aromatic H), 7.57-7.53 (1H, br m, aromatic H), 7.41-7.36 (1H, br m, aromatic H), 4.18-4.10 
(2H, q, J=7.1 Hz, CH2CH3), 3.92 (3H, s, OCH3), 1.60-1.45 (22H, m, adamantyl/cyclohexyl 
H), 1.28-1.23 (3H, t, CH2CH3). 
13
C NMR (100MHz, CDCl3)  175.0 (C=O ester), 167.8 (C=O ester), 148.7 (quaternary 
aromatic C), 130.5 (aromatic C), 130.0 (aromatic C), 128.7 (aromatic C), 127.7 (aromatic C), 
126.6 (aromatic C), 110.2 (quaternary C), 107.9 (quaternary C), 60.9 (O-CH2CH3), 52.5 
(OCH3), 42.7, 42.0, 41.9, 39.0, 36.3, 32.6, 28.1, 14.6 (O-CH2CH3). 
m.p 52-54
o
C 
IR (neat)/cm
-1
: 2935 (C-H), 1720 (C=O ester), 1184 (C-O), 937 (O-O). 
 
HRMS (ESI); 509.2160 [M+Na]
+
,
 
C27H34O8Na requires 509.2151. 
 
 
Synthesis of methyl 3-(4-oxoadamantan-1-yl)benzoate-2-spiro-3’-1’,2’,4’,5’-tetraoxane-
6’-spiro-1”- cyclohexane 68 
 
 
 
Method 1 
 To a solution of methyl 3-(4-oxoadamantan-1-yl)benzoate 58 (180mg, 0.63mmol, 
1.01eq) and Re2O7 (60mg, 0.12mmol, 20mol%) in DCM (10ml) was added 1,1-
dihydroperoxycyclohexane 23  (93mg, 0.62mmol, 1eq) in DCM (10ml). The mixture was 
stirred at room temperature for 4hrs. The crude product was adsorbed onto silica gel and 
purified by flash column chromatography using EtOAc/petroleum ether (eluting with 5:95) to 
afford the product 68 (20mg, 8%) as a colourless, sticky semi-solid. 
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Method 2 
 To a solution of methyl 3-(4-oxoadamantan-1-yl)benzoate 58 (101mg, 0.36mmol, 
1.1eq) was added MgSO4 (75mg, 0.62mmol, 1.8eq) and PMA (11mg, 6μmol, 2mol%). The 
mixture was stirred at room temperature for 20mins. 1,1-dihydroperoxycyclohexane 23 
(50mg, 0.34mmol, 1eq) in DCM (10ml) was added drop-wise over 10mins and the mixture 
was stirred at room temperature for 3hrs. The crude product was adsorbed onto silica gel and 
purified by flash column chromatography using EtOAc/petroleum ether (eluting with 5:95) to 
afford the product 68 (20mg, 14%) as a colourless solid.   
Method 3 
 To a solution of methyl 3-(4-oxoadamantan-1-yl)benzoate 58 (60mg, 0.21mmol, 
1.04eq) was added MgSO4 (45mg, 0.37mmol, 1.8eq) and PMA (23mg, 12μmol, 6mol%). The 
mixture was stirred at room temperature for 20mins. A solution of 1,1-
dihydroperoxycyclohexane 23 (30mg, 0.20mmol, 1eq) in DCM (5ml) was added drop-wise 
over 5mins and the mixture was stirred at room temperature until TLC showed that all of the 
dihydroperoxide had reacted (1hr). 1,1-dihydroperoxycyclohexane 23 (30mg, 0.20mmol, 
1eq) in DCM (5ml) was added and the reaction mixture left to stir at room temperature for 
2hrs. The crude product was adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/petroleum ether (eluting with 5:95) to afford the product 68 
(20mg, 22%) as a colourless solid. 
1
H NMR (400MHz, CDCl3)  8.04-8.02 (1H, br m, aromatic H), 7.89-7.85 (1H, br dt, 
aromatic H), 7.57-7.54 (1H, br m, aromatic H), 7.40-7.36 (1H, br m, aromatic H), 3.91 (3H, s, 
OCH3), 2.40-1.60 (23H, m, adamantly/cyclohexyl H).  
13
C NMR (100MHz, CDCl3)  167.1 (C=O), 150.2 (quaternary aromatic C), 130.5 
(quaternary aromatic C), 130.1 (aromatic C), 128.7 (aromatic C), 127.6 (aromatic C), 126.6 
(aromatic C), 110.0 (quaternary C), 108.7 (quaternary C), 52.5 (O-CH3), 44.6, 42.7, 39.0, 
37.2, 36.3, 32.6, 28.1, 25.8. 
C24H30O6 requires C 69.54 %, H 7.30 % found C 69.24 %, H 7.19 %. 
 
IR (neat)/cm
-1
: 2978 (C-H aryl), 2928 (C-H alkyl), 1749 (C=O), 1430 (O-O), 1046 (C-O). 
 
HRMS (ESI); 437.1938 [M+Na]
+
,
 
C24H30O6Na requires 437.1940. 
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Synthesis of 3-(4-oxoadamantan-1-yl)benzoic acid-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-
spiro-1”- cyclohexane 86 
 
 
 
 To a solution of methyl 3-(4-oxoadamantan-1-yl)benzoate-2-spiro-3’-1’,2’,4’,5’-
tetraoxane-6’-spiro-1”- cyclohexane 68 (20mg, 0.05mmol) in MeOH (5ml) was added 15% 
aq. NaOH (5ml). The mixture was stirred at 65
o
C for 5hrs and then acidified to pH 2 using 
2M HCl (10ml). The product was extracted with DCM (3 x 10ml). The combined organic 
extracts were dried (MgSO4) and the solvent evaporated under reduced pressure to afford the 
product 86 (19mg, 100%) as a colourless solid.  
 
1
H NMR (400MHz, CDCl3)  8.10-8.07 (1H, br s, aromatic H), 7.95-7.91 (1H, m, aromatic 
H), 7.61-7.59 (1H, m, aromatic H), 7.45-7.39 (1H, m, aromatic H), 2.40-1.20 (24H, m, 
adamantyl/cyclohexyl H). 
13
C NMR (100MHz, CDCl3)  160.1 (C=O), 145.1 (quaternary aromatic C), 131.4 
(quaternary aromatic C), 130.5 (aromatic C), 128.2 (aromatic C), 127.3 (aromatic C), 126.6 
(aromatic C), 110.2 (quaternary C), 108.5 (quaternary C), 43.7, 41.2, 40.4, 38.0, 35.3, 33.5, 
27.1, 24.9. 
C23H28O6 requires C 68.98 %, H 7.05 % found C 68.89 %, H 7.06 %. 
 
IR (neat)/cm
-1
: 3049 (OH), 2978 (C-H alkyl), 1724 (C=O), 1280 (C-O). 
 
HRMS (ESI); 399.1804 [M-H]
-
,
 
C23H27O6 requires 399.1808. 
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Synthesis of N-(4-aminophenyl)-3-(4-oxoadamantan-1-yl)benzamide-2-spiro-3’-
1’,2’,4’,5’-tetraoxane-6’-spiro-1”-cyclohexane 87 
 
 
 
 EDC.HCl (20mg, 0.1mmol, 1.6eq), HOBt (10mg, 0.07mmol, 1.2eq) and NMM 
(0.02ml, 0.18mmol, 3eq) were added to a stirred solution of 3-(4-oxoadamantan-1-yl)benzoic 
acid-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-cyclohexane 86 (25mg, 0.06mmol, 1eq) in 
DMF (5ml) at 0
o
C. The mixture was stirred at room temperature for 3hrs under a N2 
atmosphere. p-Phenylenediamine (13mg, 0.12mmol, 2eq) in DMF (5ml) was added and the 
mixture was stirred at room temperature overnight before quenching with water (30ml), the 
product was extracted with Et2O (3 x 20ml) and dried (MgSO4). The crude product adsorbed 
onto silica gel and purified by flash column chromatography using EtOAc/petroleum ether 
(eluting with 70:30) to afford the product 87 (4mg, 12%) as a sticky yellow oil.  
 
IR (neat)/cm
-1
: 3343 (N-H), 2919 (C-H), 1596 (C=O), 1060 (C-O), 933 (O-O). 
 
LRMS (ESI): 513.2 [M+Na]
+
. 
 
 
Synthesis of 3-(4-oxoadamantan-1-yl)benzoic acid-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-
spiro-1”- cyclohexane-4”-ethyl carboxylate 85 
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 To a solution of 3-(4-oxoadamantan-1-yl)benzoic acid 84 (13mg, 0.05mmol, 1eq) and 
Re2O7 (16mg, 0.03mmol, 33mol%) in DCM (5ml) was added ethyl 4,4- 
dihydroperoxycyclohexanecarboxylate 24 (21mg, 0.10mmol, 2eq) in DCM (5ml). The 
mixture was stirred at room temperature for 4hrs. The crude product was adsorbed onto silica 
gel and purified by flash column chromatography using EtOAc/petroleum ether (eluting with 
10:90) to afford the product 85 (32mg, 73%) as a colourless solid. This was an inseparable 
mixture with the starting material, 3-(4-oxoadamantan-1-yl)benzoic acid. 
IR (neat)/cm
-1
: 3048 (OH), 2938 (C-H), 1744 (C=O acid), 1730 (C=O ester), 1037 (C-O). 
 
HRMS (ESI); 495.1999 [M+Na]
+
,
 
C26H32O8Na requires 495.1995. 
 
 
Synthesis of N-(4-aminophenyl)-3-(4-oxoadamantan-1-yl)benzamide 90 
 
 
 
 EDC.HCl (67mg, 0.35mmol, 1.2eq), HOBt (46mg, 0.34mmol, 1.2eq) and NMM 
(0.07ml, 0.64mmol, 2.1eq) were added to 3-(4-oxoadamantan-1-yl)benzoic acid 84 (83mg, 
0.31mmol, 1eq) in DMF (5ml) at 0
o
C. The solution was stirred at room temperature for 3hrs 
under N2 before p-phenylenediamine (71mg, 0.66mmol, 2.1eq) was added. After stirring at 
room temperature overnight, water (50ml) was added and the product extracted with Et2O (3 
x 30ml). The combined organic extracts were dried (MgSO4) and the crude product adsorbed 
onto silica gel and purified by flash column chromatography using EtOAc/petroleum ether 
(eluting with 60:40) to afford the product 90 (37mg, 34%) as a brown oil. 
 
1
H NMR (400MHz, CDCl3)  8.04-8.01 (1H, br s, aromatic H), 7.91-7.88 (1H, br s, aromatic 
H), 7.66-7.62 (1H, d, J=7.74 Hz, aromatic H), 7.49-7.46 (1H, d, J=7.47 Hz, aromatic H), 
7.43-7.36 (5H, m, aromatic H), 6.69-6.65 (2H, d, J=8.72 Hz, NH2), 2.68-2.61 (2H, br s, 2 x 
CHC=O), 2.30-1.99 (11H, m, adamantyl H).    
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HRMS (ESI): 361.1928 [M+H]
+
,
 
C23H25N2O2 requires 361.1916. 
 
 
Synthesis of 3-benzylbicycloheptan-2-one 95
9
 
 
 LDA was prepared by reaction of 
i
Pr2NH (0.31ml, 2.21mmol, 1.19eq) with 
n
BuLi 
(1.40ml of a 1.5M solution in hexane, 2.1mmol) in dry THF (20ml) at 0
o
C for 15mins. 
Norcamphor 94 (0.20g, 1.86mmol, 1eq) in dry THF (4ml) was added and the reaction 
mixture was stirred at 0
o
C for 30mins. The flask was cooled to -78
o
C and benzyl bromide 
(0.24ml, 2.01mmol, 1.08eq) was added. The reaction mixture was stirred at -78
o
C for 30mins 
before warming to room temperature overnight. The reaction was quenched with MeOH 
(10ml) and the crude product adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/n-Hex (eluting with 5:95) to afford the product 95 (0.35g, 
94%) as a colourless oil. 
 
1
H NMR (400MHz, CDCl3)  7.25 (5H, m, aromatic H), 2.99 (2H, dd, J = 4.2, 14.0 Hz, 
benzylic CH2), 2.42 (1H, m, CHCH2), 2.04 (1H, dt, J = 3.7, 11.5 Hz, CHC=O), 1.92 (1H, dt, 
J = 1.7, 10.7 Hz, CH), 1.79 (2H, m, bridgehead CH2), 1.51 (2H, m), 1.34 (2H, m). 
13
C NMR (100MHz, CDCl3)  219.56 (C=O), 140.4 (quaternary C-CH2), 129.3 (aromatic C), 
128.9 (aromatic C), 126.7 (aromatic C), 55.9, 50.3, 38.4, 35.2, 34.9, 28.4, 24.4. 
C14H16O requires C 83.95 %, H 8.05 % found C 84.25 %, H 8.15 %. 
 
IR (neat)/cm
-1
: 2960 (C-H aryl), 2875 (C-H alkyl), 1743 (C=O), 1498 (C=C) 
 
HRMS (ESI); 223.1099 [M+Na]
+ 
C14H16O requires 223.1094. 
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Synthesis of 3-benzylbicycloheptan-2-spiro-3’-1’,2’,4’,5’-tetraoxane-6’-spiro-1”-
cyclohexane 98 
 
 To a stirred solution of 1,1-dihydroperoxycyclohexane 23 (130mg, 0.89mmol) and 
Re2O7 (38.6mg, 0.08mmol, 9mol%) in DCM (20ml) was added 3-benzylbicycloheptan-2-one 
95 (260mg, 1.30mmol, 1.5eq) in DCM (20ml). The reaction mixture was stirred at room 
temperature for 1hr. The crude product was adsorbed onto silica gel and purified by flash 
column chromatography using EtOAc/n-Hex (eluting with 2:98) to afford the product 98 
(65mg, 22%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.19-7.09 (5H, m, aromatic H), 2.30-1.30 (21H, m, aliphatic H) 
13
C NMR (100MHz, CDCl3)  129.4, 128.6, 126.2, 108.6 (quaternary C), 108.1 (quaternary 
C), 35.6, 32.7, 31.1, 29.9, 25.9, 25.7, 25.6, 23.1, 22.6, 22.3. 
m.p 122-124
o
C 
C20H26O4 requires C 72.70 %, H 7.93 % found C 72.83 %, H 8.53 %. 
IR (neat)/cm
-1
: 2938 (C-H aryl), 2861 (C-H alkyl), 1446 (C=C aromatic), 1270 (C-O), 1162 
(C-O), 923 (O-O). 
LRMS (ESI); 353.2 [M+Na]
+
. 
 
Synthesis of 3-oxobicycloheptane-2-carboxylic acid 96
9
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 LDA was prepared by reaction of 
i
Pr2NH (0.31ml, 2.21mmol, 1.21eq) with 
n
BuLi 
(1.30ml of a 1.5M solution in hexane, 1.95mmol) in dry THF (25ml) at 0
o
C for 15mins. 
Norcamphor 94 (0.20g, 1.83mmol, 1eq) in dry THF (7ml) was added and the reaction 
mixture was left to stir at 0
o
C for 30mins. A 100ml, 2-necked round bottomed flask was filled 
with dry ice and equipped with a septum and a CaCl2 drying tube. CO2 was bubbled into the 
reaction mixture at 0
o
C for 1hr via a cannula before it was allowed to warm to room 
temperature. The reaction was quenched with 1M HCl (25ml) and the product extracted with 
Et2O (3 x 25ml). The combined organic extracts were dried (MgSO4) and evaporated under 
reduced pressure to afford the product 96 (0.19g, 69%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  9.70-9.30 (1H, br s, COOH), 3.15-2.60 (3H, m), 1.95-1.40 
(6H, m). 
13
C NMR (100MHz, CDCl3)  211.9 (C=O ketone), 172.9 (C=O acid), 59.4, 49.2, 39.6, 35.7, 
27.5, 24.6. 
m.p 109-111
o
C 
 
C8H10O3 requires C 62.32 %, H 6.54 % found C 62.34 %, H 6.71 %. 
 
IR (neat)/cm
-1
: 2969 (C-H alkyl), 1749 (C=O acid), 1716 (C=O ketone), 1417, 1203, 946. 
 
LRMS (CI); 172.2 [M+NH4]
+
. 
 
Synthesis of methyl 4-(3-oxobicycloheptan-2-yl)methylbenzoate 97 
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 LDA was prepared by reaction of 
i
Pr2NH (0.31ml, 2.21mmol, 1.21eq) with 
n
BuLi 
(1.40ml of a 1.45M solution in hexane, 2.03mmol) in dry THF (25ml) at 0
o
C for 15mins. 
Norcamphor 94 (0.20g, 1.83mmol, 1eq) in dry THF (3ml) was added and the reaction 
mixture was left to stir at 0
o
C for 30mins. The flask was cooled to -78
o
C and methyl 4-
(bromomethyl)benzoate (0.46g, 2.01mmol, 1.10eq) in dry THF (5ml) was added. The 
reaction mixture changed from colourless to yellow then orange-red on addition. The reaction 
mixture was left to stir at -78
o
C for 40mins before warming to room temperature and 
quenching with MeOH (10ml). The crude product was adsorbed onto silica gel and purified 
by flash column chromatography using EtOAc/n-Hex (eluting with 2:98) to afford the 
product 97 (0.15g, 31%) as a colourless semi-solid. 
 
1
H NMR (400MHz, CDCl3)  7.98 (2H, d, J=8.2 Hz, aromatic H), 7.26 (2H, d, J=8.2 Hz, 
aromatic H), 3.93 (3H, s, CH3), 3.05 (2H, dd, J=4.3, 14.1 Hz, benzylic CH2), 2.51 (1H, m, 
CHCH2), 2.04 (1H, m), 1.91 (1H, m), 1.77 (2H, m, bridgehead CH2), 1.58 (2H, m), 1.35 (2H, 
m).  
13
C NMR (100MHz, CDCl3)  218.9 (C=O ketone), 167.4 (C=O ester), 145.9 (quaternary 
aromatic C-CH2), 130.3 (quaternary aromatic C-CO2Me), 129.4 (2 x aromatic C), 128.7 (2 x 
aromatic C), 55.5 (OCH3), 52.5, 50.1, 38.5, 35.2, 34.9, 28.4, 24.2. 
IR (neat)/cm
-1
: 2954 (C-H aryl), 2925 (C-H alkyl) 1743 (C=O ester), 1712 (C=O ketone), 
1610 (C=C aromatic), 1279 (C-O). 
 
HRMS (ESI); 281.1154 [M+Na]
+ 
C16H18O3Na requires 281.1148. 
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Synthesis of β-turn mimetics using a modified Ugi/Polonovski reaction 
 
Synthesis of N-formyl L-phenylalanine methyl ester 106 
 
Method 1 
 
 L-Phenylalanine methyl ester hydrochloride 105 (0.91g, 4.22mmol, 1eq) was added to 
methyl formate (25ml), followed by potassium carbonate (1.18g, 8.53mmol, 2eq). The 
reaction mixture was stirred at 45
o
C for 45hrs. After cooling to room temperature, water 
(40ml) was added and the crude product extracted with DCM (3 x 30ml). The combined 
organic extracts were dried (MgSO4) and the residue adsorbed onto silica gel and purified by 
flash column chromatography using EtOAc/petroleum ether (eluting with 30:70) to afford the 
product 106 (0.56g, 65%) as a colourless oil. 
 
 
Method 2
10
 
 
 Acetic formic anhydride was made by stirring acetic anhydride (20ml) and formic 
acid (9ml) under a N2 atmosphere at 50
o
C for 2hrs. L-Phenylalanine methyl ester 
hydrochloride 105 (1.04g, 4.83mmol, 1eq) was added and the reaction stirred under a N2 
atmosphere for 3 days at 50
o
C. After cooling to room temperature, the reaction mixture was 
added to water (50ml) and the crude product extracted with DCM (3 x 30ml). The combined 
organic extracts were dried (MgSO4) and the residue adsorbed onto silica gel and purified by 
flash column chromatography using EtOAc/petroleum ether (eluting with 30:70) to afford the 
product 106 (0.87g, 88%) as a colourless oil.  
 
1
H NMR (400MHz, CDCl3)  8.16-8.14 (1H, br s, NHCHO), 7.32-7.24 (3H, m, 3 x aromatic 
H), 7.12-7.09 (2H, m, 2 x aromatic H), 6.16-6.13 (1H, br s, NHCHO), 4.99-4.94 (1H, m, 
CH), 3.74 (3H, s, OCH3), 3.21-3.09 (2H, m, 2 x CH).  
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13
C NMR (100MHz, CDCl3)  172.0 (C=O ester), 160.9 (CHO), 135.9 (aromatic C), 129.8 
(aromatic C), 129.4 (aromatic C), 127.7 (aromatic C), 56.6 (CHCH2Ph), 52.2 (OCH3), 38.2 
(CH2Ph).  
C11H13NO3 requires C 63.76 %, H 6.32 %, N 6.76 % found C 63.72 %, H 6.42 %, N 6.71 %. 
 
IR (neat)/cm
-1
: 3459 (NH), 2964 (C-H alkyl), 1743 (C=O aldehyde), 1712 (C=O ester), 1666 
(C=C aromatic), 1211 (C-O), 1130 (C-N).   
 
HRMS (ESI); 225.1237 [M+NH4]
+
,
 
C11H17N2O3 requires 225.1234. 
 
 
Synthesis of (S)-methyl 2-isocyano-3-phenylpropanoate 107 
 
 
 
 
 To a stirred solution of N-formyl phenylalanine methyl ester 106 (605mg, 2.90mmol, 
1eq) in DCM (30ml) was added NEt3 (0.80ml, 5.74mmol, 2eq). The resultant mixture was 
cooled to -78
o
C under a N2 atmosphere. Triphosgene (303mg, 1.02mmol, 0.35eq) was 
quickly added in one portion (Caution: triphosgene is highly toxic!) and the reaction 
mixture was stirred at -78
o
C for 5mins. The reaction mixture was then stirred at -30
o
C for 
3.5hrs before being quenched by slow addition of water (50ml). The crude product was 
quickly extracted using DCM (3 x 30ml). The combined organic extracts were dried 
(Na2SO4) and the crude product purified by flash column chromatography using 
EtOAc/petroleum ether (eluting with 20:80) to afford the product 107 (0.47g, 85%) as a pale 
yellow oil. 
 
1
H NMR (400MHz, CDCl3)  7.37-7.23 (5H, m, aromatic H), 4.46-4.45 (1H, m, CH), 3.79-
3.78 (3H, br s, CH3), 3.28-3.22 (1H, dd, J=13.9, 4.8 Hz, CHPh), 3.16-3.10 (1H, dd, J=13.9, 
8.4 Hz, CHPh).  
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13
C NMR (100MHz, CDCl3)  171.5 (C=O), 161.4 (NC), 134.8 (quaternary aromatic C), 
129.7 (2 x aromatic C), 129.2 (2 x aromatic C), 128.2 (aromatic C), 60.8 (CHNC), 53.8 
(OCH3), 39.3 (CH2Ph). 
 
Synthesis of (S)-3-(2-(hydroxymethyl)pyrrolidin-1-yl)propanenitrile 100 
 
 
 Acrylonitrile (1.67g, 31.60mmol, 1.2eq) was added to a stirred solution of (S)-(+)-2-
pyrrolidinemethanol 99 (2.59g, 25.65mmol, 1eq) in MeOH (50ml). The resulting solution 
was stirred at room temperature overnight. The crude product was adsorbed onto silica gel 
and purified by flash column chromatography using MeOH/EtOAc (eluting with 15:85) to 
afford the product 100 (3.75g, 87%) as a yellow oil.  
1
H NMR (400MHz, CDCl3)  3.65-3.40 (2H, dd, CH2OH), 3.25-3.15 (1H, m, H2), 3.11-3.03 
(1H, dt, J=12.4, 7.7 Hz, H5b), 2.74-2.62 (2H, m, CH2CN), 2.56-2.50 (2H, t, J=7.7 Hz, 
CH2CH2CN), 2.37-2.30 (1H, m, H5a), 1.95-1.83 (2H, m, 2 x H3), 1.82-1.73 (2H, m, 2 x H4). 
13
C NMR (100MHz, CDCl3)  119.2 (CN), 65.1 (C-2), 63.0 (CH2OH), 54.4 (C-5), 50.3 
(CH2CH2CN), 27.8 (C-3), 24.1 (C-4), 18.6 (CH2CN).  
C8H14N2O requires C 62.31 %, H 9.15 %, N 18.17 % found C 61.60 %, H 9.35 %, N 18.19%. 
 
IR (neat)/cm
-1
: 3350 (OH), 2958 (C-H alkyl), 2239 (CN), 1037 (C-N).  
  
HRMS (ESI); 155.1179 [M+H]
+
,
 
C8H15N2ONa requires 155.1179. 
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Synthesis of (S)-3-(2-((allyloxy)methyl)pyrrolidin-1-yl)propanenitrile 101 
 
 
 
 (S)-3-(2-(Hydroxymethyl)pyrrolidin-1-yl)propanenitrile 100 (2.96g, 19.22mmol, 1eq) 
was added to a stirring solution of sodium hydride (0.84g of a 60% dispersion in mineral oil, 
21.00mmol, 1.1eq) in THF (40ml) at 0
o
C. The reaction mixture was stirred at 0
o
C under a N2 
atmosphere for 40mins. Allyl bromide (2.50ml, 28.89mmol, 1.5eq) was added followed by a 
trace of TBAI. Stirring was continued overnight at ambient temperature under a N2 
atmosphere. MeOH (40ml) was added, the crude product adsorbed onto silica gel and 
purified by flash column chromatography using EtOAc/petroleum ether (eluting with 40:60) 
to afford the product 101 (2.07g, 56%) as yellow oil.  
 
1
H NMR (400MHz, CDCl3)  5.95-5.85 (1H, m, CH=CH2), 5.30-5.15 (1H, m, CH=CH2), 
4.01-3.97 (2H, d, J=4.9 Hz, OCH2CH=CH2), 3.42-3.34 (2H, m, CHCH2O), 3.26-3.18 (1H, dt, 
J=12.5, 7.5 Hz, H-5b), 3.17-3.11 (1H, m, H-2), 2.74-2.68 (2H, m, CH2CN), 2.54-2.49 (2H, t, 
J=7.5 Hz), 2.36-2.28 (1H, m, H-5a), 1.95-1.85 (1H, m, H-3b), 1.82-1.70 (2H, m, 2 x H-4), 
1.60-1.50 (1H, m, H-3a).  
13
C NMR (100MHz, CDCl3)  135.1 (CH=CH2), 119.5 (CN), 117.3 (CH=CH2), 74.6 
(CH2OCH2CH=CH2), 72.7 (OCH2CH=CH2), 63.5 (C-2), 54.8 (C-5), 51.1 (CH2CH2CN), 28.7 
(C-3), 23.6 (C-4), 18.1 (CH2CN). 
C11H18N2O requires C 68.01 %, H 9.34 %, N 14.42% found C 68.36 %, H 9.66 %, N 14.41%. 
 
IR (neat)/cm
-1
: 2954 (C-H alkyl), 2219 (CN), 1621 (C=C), 1095 (C-O).   
 
LRMS (CI); 195.3 [M+H]
+
. 
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Synthesis of (S)-2-((allyloxy)methyl)pyrrolidin-1-ol 103 
 
 
 A stirred solution of (S)-3-(2-((allyloxy)methyl)pyrrolidin-1-yl)propanenitrile 101 
(1.01g, 5.21mmol, 1eq) in DCM (50ml), was cooled to -78
o
C and m-CPBA (1.00g, 
5.80mmol, 1.1eq) and potassium carbonate (1.07g, 7.53mmol, 1.45eq) were added. The 
solution was stirred for 1hr at -78
o
C then allowed to warm to room temperature and stirred 
for an additional hour. The resulting suspension was washed with aq. NaHCO3 (50ml), water 
(50ml) and brine (50ml). The organic extracts were dried (MgSO4) and solvent removed 
under reduced pressure to afford the product 103 (0.41g, 50%) as a yellow oil. The product 
could not be isolated in pure form as it underwent reverse Cope cyclisation slowly at room 
temperature. 
 
 
Synthesis of fused morpholine N-oxide template 104 
 
 
 
 (S)-2-((allyloxy)methyl)pyrrolidin-1-ol 103 (0.40g, 2.54mmol, 1eq) was stirred in 
CDCl3 (10ml) under a N2 atmosphere for 4 days. The solvent was removed under reduced 
pressure and the resulting residue purified by flash column chromatography (gradient elution 
100% EtOAc to 1:1 EtOAc/MeOH) to afford the product 104 as a yellow/orange oil (98mg, 
25% over 2 steps, ratio of diastereoisomers 1:0, 104 A:104 B). 
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1
H NMR (400MHz, CDCl3)  4.31-4.26 (1H, m, CHCH3), 3.90-3.83 (1H, m, CH), 3.81-3.75 
(1H, m, CH), 3.73-3.66 (1H, m, CH), 3.60-3.55 (1H, m, CH), 3.42-3.40 (1H, m, CH), 3.39-
3.33 (1H, m, CH), 3.31-3.22 (1H, m, CH), 2.30-2.22 (1H, m, CH), 2.21-2.12 (2H, m, CH2), 
1.97-1.85 (1H, m, CH), 1.27-1.25 (3H, d, J=6.4 Hz, CH3).  
 
LRMS (CI); 142.1 [(M-O)+H]
+
. 
 
 
Synthesis of (S)-(1-benzylpyrrolidin-2-yl)methanol 110
11
 
 
 
 
 To a stirred solution of (S)-(+)-2-pyrrolidinemethanol 99 (0.97ml, 9.97mmol, 1eq) in 
toluene (20ml) was added benzyl bromide (1.70ml, 14.3mmol, 1.4eq) and potassium 
carbonate (1.42g, 10.3mmol, 1.03eq). The reaction mixture was stirred under a N2 
atmosphere at 110
o
C for 21hrs. After cooling to room temperature, water (30ml) was added 
and the crude product extracted with DCM (3 x 30ml). The combined organic extracts were 
dried (MgSO4), the residue adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc (eluting with 100%) to afford the product 110 (1.08g, 56%) as 
a pale yellow oil.  
 
 
1
H NMR (400MHz, CDCl3)  7.35-7.23 (5H, m, aromatic H), 3.95-3.60 (2H, m, CH2Ph), 
3.45-3.40 (1H, m, CHCH2OH), 3.38-3.34 (1H, d, J=13.0 Hz, NCH2), 3.00-2.95 (1H, m, 
CH2OH), 2.77-2.70 (1H, m, CH2OH), 2.31-2.25 (1H, m, NCH2), 1.96-1.79 (2H, m, 
NCHCH2), 1.73-1.64 (2H, m, NCH2CH2). 
13
C NMR (100MHz, CDCl3)  139.7 (quaternary aromatic C), 129.4 (2 x aromatic C), 128.7 
(2 x aromatic C), 127.5 (aromatic C), 64.6 (NCHCH2), 62.1 (CH2OH), 60.6 (CH2Ph), 54.8 
(NCH2CH2), 28.2 (CH2CH), 23.9 (CH2CH2CH2). 
C12H17NO requires C 75.35 %, H 8.96 % N 7.32 % found C 75.38 %, H 8.98 % N 7.32 %. 
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IR (neat)/cm
-1
: 3346 (OH), 2937 (C-H alkyl), 1609 (C=C aromatic), 1029 (C-N).   
 
LRMS (CI); 192.29 [M+H]
+
. 
 
 
Synthesis of (1R, 2S)-1-benzyl-2-(hydroxymethyl)pyrrolidine-1-oxide 111 
 
 
 To a stirred solution of (S)-(1-benzylpyrrolidin-2-yl)methanol 110 (0.80g, 4.21mmol, 
1eq) in DCM (20ml) at -78
o
C was added m-CPBA (0.80g, 4.64mmol, 1.1eq) and potassium 
carbonate (0.89g, 6.44mmol, 1.5eq). The reaction mixture was stirred under a N2 atmosphere 
at -78
o
C for 2hrs and then allowed to warm to room temperature overnight. The resulting 
suspension was filtered through MgSO4. The crude product was adsorbed onto silica gel and 
purified by flash column chromatography using MeOH/EtOAc (eluting with 1:1) to afford the 
product 111 (0.61g, 70%) as a pale yellow solid.  
 
1
H NMR (400MHz, CDCl3)  7.51-7.40 (5H, m, aromatic H), 4.63-4.45 (2H, m, CH2Ph), 
4.40-4.35 (1H, m, CHCH2OH), 3.87-3.80 (1H, d, J=13.0 Hz, NCH2), 3.48-3.46 (2H, m, 
NCHCH2), 3.37-3.27 (1H, m, CH2OH), 3.17-3.11 (1H, m, CH2OH), 2.73-2.63 (1H, m, 
NCH2), 2.43-2.30 (1H, m, NCH2CH2), 1.97-1.80 (1H, m, NCH2CH2).  
13
C NMR (100MHz, CDCl3)  132.6 (quaternary aromatic C), 131.0 (2 x aromatic C), 130.0 
(2 x aromatic C), 129.1 (aromatic C), 71.1 (NCHCH2), 70.7 (CH2OH), 66.8 (CH2Ph), 59.9 
(NCH2CH2), 23.5 (CH2CH), 20.5 (CH2CH2CH2). 
C12H17NO2 requires C 69.54 %, H 8.27 % N 6.76 % found C 66.47 %, H 8.36 % N 6.45 %. 
IR (neat)/cm
-1
: 3147 (OH), 2947 (C-H alkyl), 1743 (C=C aromatic), 1068 (C-N).   
 
LRMS (CI); 208.1 [M+H]
+
, 190.1 [(M-O)+H]
+
.  
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Synthesis of β-turn mimetics using a reverse-Cope cyclisation 
 
 
 
Synthesis of methyl 4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoate 113 
 
 
 
 
 2-(prop-2-yn-1-yloxy)tetrahydro-2H-pyran 112 (2.14g, 15.27mmol, 1eq) in THF 
(25ml) was stirred under a N2 atmosphere at -78
o
C. EtMgBr (17ml, 1.0M, 17.00mmol, 1.1eq) 
was added slowly drop-wise. The reaction mixture was stirred for 30mins. Methyl 
chloroformate (1.22ml, 15.69mmol, 1.1eq) in THF (10ml) was added drop-wise. The reaction 
mixture turned a cloudy straw colour and was left to stir for 30mins before warming to room 
temperature for 5hrs (colour change to orange). The reaction was quenched with MeOH 
(30ml) and the crude product adsorbed onto silica gel and purified by flash column 
chromatography using EtOAc/petroleum ether (gradient elution 2:98 to 5:95) to afford the 
product 113 (0.71g, 25%) as a pale, straw coloured oil.  
 
1
H NMR (400MHz, CDCl3)  4.82-4.80 (1H, t, J=3.3 Hz, OCH), 4.40-4.38 (2H, s, CH2O), 
3.80-3.78 (3H, s, CH3), 1.85-1.70 (2H, m, OCH2), 1.67-1.50 (2H, m, CH2), 1.27-1.16 (2H, m, 
CH2), 1.01-0.85 (2H, m, CH2). 
13
C NMR (100MHz, CDCl3)  154.0 (C=O), 97.5 (OCHO), 96.8 (OCH2CC), 84.4 (C-
CO2Me), 62.4 (CH2O), 54.0 (OCH3), 53.2 (CC-CH2O), 30.4 (CH2), 25.6 (CH2), 19.2 (CH2). 
C10H14O4 requires C 60.59 %, H 7.12 % found C 61.37 %, H 7.90 %. 
IR (neat)/cm
-1
: 2946 (C-H alkyl), 2241 (CC), 1716 (C=O), 1249 (C-O).   
 
LRMS (CI); 216.1 [M+NH4]
+
. 
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Synthesis of methyl 4-hydroxy-2-butynoate 114 
 
 
 
 
 To a solution of methyl 4-((tetrahydro-2H-pyran-2-yl)oxy)but-2-ynoate 113 (557mg, 
2.81mmol, 1eq) in MeOH (10ml) was added p-TSA (54mg, 0.31mmol, 0.11eq). The reaction 
mixture was stirred at room temperature for 3.5hrs before washing with aq. NaHCO3 (30ml) 
and the product extracted with DCM (4 x 30ml). The combined organic extracts were dried 
(MgSO4) and the solvent removed under reduced pressure to afford the crude product 114 
(432mg) as a yellow liquid, which was used in the next step without further purification. 
 
 
Synthesis of methyl 4-((methylsulfonyl)oxy)but-2-ynoate 115 
 
 
 
 
 Methyl 4-hydroxy-2-butynoate 114 (306mg, 2.68mmol, 1eq) in dry DCM (20ml) was 
cooled to -40
o
C under a positive pressure of N2. NEt3 (0.55ml, 3.94mmol, 1.5eq) was added 
drop-wise with vigorous stirring, followed by the slow addition of mesyl chloride (0.22ml, 
2.89mmol, 1.1eq). The reaction mixture was allowed to warm to room temperature for 2hrs 
and there was a colour change to yellow. Water (30ml) was added and the product extracted 
with DCM (3 x 30ml). The combined organic extracts were washed with water (30ml), brine 
(30ml) and dried (MgSO4). The solvent was removed under reduced pressure to afford the 
crude product 115 (377mg, 73%) as a yellow/orange oil, which was used immediately in the 
next step without further purification. 
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Synthesis of chiral enamine N-oxides 
 
 
Synthesis of (R)-3-(2-(hydroxydiphenylmethyl)pyrrolidin-1-yl)propanenitrile 122 
 
 
 Acrylonitrile (0.70g, 13.20mmol, 1.36eq) was added to a stirred solution of (R)-2-
diphenylpyrrolidinemethanol 120 (2.46g, 9.73mmol, 1eq) in MeOH (40ml). The resulting 
solution was stirred at room temperature under a N2 atmoshere overnight. The solvent was 
removed under reduced pressure to afford the product 122 (2.89g, 97%) as a colourless solid. 
 
1
H NMR (400MHz, CDCl3)  7.63-7.50 (4H, m, 4 x aromatic H), 7.32-7.24 (4H, m, 4 x 
aromatic H), 7.19-7.14 (2H, m, 2 x aromatic H), 4.32-4.28 (1H, br s, OH), 3.91-3.86 (1H, m, 
N-CH), 3.31-3.26 (1H, m, CH), 2.45-2.31 (2H, m, CH2), 2.19-2.11 (1H, m, CH), 2.10-2.02 
(2H, m, CH2), 2.00-1.88 (1H, m, CH), 1.80-1.68 (3H, m, 3 x CH).       
13
C NMR (100MHz, CDCl3)  147.8 (2 x quaternary aromatic C), 128.7 (4 x aromatic C), 
126.8 (4 x aromatic C), 125.9 (2 x aromatic C), 118.7 (C≡N), 78.5 (C-OH), 71.9 (C-COH), 
56.0 (C-5), 51.9 (CH2CH2CN), 29.8 (C-3), 25.1 (C-4), 18.1 (CH2CN).  
m.p. 130-132
o
C 
 
C20H22N2O requires C 78.40 %, H 7.24 % N 9.14 % found C 78.86 %, H 7.13 % N 8.96 %. 
 
IR (neat)/cm
-1
: 3363 (OH), 2938 (C-H alkyl), 2244 (CN), 1492 (C=C aromatic).   
 
HRMS (ESI); 329.1623 [M+Na]
+
, C20H22N2ONa requires 329.1630. 
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Synthesis of (R)-2-(hydroxydiphenylmethyl)pyrrolidin-1-ol 124 
 
 
 
 A stirred solution of (R)-3-(2-(hydroxydiphenylmethyl)pyrrolidin-1-yl)propanenitrile 
122 (1.01g, 3.29mmol, 1eq) in DCM (20ml), was cooled to -78
o
C and m-CPBA (0.63g, 
3.65mmol, 1.1eq) and potassium carbonate (0.73g, 5.26mmol, 1.60eq) were added. The 
solution was stirred at -78
o
C and allowed to warm to room temperature overnight. The 
reaction mixture was filtered and the crude product adsorbed onto silica gel and purified by 
flash column chromatography using EtOAc/petroleum ether (eluting with 20:80) to afford the 
product 124 (0.51g, 57%) as a colourless solid.  
 
 
1
H NMR (400MHz, CDCl3)  7.65-7.44 (4H, m, 4 x aromatic H), 7.33-7.25 (4H, m, 4 x 
aromatic H), 7.20-7.13 (2H, m, 2 x aromatic H), 4.20-4.10 (1H, m, CH), 3.25-3.18 (1H, m, 
CH), 2.98-2.90 (1H, m, CH), 2.45-2.02 (1H, m, CH), 1.99-1.85 (1H, m, CH), 1.80-1.70 (2H, 
m, CH2).     
13
C NMR (100MHz, CDCl3)  147.7 (2 x quaternary aromatic C), 128.7 (4 x aromatic C), 
127.1 (4 x aromatic C), 126.1 (2 x aromatic C), 78.5 (C-OH), 71.9 (C-COH), 56.0 (C-5), 29.8 
(C-3), 18.1 (C-4).   
m.p. 84-86
o
C 
 
C17H19NO2 requires C 75.81 %, H 7.11 % N 5.20 % found C 75.94 %, H 7.09 % N 5.64 %. 
 
IR (neat)/cm
-1
: 3336 (O-H), 2969 (C-H), 1446 (C=C aromatic).   
 
HRMS (ESI); 270.1484 [M+H]
+
, C17H20NO2 requires 270.1494. 
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Synthesis of (S)-2-(hydroxydiphenylmethyl)pyrrolidin-1-acrylamide-N-oxide 126 
 
 
 
 To a stirred solution of (S)-2-(hydroxydiphenylmethyl)pyrrolidin-1-ol 123 (202mg, 
0.75mmol, 1eq) in CDCl3 (5ml) was added propiolamide (54mg, 0.74mmol, 1eq) in CDCl3 
(5ml). The reaction mixture was stirred at room temperature under N2 for 3 days with 
monitoring by TLC analysis and 
1
H NMR. The solvent was evaporated under reduced 
pressure to afford the crude product as a yellow solid. Purification by crystallisation from 
CHCl3/hexanes gave the product 126 (207mg, 83%) as colourless crystals.  
 
1
H NMR (400MHz, CDCl3)  7.71-7.65 (2H, m, 2 x aromatic H), 7.60-7.55 (2H, m, 2 x 
aromatic H), 7.35-7.29 (4H, m, 4 x aromatic H), 7.23-7.17 (1H, m, aromatic H), 7.14-7.08 
(1H, m, aromatic H), 6.67-6.64 (1H, d, J=12.4 Hz, CH alkene), 6.44-6.41 (1H, d, J=12.4 Hz, 
CH alkene), 5.30-5.20 (2H, br s, NH2), 4.66-4.60 (1H, m, NCHCH2OH), 3.56-3.49 (1H, m, 
NCHCH2), 3.14-3.07 (1H, m, NCHCH2), 2.74-2.63 (1H, m, NCH2), 2.50-2.38 (1H, m, 
NCH2), 2.21-2.10 (1H, m, NCH2CH2), 2.08-1.97 (1H, m, NCH2CH2). 
13
C NMR (100MHz, CDCl3)  165.4 (CONH2), 150.2 (NCH=CHCONH2), 128.8 
(CHCONH2), 127.4 (2 x quaternary aromatic C), 126.7 (4 x aromatic C), 125.0 (4 x aromatic 
C), 119.8 (2 x aromatic C), 80.4 (NCHCH2OH), 73.7 (COH), 54.2 (NCH2), 25.3 (NCHCH2), 
21.7 (NCH2CH2). 
m.p. 128-130
o
C 
 
C20H22N2O3 requires C 70.99 %, H 6.55 % N 8.28 % found C 65.11 %, H 6.12 % N 7.41 %. 
 
IR (neat)/cm
-1
: 3312 (N-H), 3170 (OH), 2943 (C-H), 1689 (C=O), 1515 (C=C aromatic), 
1392 (C=C).   
 
HRMS (ESI); 339.1706 [M+H]
+
, C20H23N2O3 requires 339.1709. 
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Synthesis of propiolaldehyde 130
12
 
 
 
 Jones’ reagent was made as follows: CrO3 (1.70g) was dissolved in distilled water 
(7.8ml) to give an orange solution. Conc. H2SO4 (2.4ml) was added dropwise at 0
o
C.  
 Jones’ reagent was added dropwise to propargyl alcohol 128 (1.0ml) in butanone 
(15ml) at 0
o
C over 10mins. There was a colour change to blue-green during the addition. 
TLC analysis showed that the reaction had reached completion after 30mins. Water (30ml) 
was added and the organic layer separated. The aqueous layer was extracted with Et2O (2 x 
40ml), dried (MgSO4). Distillation gave the product 130 (b.p. 55-57
o
C, 0.62g, 67%) as a 
colourless, volatile liquid.     
 
1
H NMR (400MHz, CDCl3)  9.23 (1H, s, CHO), 2.17 (1H, s, C≡C-H). 
13
C NMR (100MHz, CDCl3)  176.8 (CHO), 83.1 (C≡CH), 81.9 (C≡CH). 
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